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SYllopsis 
Synopsis 
Oral administration of autoantigens is a safe and convenient way to induce 
peripheral T-cell tolerance in animal models of autoinnnune diseases such as multiple 
sclerosis (MS). However, oral administration of myelin has not been successful as 
treatment of MS patients yet. In order to increase the efficacy of oral tolerance 
induction, we use genetically modified lactobacilli which express myelin antigens. 
The lactobacilli serve as producers of the antigen and as vehicles to transpOli the 
antigen to the gut mucosa. The fact that those Gram-positive lactobacilli are generally 
regarded as safe (GRAS), makes them attractive candidates for this application. 
It is known that lactobacilli may possess properties that influence the immune 
system, but such properties differ between Lactobacillus strains. Therefore 
Lactobacillus strain selection is very important. In order to select an appropriate 
Lactobacillus strain for the expression of myelin antigens, different wild type 
Lactobacillus strains were studied for several effects they have on the immune system 
after oral administration. 
Of eight analyzed Lactobacillus strains, harvested in log phase, only three 
strains, L. reuteri, L. brevis and L. ferJllelltuJll appeared to be able to enhance the 
specific antibody response against a parenterally administered T-cell dependent 
antigen. When the same strains were tested for their ability to indnce cytokines in the 
gut villi upon oral administration, L. reuteri and L. brevis induced appearance of 
TNF-a, IL-lB and IL-2 producing cells. In contrast, L. casei and L. lIlurilles tended to 
increase the number of TGF-Il and IL-IO producing cells. These results suggest that 
L.casei and L. JIlurilles might be suitable strains for the induction of oral tolerance. 
Determination of the specific IgG IIIgG2a ratio against a parenterally 
administered antigen, revealed a growth phase dependent skewing of T-cell pathways 
upon oral administration of some of the Lactobacillus strains. Feeding of stationary 
phase cultures of L. casei and L. JIlurilles induced higher IgG l/IgG2a ratios than after 
feeding of log phase cultures. Since IgG I production is a reflection of Th2 responses 
and IgG2a reflects Thl responses, these results imply that stationary phase cultures of 
those Lactobacillus strains skew more towards Th2, whereas log phase cultures direct 
the response towards Thl. 
A series of vectors has been constmcted which, upon transformation to 
lactobacilli, direct the expression of antigens either intracellularly or secreted into the 
environment. Among others, guinea pig myelin basic protein (gpMBP), human MBP, 
MBPn.85 and PLP139. 151 were expressed by L. casei. 
Nasal administration of MBPn.85 prior to disease induction with 
siginificarltly reduced EAE In cOlltrast,~6wo 
! it is possible to reduce by 
mucosal of recombinant lactolJat,tni" expressing myelin antigens. 
Further studies are required to develop this approach for treatment of MS in humans. 
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General introduction 
1.1 Multiple sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system (eNS) that affects eNS myelin which isolates nerve axons and allows saltatory 
pulse conduction. It is the most important chronic disabling neurological disease in 
young adults, with a mean age of onset around 30 years. It has a prevalence of 
approximately I per 1000 in Western European countries and it affects women versus 
men at a ratio of 1.5 to I (Sadovnick and Ebers, 1993). Although the cause and 
pathogenesis of MS are unknown, it is generally believed that MS is an autoimmune 
disease in which environmental factors as well as genetic factors are involved. Studies 
with monozygotic twins reveal an MS concordance rate of 20-30%, ·whereas this is 
3-5% for dizygotic twins (reviewed by Ebers and Sadovnick, 1994). This high 
concordance rate is a strong argument in favor of a genetic basis of MS, but can also 
be used as an argument for an environmental involvement in MS. The role of 
environmental factors in MS is supported by the presence of geographic gradients in 
the distribution of the disease. The general pattern is that MS prevalence rises with 
increasing distance from the equator. The nature of these environmental factors is 
unknown. Dietary factors, climate variation and infectious agents have all been 
postulated to be involved in MS, but there is no definitive proof for involvement in 
MS of any of these factors. Especially herpes viruses have gained interest the last few 
years (Dalgleish, 1997). 
The notion that MS is a multifactorial disease is strengthened by the fact that the 
clinical course of MS is highly variable for each individual patient, and can be divided 
into four categories (Lublin and Reingold, 1996). The first category is relapsing-
remitting disease, in which discrete attacks are alternated with periods in which a 
patient returns to the pre-attack base line. In the relapsing-progressive form of MS, the 
patients do not return to base-line level in between attacks and disability increases in 
these patients. In chronic-progressive disease, the disease progresses without periods 
of stability. The uncommon fourth form is characterized by a progressive relapsing 
course of MS. 
The most important pathological characteristics of MS are the presence of areas 
of demyelination (plaques) in the eNS white matter. In general, active demyelination 
is accompanied by inflammation. The inflammatory infiltrates are mainly composed of 
T lymphocytes, activated macrophages, microglia and some B cells. Proliferation of 
astrocytes accompanies the inflammatory changes (gliosis), eventually leading to scar 
formation. In inactive plaques, remyelination is often present at the lesion margin. The 
heterogeneity of lesions within and among different patients is large, as is the response 
to inununomodulatory treatments. These are additional arguments that the disease MS 
may be more heterogeneous than previously suspected (Lassmann et al., 1998). 
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1.2 Therapies for MS 
NOll alltigell-specific therapies 
Rational development of immunotherapy for MS is hampered by limited insight into 
the effector cells and effector mechanisms involved in demyelination. Since an 
effective curative therapy for MS is not yet available, symptomatic treatment of the 
disease to improve the quality of life is still very important. Acute attacks in MS are 
usually treated with adrenocorticotropic hormone (ACTH) or the corticosteroids 
prednisone or methylprednisone, which have both immunosuppressive and 
anti-inflammatory properties. Based on the assumed inflammatory and 
immunologically mediated pathogenesis of MS, a large number of possible new 
therapies directed at immune intervention has been put forward (reviewed by Waubant 
et al., 1997). IFNB-la and IFNB-lb have been used in the clinic for treatment of 
relapsing-remitting patients for some time now. Although its mechanism of action ill 
vivo are unknown, ill vitro IFN-fl antagonizes IFN-y, inhibits T-cell proliferation, it 
can restore T suppressor cell function and it can reduce T-cell migration by inhibiting 
the activity ofT cell matrix metalloproteases (MMP)(reviewed by Yong et al., 1998). 
These properties could be responsible for the positive effects of IFN-fl on relapse rate, 
disease activity (as measured by serial gadolinium-enhanced magnetic resonance 
imaging (MRI) and disease progression (as measured by annual TI-weigthed 
MRI)(reviewed by Amason, 1999). 
Treatment with Copolymer-l has also been approved for use in human. 
Copolymer-l is a mixture of synthetic peptides, composed of four amino acids 
(Johnson et al., 1995). There is evidence that Copolymer-l blocks or competes with 
binding of encephalitogenic peptides to MHC class II molecules, this way reducing the 
autoimmune response (Aharoni et al., 1999). Many more immunomodulatory 
compounds are used in MS treatment or are analysed in ongoing trials, but most of 
these therapies are not antigen-specific. Several non antigen-specific approaches are 
currently under investigation, in order to be used for application in human later, but 
also to reveal immunological mechanisms involved in autoimmune disease. Examples 
of such approaches are administration of cytokines or cytokine antagonists, blockade 
of migration of auto-reactive T-cells into the CNS and blocking lymphocyte 
co-stimulation by administration of anti-CD40 or anti-CD40 ligand monoclonal 
antibodies (Laman et al., 1998a; Gerritse et al., 1996). Such therapies may affect the 
entire immune system, both by suppression or by directing it into non-inflammatory 
immune responses. This could lead to unwanted side effects and a higher susceptibility 
for infectious diseases. Practically, this could mean that such treatments can not be 
given repeatedly or for a longer period. 
Alltigell-specific therapies 
A major goal in the treatment of T-cell mediated autoimmune diseases is the 
establishment of a therapy that selectively targets only pathogenic T cells, leaving the 
remainder of the T-cell repertoire intact. One of the reasons that such antigen-specific 
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therapies are not easy to develop is the fact that the autoantigens in many autoimmune 
diseases and in MS in particular are as yet unknown. Nevertheless, extensive research 
in experimental autoimmune diseases in which the autoantigen is known, has provided 
information related to antigen-specific therapies. Some of the approaches for 
development of antigen-specific therapy are discussed below. 
Intrathymic injection of auto-antigen 
The thymus plays a major role in development of self-tolerance. Intrathymic injection 
of neonatal BB rats with pancreatic islets prevented insulitis (Koevary and Blomberg, 
1992). It was possible to prevent experimental autoimmune encephalomyelitis (EAE), 
an animal model for MS, by intrathymic injection of myelin basic protein (MBP) or 
the immunodominant peptide of MBP71 _90, without otherwise compromising the 
peripheral lymphocyte pool in adult Lewis rats (Khoury et al., 1993). This was also 
demonstrated by intrathymic injection of S-antigen in autoimmune uveoretinitis 
(Koevary and Caspi, 1997). However, intrathymic injection of acetylcholine receptor 
protein could not prevent experimental autoinunune myasthenia gravis, indicating that 
suppression of Th I function alone may not be sufficient for the prevention of 
antibody-mediated autoimmune disease (OhtsUlu et al., 1995). The mechanism of 
intrathymic injection of antigen for tolerance induction is unclear, but a role for 
CTLA4 has been postulated (Issazadeh et al., 1999). This approach is not likely to be 
used in human autoimmune diseases, but it may help to elucidate the role of the 
thymus in acquired systemic tolerance of autoreactive T-cells. 
Systemic antigen immunotherapy 
It is well known that systemic injection of soluble deaggregated protein antigen 
specifically inhibits the induction of a subsequent T cell response to that antigen. 
Whether such suppression of the T cell response indeed is established and to what 
extent, is dependent on several parameters. The route of administration, the dose, the 
adjuvant and the nature of the antigen appear to be clUcial parameters. Intravenous and 
intraperitoneal administrations are more effective in tolerance induction than the 
subcutaneous route. In most experimental set-ups, high doses of antigen are required. 
The efficacy of tolerance induction is enhanced by the use of adjuvant such as alum or 
incomplete Freund's adjuvant (IFA), which are known to induce CD4+ T helper 2 
(Th2) function. Pep tides or monomeric antigens are more potent tolerogens than 
aggregated proteins, which tend to be immunogenic. In addition, the 
immunodominance of an antigen or epitope, defined as the capacity to generate an 
immune-response, seems to correlate with its potential to induce hyporesponsiveness 
(Liblau et al., 1997). Intravenous or intraperitoneal injection of myelin protein or 
peptides can prevent EAE (reviewed by Liblau et al. 1997). 
Other approaches to systemically target antigen-specific T cells are the use of 
peptide analogues (also known as altered peptide ligands (APL)) and soluble peptide-
MHC-complexes. Peptide analogues are capable of binding to the MHC molecule with 
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the same affinity as the wild-type peptide but have decreased affinity for the T-cell 
receptor (TCR) through mutations in primaty TCR contact residues. Administration of 
peptide-MHC complexes is thought to act via occupation of the TCR of the targeted T 
cells. The T celIs receive only signal one, without co-stimulation, leading to anergy 
and/or deletion of the autoreactive T cells. 
APL as well as peptide-MHC complexes of myelin antigens can prevent EAE 
(reviewed by Liblau et al., 1997)). Evidence for the treatment of established disease 
by systemic administration of antigen was obtained by Brocke et al. (1996), who used 
an APL of MBP'7.99 in a T cell line specific for MBPS7.99 induced EAE in 
(PLlJxSJLlJ)/F, mice. A major drawback of the use of APLs and peptide-MHC 
complexes in humans is that they require knowledge of the peptide epitopes 
recognized by the pathogenic T cells in individual patients. 
Oral and nasal tolerance 
A promising approach to antigen-specific therapy in autoimmune diseases is the 
induction of peripheral T cell tolerance by oral or nasal administration of autoantigen, 
termed mucosal tolerance induction (definition see 1.4). Extensive research has been 
performed in animal autoimmune models, but also in humans, to induce tolerance by 
the oral and nasal route and to elucidate the mechanisms involved. Since the mucosal 
immune system has some unique features compared to the peripheral immune system, 
which play a role in the induction of mucosal tolerance, first some properties of the 
mucosal immune system will be discussed. 
1.3 The mucosal immune system 
III/mune exclusion versus tolerance 
The mucosal surface area of the respiratory tract and the gastrointestinal tract are over 
a hundred times the surface area of the skin. Such a large area allows efficient uptake 
of oxygen and absorption of nutrients and excretion of waste products. As a 
consequence, a large area of the body is continuously exposed to many pathogens of 
the external milieu. To cope with both pathogens and innocuous substances, the 
mucosal immune system has generated two major arms of immune reactivity 
(reviewed by Brandtzaeg, 1995; 1998; Brandtzaeg et al., 1999). 1) Immune exclusion 
and elimination. Immune exclusion is a noninflammatory way of preventing 
colonization and penetration of harmful foreign material performed by the physical 
presence of indigenous bacteria leaving no niche for ingested pathogens, as well as by 
secretOlY IgA (and to some extent sIgM and IgG), which has a higher general cross-
reactivity with antigens than has IgG (Waldman et al., 1970, Shvartsman et al., 1977). 
Itlllnune elimination involves neutralization and removal of foreign material that has 
penetrated the epithelium by mainly proinflammatory, non-specific innate defense 
mechanisms like complement-activating IgG and IgM, and cytokines released from 
activated T cells and macrophages. 2) Oral tolerance. Since the mucosal epithelium 
has evolved for efficient transport of molecules, a continuous inflammatory response 
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evoked against indigenous microflora, ingested food antigens or inhaled antigens is 
undesirable. Therefore, under physiological circumstances, penetrating soluble 
antigens and the indigenous microflora mainly induce hyporesponsiveness. Since the 
mucosae are natural sites of tolerance induction, they can be used to reinduce 
tolerance against antigens to which tolerance has been lost and has resulted in 
autoimmune disease. 
RespiratO/y tract versus gastrointestinal tract 
The mucosae comprise a specific epithelial layer and underlying connective tissue that 
form the border between the internal and external milieu in the airway system, the 
gastrointestinal tract and other mucosal surfaces. It is a unique property of the 
intestinal immune system and some parts of the respiratory immune system that it is 
separated from the antigens by only one cell layer, and is not drained by lymphatic 
vessels (Neutra et al., 1996). When comparing the immune system of the upper 
respiratory tract and the gastro-intestinal tract, some differences are obvious. One 
difference is the presence of large numbers of intraepitheliallymphocytes (IEL) in the 
gut villi, which are mainly of the CD8+ phenotype, in contrast to the low numbers of 
IEL in the airways, which are mostly CD4+ T cells (Abreu-Martin and Targan, 1996). 
Another difference is the distribution of subepithelial and intraepithelial professional 
antigen presenting cells (APC). In the gut, most APC are located under the epithelial 
cell layer, whereas many APCs of the upper respiratory tract are located between the 
epithelial cells (Holt et al., 1990). How these differences may relate to mucosal 
tolerance induction is unclear. However, there is mounting evidence suggesting that 
the epithelium of the gastrointestinal tract, enterocytes, may act as antigen presenting 
cells (APC), preferentially stimulating CD8+ cells, probably IELs (Bland and 
Whiting, 1989; Yamamoto et al., 1998). It has been postulated that (human) 
enterocytes present antigen to CD8+ cells via CDld (Blumberg et al., 1991). 
However, for proper activation co-stimulatory molecules arc a prerequisite, but CD80 
and CD86 costimulatory molecules have not been detected yet on enterocytes (Bloom 
et al., 1995). This lack of costimulation may promote the induction of tolerance to 
luminal antigens In contrast, due to scarcity of such CD8+ IEL and the limited amount 
of antigen that enters via the airways, the induction of peripheral tolerance probably 
will be mainly regulated by CD4+ Th2 cells stimulated in draining lymph nodes by 
migrated dendritic cells (Brandtzaeg, 1996). 
1.4 Mucosal tolerance induction 
Definition 
The definition of mucosal tolerance induction in this thesis is: Any mechanism by 
which a potentially injurious immune response is prevented, suppressed or shifted to a 
noninjurious class of immune response by mucosal (e.g. oral and nasal) administration 
of antigen (Weiner HL, 10th Int. Congress Mucosal Immuno!., Amsterdam). In this 
thesis the injurious immune response is a Th I mediated inflammation of the central 
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nervous system in EAE. Although the term oral administration strictly taken refers to 
administration of the antigen in the oral cavity, we use the term for intragastric 
intubation of the antigen in rodents, as is generally applied throughout the literature. 
On application of aerosolized antigen taken up via the nose, a small amount is thought 
to enter the gastro-intestinal tract, in contrast to administration of antigen in the nose 
by use of a pipet. 
Mucosal tolerance induction in animal models 
Oral tolerance was first described in 1911 when Wells fed hen egg proteins to guinea 
pigs and found them resistant to anaphylaxis when challenged with the same antigens 
(Wells, 1911). It was shown that this is an antigen specific phenomenon by numerous 
investigators who demonstrated that animals fed proteins such as ovalbumin (OVA) 
do not respond as well to these antigens when subsequently immunized, but do 
respond normally to other antigens (reviewed by Strobel and Mowat, 1998). An 
example of peripheral T cell tolerance induction without concomitant induction of B 
cell tolerance was observed after oral administration keyhole limpet hemocyanin 
(KLH) in humans (Husby et 01., 1994). Although the T cell responses were down-
regulated, the oral administration of KLH primed the humoral response systemically 
as well as mucosally. 
The T-cell hyporesponsiveness induced by autoantigen administered mucosally, 
could be beneficial in the treatment of autoimmune diseases. During the last decade, 
oral and nasal tolerance has been used successfully to treat autoimmune phenomena in 
animals (Table 1). Mucosal tolerance has been extensively studied, especially in Thl 
mediated experimental autoimmune disease such as EAE. In addition to T cell 
mediated autoimmune diseases, the antibody-mediated experimental autoimmune 
diseases myasthenia gravis and thyroiditis could be suppressed by previous nasal 
and/or oral administration of acetylcholine receptor (AChR) or thyroglobulin, 
respectively (Table 1). A wide range of experimental diseases (Table 1) could be 
prevented by oral administration of the autoantigen. A complicating factor is that 
treatment of humans occurs when the disease is already fully established. Therefore, 
treatment of ongoing disease in chronic autoimmune models is clinically more 
relevant. Miller et 01. (1993b) showed that orally MBP tolerized mice were not 
protected against adoptive transfer of EAE, indicating that suppression of active 
autoreactive T cells is much more difficult than prevention of induction. However, 
treatment of ongoing disease by oral administration of (auto)antigen has been 
demonstrated in several chronic autoimmune models such as EAE (Table 
2)(al-Sabbagh et 01., 1996; Benson et 01., 1999; Brad et 01., 1991; Meyer et 01., 1996), 
collagen induced arthritis (CIA)(Khare et 01., 1995) and experimental autoimmune 
uveoretinitis (EAU)(Thurau et 01., 1997; Torseth and Gregerson, 1998). 
Experimental autoimmune diseases have also been treated by nasal 
administration of (auto)antigen (Table 1). Nasal administration of high doses of AChR 
could ameliorate the manifestations of experimental autoimmune myasthenia gravis 
15 
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(EAMG)(Shi et al., 1999). Aerosol MBP decreased the severity of subsequent relapses 
in animals with EAE recovered from the first attack (ai-Sabbagh et al., 1996). Nasal 
administration of residues 139-151 from proteolipid protein (PLP139.15I ) after onset of 
myelin induced EAE, reduced the number of relapses (Anderton and Wraith, 1998). 
Also nasal co-administration of MBP68.86 and MBP87.99 could reverse the disease in 
Lewis rats (Liu et al., 1998). Aerosol insulin could treat IDDM in NOD mice 
(Harrison et al., 1996). 
Table 1. Oral alld "asal tolerallce illduction ill experimelltal autoimmune models 
Experimental 
Human disease autoimmune Toicrogen References 
disease 
ORAL mUltiple sclerosis EAE MBP (peptides), PLP (peptides) see Table 2 
rheumatoid arthritis CIA,AIA, AA ClI, crr peptides, inducing-antigen 1·13 
type I diabetes IDDM insulin (peptide), GAD65 14·18 
uveitis EAU S·Ag (pep<ides), IRBP (peptide) 19·27 
myasthenia gravis EAMG AChR 28,29 
Guillain-Barre syndrome EAN bovine peripheral nerve myelin 30 
autoimmune thyroid disease EAT thyroglobulin 31,32 
inflammatory bowel disease EGC haptenized colonic proteins, WBS, 33·35 
colitis extracted proteins 
NASAL multiple sclerosis EAE gpMBP, MBP-peptides, PLPI39.]51 1,36-40, 
this thesis 
rheumatoid arthritis CIA, AlA Cll, CII peptides or fragments, 1,41·47 
inducing-antigen peptide 
type I diabetes IDDM insulin, GAD65-peptides 48,49 
uveitis BAU retinal extract, IRBP. S-Ag 50,51 
myasthenia gravis EAMG AChR (peptides) 52·55 
Guillain-Barre syndrome EUN P2 peptide 57·81 56 
EAE: experimental autoimmune encephalomyelitis, CIA: collagen induced arthritis, AlA: antigen-
induced arthritis, AA: adjuvant arthritis, IDDM: insulin-dependent diabetes mellitus, EAU: experimental 
autoimmune uveoritinitis, EAMG: experimental autoimmune myasthenia gravis, BAN: experimental 
autoimmune neuritis, EAT: experimental autoimmune thyroiditis, EGC: experimental granulomatous 
coli lis, (gp)MBP: (guinea pig) myelin basic prolein, PLP: proleolipid prolein, Cll: Iype II coilagen, 
GAD65: glutamate decarboxylase peptide, S·Ag: S·anligen, AChR: acely1choline receptor, TNBS: 
trinitrobenzene sulfonic acid, IRBP: interphotoreceptor retinol binding protein. lui-Sabbagh et al., 1996; 
2Haque el al., 1996; lInada et al., 1997; 4Jorgensen et al., 1998; 5Khare et af., 1995; tiMyers el (11., 1998; 7Thompson el 
af., 1988; tyhompson et al., J993a; 9Thompson et al.,1993b; l6yhorbecke el al., 1999; IIYoshino, 1996b; 12Yoshino, 
1996a; 13Zhang el al., 1990a; t4Bergerot et (II., 1994; 15Polanski el al., 1997; 16Ramiyu et al., 1997; Hvon Herrath MG 
et al., 1996; I~ang et al., 1991; 19Rizzo el al., 1994; 26yhurau el al .• 1991; 21Thumu el af., 1997; 2~orseth and 
Gregerson, 1998; 23Gregerson et al., 1993; 24Nussenbfatt e/ al., 1990; 25Silver e/ al., 1998; UiSingh et al., 1996; 
27Yrabec et al .• 1992; 2S0kumum et al., 1994; 2"\Vang el (/1., 1993. 3{1Gaupp et af .• 1997, 31Guimaraes et al., 1995; 
31Peterson and Braley-Mullen, 1995 ,3lEIson et al., 1996; 3-lNeurath et al., 1996; 3sTrop el al., 1999; 3tiAnderton and 
Wraith, 1998; l7Liu el al., 1998; l8Bai et lIl., 1997; 39Li et at., 1998; ~etzler and Wraith. 1993; 41Bayrak and 
Mitchison, 1998; 42Chu and Londei, 1999; 43Matsumoto et al., 1998; MMyers et al., 1997; 4sPrakken et al., 1997; 
4tiStaines e/ al., 1996; 47Yerheijden et al., 1997; 48Harrison el af., 1996; 49Tian et al., 1996; SOoick et al., 1994; 
5lL'l.liotou et al., 1997; 52Shi e/ al., 1998a; 53 1999; stKarachunski et al., 1997; 5sMa e/ ar, 1995; 5tizhu e/ al., 1998. 
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Conversely, oral or nasal administration of antigen can lead to more severe clinical 
signs. Meyer et al. (1996) have shown that oral administration of a low dose of MBP 
enhanced the clinical signs of chronic EAE in B 1O.PL mice. As demonstrated in this 
thesis, nasal administration of two doses of gpMBP in Lewis rats enhanced the clinical 
signs of EAE in Lewis rats (Chapter 4.2). Nasal administration of MBP led to 
exacerbation of ongoing EAE in DA rats (Bai et al., 1998). Exacerbation was also 
found when rats with mild EAU were treated with S-antigen peptides, although mild 
disease could be treated with high doses of antigen. Oral administration of autoantigen 
can also lead to induction of disease as oral administration of OVA induced cytotoxic 
T cells in B6 mice and increased incidence of diabetes in chimeric RIP-OVA mice 
with high levels of CD8+ T cells specific for OVA infiltrates in Il-islets (Blanas et al., 
1996). Terato et al. (1996) showed that oral administration of chicken collagen type II 
induced arthritis in DBN 1 mice. 
Table 2a. Oral tolerance ill rat EAE models 
Oral Animal EAE Inducing Prevention! References tolcrogen model antigen treatment 
gpMBP Lewis rat acute gpMBP prevention Bitar and Whitacre, 1988; Higgins and 
Weiner, 1988; Miller el al., 1992a 
hMBP Miller el af., 1992a 
rMBP Miller et af., 1992a 
bMBP Higgins and Weiner, 1988; Miller et al., 
1992a 
gpMBPl_37 Lewis acute gpMBP prevention Higgins and Weiner, 1988 
gpMBP-U89 
gpMBP9(}.17o 
b:MBP ene. 
decapeptide 
bMBPnoll-
enceph. S79 
hMBP Lewis acute hMBP prevention Bitar and Whitacre, 1988 
gpMBP Lewis acute eMBP prevention Miller et ai., 1992a 
eMBP 
hMBP 
bMBP 
gpM BP6S.SS Lewis acute gpMBP6S-88 prevention Javed et al .• 1995 
gpMBP6S.sg Lewis acute rMBP6S.~g prevention Javed et aI .. 1995 
gpMBP21-40 Lewis acute gpMBPJ1 .90 prevention Miller et al .. 1993a 
gpMBP7I.90 
gpMBP Lewis chronic gpSCH treatment Brod e/ at., 1991 
gpmyclin 
EAE can be induced in the susceptible Lewis rat with distinct myelin antigens. Oral administration of 
the disease inducing antigen or another myelin antigen can prevent or treat EAE. Studies describing 
effective oral tolerance protocols in the Lewis rat are listed. 
gp: guinea pig. h: human. r: mt. b: bovine. MBP: myelin basic protein, SCH: spinal cord homogenate. 
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Apparently, there is a delicate balance between tolerance and immunity. The dosage, 
timing, frequency and route of application are important factors in the success of 
mucosal tolerance strategies for treatment of chronic autoimmune diseases. Many 
different EAE models have been used to demonstrate oral and nasal tolerance with 
many different antigens and protocols (Table 1 and 2) and these studies have been the 
basis for elucidation of mechanisms of mucosal tolerance. However, oral 
administration of (potential) autoantigens in humans has not been successful yet, as 
discussed below. 
Table 2b. Oral tolerallce ill guinea pig and mOllse EAE models 
Oral Animal EAE Inducing Prevention! References tolerogen model antigen treatment 
gpMBP strain 13 chronic gpSCH treatment Brode/al., 1991 
gpmyelin guinea pig 
hmyelin 
hMBP Hartley acute gpMBP prevention Miller et al., 1992a 
bMBP guinea pig 
gpMBP 
gpMBP SJUJ acute mmyelin prevention Miller el al., 1992a 
,MBP mouse Miller el al., 1992a 
hMBP Miller e/ al., 1992a 
bMBP Miller e/ al., 1992a 
mMBP Miller el al., 1992a; ai-Sabbagh el al., 1994 
bPLP al-Sabbagh el al .• 1994 
PLP139.151 SJUJ acute PLP139.151 prevention Kamus e/ ai., 1996 
mMBP SJUJ acute PLP14(}'159 prevention ai-Sabbagh et al., 1994 
bPLP 
gpMBP SJUJ acute PLP prevention Santos et a/., 1994 
gpMBP'.1I ai-Sabbagh et af., 1994 
gpMBPS9.101 aI-Sabbagh etat., 1994 
PLP1.w.l~9 ai-Sabbagh et ai" 1994 
PLPI39.151 Karpus et al., 1996 
bPLP Karpus et at., 1996 
bmyelin SJUJ chronic nlSCH treatment al-Sabbagh el al .• 1996 
gpMBP BIO.PL acute! gpMBP prevention! Meyer et al., 1996 
mouse chronic treatment 
gpMBP BIO.PL chronic gpMBP preventionJ Benson el al., 1999 
treatment 
EAE can be induced in several susceptible animal species with distinct myelin antigens. Oral 
administration of the disease inducing antigen or another myelin antigen can prevent or treat EAE, 
Studies describing effective oral tolerance protocols in the guinea pig strain 13, Hartley guinea pig, SJUJ 
and B 1O.PL mice are listed. 
gp: guinea pig, h: human, r: rat, b: bovine, m: mouse, MBP: myelin basic protein, PLP: proteolipid protein, SCH: 
spinal cord homogenate. 
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Oral tolerance induction in hUlIlan trials 
From animal experiments it is known that dose, timing, frequency and route of 
administration are important factors influencing the efficacy of mucosal tolerance 
induction. Additional complications in the treatment of humans with chronic 
autoimmune disease by mucosal administration of (auto)antigen are the established 
disease and the fact that in most cases the autoantigen is unknown. Despite these 
difficulties, several clinical trials have been initiated or are currently planned (Table 
3). These initial trials suggest that there is no systemic toxicity or exacerbation of 
disease associated with the oral administration of antigen. Although some positive 
effects have been observed with low doses of collagen in human arthritis (Barnett et 
al., 1998), consistent clinical efficacy has not yet been demonstrated. Results in 
humans, however, have mirrored several aspects of what has been observed in animal 
models. For instance, MS patients treated with oral bovine myelin contain MBP and 
PLP specific TGF-B secreting in peripheral blood, in contrast to untreated patients 
(Fukaura et al., 1996). The possible involvement of TGF-B in oral tolerance will be 
discussed in the next paragraph. 
Table 3. Oral lolerance inductioll ill humall au(o;,mmme disease 
Disease trial 
Multiple sclerosis 
Rheumatoid arthritis 
(also juvenile rheumatoid arthritis) 
Uveitis 
Thyroid disease 
Myasthenia gravis (planned) 
Type I diabetes 
(planned in new-onset diabetes) 
Oral antigen 
bovine myelin 
type II collagen 
S-Ag, retinal antigens 
thyroglobulin 
acetylcholine receptor 
insulin 
References 
Fukaura eta/., 1996; Hohol et ai., 1996; 
Weiner et al., 1993 
Barnett et al., 1996; Barnett e/ al., 1998; 
Sieper et al., 1996; Trentham et al., 1993 
Nussenblatt ela!., 1997 
Lee et al., 1998 
Drachman e/ af., 1996 
Carel and Bougneres, 1996 
Proteins were taken orally as treatment in several human autoimmune diseases in order to induce oral 
tolerance leading to reduced disease activity. Those human trials arc listed, as arc two planned trials. 
S-Ag: S-antigen, AChR: acetylcholine receptor 
Mechanisllls of 11111 co sal tolerance 
Three main mechanisms that have been identified by which mucosal tolerance is 
mediated include active suppression, anergy and clonal deletion. These mechanisms 
appear to be determined primarily by the dose of administered antigen. Low doses of 
antigen favor the generation of regulatory cells that suppress the specific immune 
response in the target organ, whereas high doses of antigen induce an antigen-specific 
anergic state or deletion of peripheral T cells. Active suppression is the mechanism of 
peripheral T cell tolerance induction which is mediated by regulatory cells that 
suppress the specific immune response in the target organ. The tolerogenic state can 
be adoptively transferred by the regulatory T cells from mucosally tolerized animals to 
na'ive recipients. Several phenotypes of such regulatory T cells have been described. 
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Initially, regulatory T cells of the CD8+ subset have been described to be involved in 
oral tolerance (Nussenblatt et al., 1990; Lider et al., 1989). Miller et al. (1992b) have 
demonstrated that the suppressive activity of such CD8+ cells may be due to induction 
of TGF-3. TGF-3 is generally a negative regulator of immune responses. Injection of 
TGF-3 has been shown to suppress EAE and other experimental autoimmune diseases 
(Kuruvilla et al., 1991; Racke el al., 1991). The appearance of TGF-3 in inflammatory 
infiltrates in the brain of animals recovering from EAE, indicates a down-regulatOlY 
role for TGF-3 in inflammatory processes (Khoury et al., 1992). Another group of 
regulatOlY T cells, are CD4+ Th2 cells (e.g. Tian el al., 1996; Chen el al., 1995), 
producing non-inflammatory cytokines such as JL-4, JL-IO and TGF-3. When in a Th I 
mediated autoimmune disease, the inflammatory Th I response shifts to a specific, 
non-inflammatory Th2 response, the mechanism of active suppression is further 
specified as immune deviation. However, LaFaille el al. (1997) have demonstrated 
that Th2 cells do have the potential to induce EAE in immunodeficient mice, implying 
that in the absence of a normal immune system Th2 cells can be equally pathogenic. 
The existence of a third T cell subset (Th3), potentially involved in 
induction/maintenance of mucosal tolerance, was proposed by Chen et al. (1994). 
These Th3 cells express CD4+ and produce TGF-3 mainly, sometimes with low 
co-expression of JL-4 or IFN-y. 
T cell anergy is defined as a cellular state in which a T cell is alive but fails to 
display certain functional responses when optimally stimulated through both its 
antigen-receptor and other receptors that are normally required for T cell activation 
(Schwartz, 1996). Anergy is induced when no or no proper co-stimulation is present 
(Lafferty et al., 1983). In vilro, stimulation of anergic cells with antigen does not lead 
to proliferation and JL-2 production. Peripheral T cell tolerance can not be adoptively 
transferred to naIve animals with anergic antigen specific T cells. 
Clonal deletion, peripheral deletion of antigen specific T-cells, has not yet been 
described in normal animals after mucosal administration of antigen. Deletion of 
specific T cells has only been shown after oral administration of very high doses of 
antigen in T cell receptor (TCR) transgenic mice (Chen et al., 1995a; Whitacre el al., 
1996b). Circumstantial evidence for a role of clonal deletion as mechanism of mucosal 
tolerance has been provided by the observation that orally OVA tolerized lymphocytes 
die by apoptosis when cultured in vitro after an in vivo challenge with OVA (Garside 
et al., 1996). 
All described mechanisms target T cells specific for the mucosally administered 
antigen. However, the regulatOlY effector T cells can also suppress T cell responses 
evoked by other antigens. By secretion of suppressive cytokines such as TGF-3 and 
JL-IO into the microenvironment, an ongoing response against a co-localized antigen 
may be down-regulated (Anderton and Wraith, 1998; Bayrak and Mitchison, 1998; 
reviewed by Weiner, 1997). This mechanism of active suppression is further specified 
as bystander suppression. Successful induction of this bystander suppression is of 
major importance for the therapeutic use of mucosal tolerance in the treatment of 
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autoimmune disease, as it may obviate the need to identify and use specific 
autoantigens, and may circumvent complications of determinant/epitope spreading 
(reviewed by Vanderlugt et al., 1998). 
Modulation 0/ mucosal tolerance 
When mucosal tolerance is mediated via active suppression, inducing Th2 or Th3 
regulatory cells, any stimulus that favors Th I versus Th2ITh3 responses could 
potentially abrogate mucosal tolerance (reviewed by Weiner, 1997). For example, high 
doses of IFN-y abrogated oral tolerance (Zhang et al., 1990b). Conversely, 
administration of factors that favor Th2ITh3 over Thl may augment mucosal 
tolerance. Indeed it has been shown that factors such as oral IL-4 can enhance oral 
tolerance (Inobe et al., 1998). Surprisingly, also administration of IL-2 potentiated oral 
tolerance in the uveoretinitis model possibly by increasing TGF-Jl, IL-4 and IL-IO 
production in Peyer's patches (Rizzo et al., 1994). Peripheral T cell tolerance was also 
increased by oral administration of cholera toxin subunit B (CTB) and LPS, often used 
to enhance the immunogenicity of (mucosally) administered antigens for vaccination 
purposes (Arakawa et al., 1998; Bergerot et al., 1997; Gaupp et al., 1997; Khoury et 
al., 1990; Sun et al., 1996). Similar effects may be obtained with bacteria that can 
influence the immune response in a non-inflammatory fashion, an effect that could be 
obtained by oral administration of a specified Lactobacillus strain. 
1.5 Lactobacilli 
Microorganisms as antigen delivel)' system/or vaccination purposes 
Oral vaccination against certain viruses or bacteria appears to be feasible when 
administered attenuated (Kaul and Ogra, 1998). However, there always will be a 
(small) risk of infection. Oral vaccination solely with pathogenic protein antigens is 
difficult to achieve, since oral administration of soluble antigen normally leads to 
hyporesponsiveness. Therefore a wide range of antigen delivery systems is being 
developed, which enable antigen delivery at the proper sites of antigen presentation 
and in addition may fulfill an adjuvant function. Transformed microorganisms 
expressing heterologous proteins of the target pathogen are used as such antigen 
delivery systems to evoke a protective immune response against the pathogen. The 
strains of microorganisms employed are usually genetically attenuated mutants of 
pathogenic bacteria (the carrier) transformed with a vector designed to obtain an 
adequate expression of antigens from another pathogen. Such carriers can then be used 
as local antigen producers at the gut mucosa, with the additional advantage of 
circumventing expensive and difficult antigen purification processes. For instance, 
Salmonella strains have been used as carrier for hepatitis B virus antigens 
(Fairweather et al., 1990). Other bacteria which are potentially useful as carriers 
include strains of E. coli, Mycobacteria, Vibrio cholera and Shigella (Butterton et al., 
1997; Killeen et al., 1999; Noriega et al., 1996; Hale, 1990). The effectiveness of 
pathogenic bacteria as carrier probably is related to the pathogenicity of the bacterial 
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strains. Most pathogenic bacteria have specific mechanisms to invade the human or 
animal body, normally evoking a strong immune response. This strong immune 
response against the carrier probably stimulates the immune response against the 
heterologous expressed antigen. However, due to the pathogenic character of most 
transformed microorganisms used for oral vaccination, their use as antigen carrier is 
limited. For this reason the use of a GRAS (generally regarded as safe) organism, such 
as Lactobacillus, as a safe antigen carrier for the delivery of foreign antigens in the 
gastrointestinal tract is to be preferred. 
Microorganisms as antigen delivel}' system/or tolerance induction 
Using microorganisms as antigen delivery system is an approved method of 
vaccination in experimental animal models. We reasoned that the same technique 
could be used to establish the induction of oral tolerance for the treatment of 
autoimmune diseases. An ideal therapy consists of a continuous production and 
presence of the autoantigen at the site of tolerance induction, i.e. the gut associated 
lymphoid tissue (GALT). Oral administration and possibly subsequent colonization of 
microorganisms expressing autoantigens might realize the continuous presence of 
autoantigen at the gastro-intestinal tract. This approach provides several advantages 
over feeding purified autoantigens. Degradation of the autoantigens in the stomach 
and the rest of the gastrointestinal tract will be decreased and no bulk purification of 
human proteins is necessary, which makes this method also much cheaper. In addition, 
the use of recombinant lactobacilli increases safety of the method, because there is no 
risk of co-administering viruses or prions. When the transformed lactobacilli are able 
to colonize the gut, the antigens are released continuously in the gut, restricting the 
therapy to a single or a few administrations. Specified Lactobacillus strains could be 
suitable for this approach due to their GRAS-status and low intrinsic immunogenicity 
(Gerritse et al., 1990). 
Lactobacillus 
Lactobacilli are Gram-positive rod-shaped lactic acid bacteria. Although there are 
some exceptions, most of the Lactobacillus strains are not pathogenic and lactobacilli 
are major constituents of the human and animal gut. Because of their harmless 
character they have the GRAS-status, and are frequently used in bio-processing and 
preservation of food and feed. Nowadays, lactobacilli are mainly known for their 
health stimulating properties. The importance of lactobacilli for human health was first 
recognized by Metchnikoff at the beginning of the century (Metchnikoff, 1908). He 
suggested that harmful effects of undesired bacteria could be overcome by establishing 
a new balance between intestinal bacteria, through ingestion of lactobacilli or 
fermented products made by these organisms. Especially during the last few decades, 
extensive research on the positive effects of Lactobacillus strains has been carried out, 
suggesting additional health and/or nutritional benefits for humans and animals by oral 
administration of lactobacilli. Such intrinsic properties include: anti-carcinogenic 
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activity, control of intestinal infections, improvement of lactose metabolism, 
improvement of gnt barrier function, control of serum cholesterol levels and positive 
effects on allergy as well as on (experimental) autoimmune diseases (e.g. Matsuzaki et 
al., 1990; Mnrosaki et al., 1998; Perdigon et al., 1995; Salminen et al., 1996b; 
Shornikova et al., 1997). It should be noted that not all strains from the very large and 
diverse (e.g. in fermentation pathways) genus Lactobacillus exhibit the same 
health-stimulating properties and may vary in strength of the effect obtained (Klein et 
al., 1998). Some of the positive effects of lactobacilli are mediated by non-immune 
components such as modulation of vitamin production, enzymes, and antibiotics, but 
especially modulation of the immune system seems to play an important role 
(reviewed by Holzapfel et al., 1998; Femandes et al., 1987; Rao and Shah ani, 1987; 
Shahani et al., 1977). 
bl1llll1ll0lllodlllatioll by lactobacilli 
One of the possible mechanisms for lactobacilli to influence allergy, autoimmunity, 
infection and carcinogenesis is by affecting cytokine expression in a specific or 
non-specific manner. Modification of the local cytokine profile in the gut probably is 
most effective. Therefore oral administration of lactobacilli could enhance protection 
and improve treatment of intestinal infections, food allergy and colon cancer by 
inducing or reducing levels of distinct cytokines. But apparently, oral lactobacilli can 
also influence non-mucosal disease sites, like autoimmune diseases affecting the joints 
or cancer of the pancreas and bladder. Figure 1 shows which cytokines positively 
influence certain disorders when their expression is altered by oral administration of 
lactobacilli. 
Effect of lactobacilli on cytokine expression in infection 
It has been extensively reported that lactobacilli have probiotic effects (i.e. beneficial 
effects by improving the properties of the indigenous flora) which enhance protection 
against infections (Perdigon et al., 1995, partially reviewed by Salminen et al., 1996). 
These effects could be due to activation of innate immune defence effector functions 
(e.g. macrophages) andlor to support of the specific response against infectious agents 
by upregulation of IgA production. These two pathways are discussed below. 
Many studies have shown that different strains of lactobacilli are able to activate 
macrophages ill vitro and ill vivo (Lehman et al., 1988; Nanno et al., 1989; Perdigon et 
al.,1986; Pool-Zobel et al.,1996; Tomita et al.,1993). Lactobacilli induce cytokines 
produced by macrophages, TNF-a, IL-l, IL-6, IL-12 andlor IFN-alB, in macrophage 
cell lines, human blood monocytes, spleen macrophages, Peyer's patch (PP) adherent 
cells or peritoneal macrophages (Table 4)(Kitazawa et al., 1992; 1994; Klebanoff et 
al., 1999; Marin et al., 1998; Murosaki et al., 1998; Popova et al., 1993; Shida et al., 
1998; Tomita et al., 1993). Since IFN-y is the major macrophage-activating cytokine, 
induction of this cytokine by lactobacilli provides indirect evidence of 
macrophage-activating properties of lactobacilli (Laffineur et al., 1996; Murosaki et 
al., 1998; Shida et al., 1998; Solis-Pereyra et al., 1997). Intraperitoneal administration 
23 
Gelleral illtrodllctioll 
ORAL 
TOLERANCE 
ORAL LACTOBACILLI 
gut lumen 
REDUCTION 
JgE 
STIMULATION 
JgA 
ACTIVATION 
MACROPHAGES 
D ~() D D 
Prevention/treatment Protection/treatment Tumour Prevention/treatment 
autoimmune disease infection inhibition food allergy 
Figure 1. Modulation of c)'tokines by oral administration of lactobacilli call affect disease. 
Oral administration of lactobacilli can modulate cytokine expression in the gastrointestinal tract and 
possibly elsewhere in the body. By inducing (lined arrows) and/or reducing (broken arrows) expression of 
one or more cytokines positive effects on infection and disease may be achieved, Enhancement of oral 
tolerance towards orally administered soluble (auto)antigens, even in the periphery, could limit 
autoimmune disease. Stimulation of IgA production and macrophage activation might improve protection 
against pathogens that enter via the gastrointestinal tract. The cytotoxic action of macrophages can inhibit 
tumour-growth. Reduction of IgE levels has positive effects on food allergy. 
of L. casei cell wall, leading to macrophage activation, is now being used as a model 
for Kawasaki disease (cardiac arteritis)(Okitsu-Negishi et al., 1996; Tomita et al., 
1993; Lehman et al., 1988). When lactobacilli are added to ill vitro cultures of mixed 
cell populations like splenocytes or human PBMC, upregulation or 110 effect on 
expression of IL-12, IL-l, IL-6, IFN-alB, IFNy and TNF-a was found (Laffineur et 
al., 1996; Matsushima et al., 1998; Miettinen et al., 1996,1998; Murosaki et al., 1998; 
Shida et al., 1998; Solis-Pereyra et al., 1997). This could reflect activation of the 
monocyte lineage, but may also be (partially) due to modulation of lymphocytes. The 
peptidoglycan layer of lactobacilli is able to activate macrophages to produce IL-l, 
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IL-6 and TNF-a by binding to the CD14 receptor (e.g. Schrijver et al., 1999). 
However, there is some discrepancy between studies as to whether it is the 
peptidoglycan layer which is responsible for macrophage activation (de Ambrosini et 
al., 1996). III vivo administration of lactobacilli can also result in activation of 
macrophages. In different studies one or more of the cytokines IL-12, IL-I, TNF-a 
and IL-6 were upregulated by peritoneal macrophages after oral, intramuscular or 
intraperitoneal administration of the lactobacilli (Table 5)(Murosaki et al., 1998; 
Okitsu-Negishi et al., 1996; Popova et al., 1993; Saito et al., 1987). Although almost 
all Lactobacillus strains could activate macrophages, the extent of cytokine induction 
differed between strains. TNF-a was also induced in the gut after oral administration 
of different Lactobacillus strains (Maassen et al., 1999b). Significantly increased 
numbers of TNF-a producing cells in the gut villi and in the submucosa were 
demonstrated by immunohistochemistry after feeding BALB/c mice with L. reuteri 
(Chapter 2.2). 
Lactobacilli can affect infection by macrophage activation (immune 
elimination), but also by stimulating IgA production (immune exclusion). It has been 
shown previously that lactobacilli are able to upregulate IgA production, locally as 
well as systemically (Perdigon et al., 1991; Link-Amster et al., 1994; Kaila et al., 
1995; Majamaa et al., 1995). This is probably linked to upregulation of one or more 
cytokines. For instance, TGF-Il is necessary for the isotype switch to IgA (reviewed by 
Brandtzaeg, 1995). Terminal differentiation of B cells into plasma cells in the 
secretory tissues involves cytokines such as IL-5, IL-6 and IL-IO and possibly IFN-y. 
These cytokines can all be produced by mucosal T-cells (Nilsen et al., 1995). Little is 
known about the cytokine profile or other microenvironmental requirements for the 
enhancement of J chain production by mucosal B cells, a necessary component of 
secretory IgA and IgM. Probably IL-2, IL-5 and maybe IL-6 are involved in its 
upregulation, whereas IL-4 may have an opposing effect (Brandtzaeg, 1994). In a 
T-cell line the expression of IL-2 and IL-5 was enhanced by L. bulgaricus (Marin et 
aI., 1998), possibly correlating with the upregulation of J-chain expression by plasma 
cells (Table 4). In other cultures no effect or an increased expression of IFN-y, IL-2, 
JL-4, IL-6 and IL-IO was measured (Table 4). It is noteworthy that JL-4 levels 
remained either unaffected or were down-regulated. This is consistent with the results 
found ill vivo when, after intraperitoneal or oral application of lactobacilli, JL-4 levels 
were down-regulated (Table 5)(Kato et al., 1998; Maassen et al., 1999b; Matsuzaki et 
al., 1998; Murosaki et al., 1998b). In conclusion, lactobacilli may reduce infection by 
modulation cytokine expression. 
In tumour growth 
Lactobacilli show anti-tumour effects not only in rodents, but also in humans. In 
particular, intralesional injection of lactobacilli effectively inhibits tumour growth 
(lung carcinoma)(Masuno et al., 1991), but also oral administration of lactobacilli can 
prevent tumour growth (colon/bladder cancer)(Aso et aI., 1995). JL-l and TNF-a 
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Table 4a LactobaciJIus strains affect cylokille expression in vitro 
(Possible) effect of Lactobacillus strains Technique used Ref. lactobacilli 
L. acidophilus DDS-J 
anti-tumour L acidophilus NRRL 6934 culture! ELISA 1 L acidophillls NRRL B4527 
L. acidopliillls NRRL 0734 
immunomodulation L. buigariclls Lr 78 culturc/ ELISA 2 L. buigariclIs NCK 231 
prevention IgE- L. casel Shirota culture! ELISA 3 
mediated allergy 
influence on vaginal 
physiology and host L. crispatlls culture! ELISA 4 
defense 
induction of L. case; (cell wall) culture! immunoradiometry (lNF-a) 5 
cnrdioangitis cuiture! ELISA (IL-l S, INF-y) 
resistance against L. bulgaricus thymocyte proliferation! 6 bacterial infections (lysozyme lysate) imlllll 00-fluorescence 
physiologically L gasseri culture! 50% plaque reduction! 7 functional food neutralization. rt-peR 
physiologically L. acidophilus (4 strains) culture! neutralization 8 functional foods 
prevention! treatment L. plolltanlm L-137 culture! ELISA 9 
of food allergy 
prevention IgB- L. case; Shirota 
culture! ELISA 3 
mediated allergy L. joJmsollii JCM 0212 
induction of pulpit is L. case; (peptidoglycan) rt·PCR JO 
immunomodulation L. hlilgaricus culture! immunoradiometry II 
immunomodulation L. heivelicus 5089 (medium) culture! ELISA 12 
L. paracasei ssp paracasei E506 
L partlcasei ssp paracasei E510 
L. acidophillis E507 
culture! ELISA. immunomodulation L pltllltanim E98 Northern blot 13,14 L. rlwl1l11osliS E509 
L rhamllosus GG E522 
L buiJUlriclls E585 
immunomodulation L buigariclis Lr 78 culture! ELISA 2' L. blligariclls NCK 231 
Tables 4a and 4b show an overview of studies on the in vitro effects of Lactobacillus strains on 
cytokine expression. From top to bottom the analyzed cytokine producing cells are divided into 
macrophages, mixed cell populations and T-cells. All experiments were performed with material from 
mice or humans. The experiments using human material are indicated in the column with cytokine 
producing cells. Northern blotting and rt-PeR were used to determine mRNA levels of cytokine 
genes. The cytokines analysed are indicated by I (inducJion), I (inhibition) or - (no effect). 
References including remarks: IRangavajhyala et al.. 1997 (L acidophilus DDS-1 far best inducer); 2Marin ct 
aI., 1998; lShida et al.. 1998; 4K}ebanoff et al.. 1999; sTomita et al.. 1993; 6Popova et al., 1993; 7Kitazawa et al.. 
1994; 8Kitazawa et aI., 1992; 9Murosaki et aI., 1998; IOMatsushima ct al., 1998; IISolis-Pereyra cl al.. 1997; 
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Table 4b. Lactobacillus strains affect cyfokille expression in vitro 
Lactobacillus strains Cytokine producing Cytokines analyzed Ref. 
cells analyzed 
\" \" \" \" ~ ~ ~ \" ~ \" \" Z N ~ Q ~ '" v. 0, 
'" Q 8. -< 0 
'" 
L. addophilus DDS-J I I 
L acidophillls NRRL 6934 macrophage cell line I I 1 L. acidophifus NRRL 84527 (RAW 264.7) 1 1 
L. acidonhilus NRRL0734 1 1 
L. blt/garlclls Lr 78 macrophage ceHline 1 I 2 L. bu/gariclts NCK 231 (RAW 264.7) 1 I 
L. easel Shirota macrophage cells J774.1 1 3 
L. crispatffs macrophage cell line 1 1 4 (THP-I) 
L. easel (cell wall) human blood monocytes 1 I 5 
L. buigaricils human blood monocytes 1 1 6 (lysozyme lysate) 
L. gasseri spleen macrophages 1 - 7 PP adherent cells 1 . 
L. acidopliilus (4 strains) peritoneal macrophages 1 8 
L. plantan/III L-137 peritoneal macrophages 1 9 
splenocytes 1 1 
L. casei Shirola 
splcnocytes 1 1 I 1 3 L. jo/msonii JCM 0212 . . . 
L. easel (peptidoglycan) dental pulp cells 1 10 
L. bulgaricus humanPBMC 1 1 1 II 
L. heiveticfls 5089 (medium) humanPBMC I I 12 
L. paracasei ssp parac.E506 1 
L. paracasei ssp parac.E510 . 
L. acidophilffS E507 1 13, L. pialltamm E98 humanPBMC 1 1 14 L. rhamllosus E509 1 1 I I 1 1 
L. rhamllosus GG E522 1 1 1 I 1 I 
L. bulgariclfs E585 . 1 1 1 1 
L. bulgariclfs Lr 78 T-heJper cell line 1 I 
2' L. bulgariclfs NCK 231 (EIA.IL·2) 1 1 
12L.'lffineur et aI., 1996 (in 2 out of 4 strains); 13Miettinen et aI., 1998; 14Mietlinen et aI., 1996 (fixed bacteria: no 
cytokine induction, IL-18 induced by L ralmmosus and L. bulgan'clfs, other strains not tested) '" only with 
co-stimulation by phorboI12-myristate-13-acetate. 
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Table Sa. Lactobacillus straills affect cylokille expressioll in vivo 
(Possible) effect of Lactobacillus strains Route Technique used Ref. lactobacilli 
resistance bacterial L. bulgariclls thymocyte proliferation! I infections (Ivsozvrne lysate) po immunofluorescence 
anti·infcclion L. casei Y1T9018 im JH thymidine incorporation 2 
culture! ELISA (TNF~"), 
induction of L. casei (cell wall) ip proliferation of B3B I cells 3 
cardioangitis (lL-6), Northern blo. (lL-lB, 
TNF~") 
prevention! treatnient L. plamamlli L~137 ip culturel ELISA 4 
of food allergy 
L. casel 
L. acidophillfs 
probiotic L. hel~'eticlls POy culture! ELISA 5 
L. gasseri 
L. reuteri 
reduction CIA L. case; Shiro/a po y culture! ELISA 6 
prevention JDDM L. easel DO flV culture! ELISA 7 
treatment NIDDM L. casel DOny culturel ELISA 8 
inhibition of IgE L. case; SIJirofa po flV culture! ELISA 9 production 
anti-tumour L. easei Shirota ipl culture! ELISA, rt-PCR 10, II 
L. rellteri 
L. brevis 
L. gasseri 
immunomodulation L. murilles inununohistochemistry 12 L. plalllamlll NelB POy 
L. plal/lamlll 14917 
L. easei 
L. (enllentll11/ 
immunomodulation L. brevis ssp. coagulalls po y 2'-5' A synthetase 13 
! DO nv 
treatment neoplastic L. bulgaricfls po ELISA 14 disease (lysozyme lysate) 
food processing L. bulJ!llriclIs in ELISA 15 
anti-Trichinella L. easei ip v ELISA 16 
spiralis infection 
prevention! treatment L. plalllarum L-137 ip ELISA 4 
of food allergy 
I jH thymidine incorpomtion 
10, 
anti-tumour L. casei Y/T9018 iI (lL-I, IL-2), ELISA (IFN~y), 
cvtoslasis (TNF-a) 17 
Tables 5a and 5b show an overview of studies on the ill vivo effects of Lactobacillus strains on 
cytokine expression. From top to bottom the analyzed cytokine producing cells are divided into 
macrophages, mixed cell populations, T-cells and soluble components. All experiments were 
performed in mice or humans. TIle experiments in humans are indicated in the column with 
cytokine producing cells. The route of administration is indicated as follows; orally (po), 
intramuscular (im), intraperitoneally (ip), intrapleural (ipl), intralesional in the lung of tumour-
bearing L. casei primed mice (i1). Where known it was indicated whether viable (v) or non-viable 
(nv) lactobacilli were used. Experiments which demonstrated that lactobacilli had no effect on 
cytokine expression are not included in this table. Experiments in which mixed bacterial cultures 
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Table Sb. Lactobacillus strains affect cylokille expression in vivo 
Lactobacillus stmins Cylokine producing Cytokines analyzed Ref. 
cells analyzed 
I;' I;' I;' I;' ~ ~ ~ I;' ~ ~ I;' I;' ~ ~ Q t;; '0 '" ::; '" Q 
"-
-< 
'" 
L. blligariclfs peritonealmacrophages 1 I (lysozyme Iysale) 
L. case; YfF9018 peritoneal mncrophages 1 2 
L. casei (cell wall) peritoneal macrophu.l!;es I 1 1 3 
L. pial//amlll 1.-137 peritoneal macrophages I 4 
splenocvtes 
-
1 
L ellsei I 
-
1 
L. acidophillis I I 1 
L helve/iells peritoneal leukocytes 
- -
I I 5 
L. gasser; 
-
I I 
L. refller; 
-
I I 
L. case; Shiro/a splenocytes I 6 
L case; spleno~ytes I 1 1 7 
L. case; spleno~ytes I I 8 
L. casei Shiro/a splenocytes 1 1 1 I I I I 9 
f.,. case; Shirola thoracic exudated cells 1 1 1 1 1 10, II 
L. rellfer; 
-
1 I 1 
- -
L. brevis 
-
1 1 
-
-
L gasser; 
-
I 
- -
-
L. IIlflrilies gut villi 1 - - - 12 L p/(mlantm NelB 
- -
1 
- - - -
L plallfarum 14917 
- -
1 
-
- -
L. case; 
-
1 
- - -
L. Ierll/elllum 
- - -
L. brevis ssp. coaglliolls (v) humanPBMC 1 13 (ny) 
-
L. bllfgariclfs 
serum 1 14 (Ivsozyme lysate) 
L. bu/f;:ariclls senlln 1 1 15 
L. casei serum 1 16 
L. plal/tamlll L-J37 serum 1 4 
/" casei YlT9018 peritoneal exudate 1 1 1 I 10, 17 
were used and where the effect of lactobacilli could not be positively identified were also excluded. 
3H~thymidine incorporation in cells dependent for their growth on the cytokine of interest, was used 
as a measure for specific cytokine production of the effector cells. Northern blotting and rt-PCR were 
used to determine mRNA levels of cytokine genes. TIle cytokines analysed are indicated by 1 
(induction), I (inhibition) or - (no effect). References including remarks: IPopova et aI., 1993; 2Saito et 
al., 1987 (only with infection); 30kitsu-Negishi et a!., 1996 (depictcd results obtained from experiments done in 
BALB/c, in C3H/HcJ mice no cytokine induction); "Murosaki et aL, 1998; s-rejada-Simon et aI., 1999 (no effects 
detected in sF,lenocytes and Peyer's patches); 6Kalo et a!.. 1998 (only after collagcn immunization); 7Matsuzaki et 
at, 1997a; Matsuzaki et aI., 1997b; 9Matsuzaki et aI., 1998; IOMalsuzaki, 1998; IIMatsumki et al., 1996; 
12Maassen et al., 1999b; 13Kishi ct al., 1996; 14Davidkova et al., 1992; ISPcreyra et ai., 1991; 16Bautista-Garfias et 
al.. 1999; 17Matsuzaki et al .• 1990. 
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secreted by macrophages exhibit cytostatic and cytocidal effects on several tumour 
cell lines il/ vitro (Onozaki et al .• 1985; Urban et al., 1986). It is thought that the 
tumour-suppressive activity of lactobacilli is dependent on the activation of 
macrophages producing IL-l and TNF-cx (Table 4 and 5)(Davidkova et al., 1992; 
Matsuzaki et al., 1996; Matsuzaki, 1998; Rangavajhyala et al., 1997). IFN-V not only 
activates macrophages but also natural killer cells, which can nonspecifically kill 
tumour cells. Therefore, induction of IFN-V by lactobacilli could positively affect 
anti-tumour activity. 
In autoimmunity 
Many of the autoimmune diseases are chronic inflammatory disorders mediated by 
Thl cytokines, such as IFN-V and TNF-a (Liblau et al., 1995; Powrie and Coffman, 
1993). As discussed in section 1.4, oral administration of the autoantigen can 
prevent/treat experimental autoimmune diseases. Immune deviation towards Th2fTh3 
can be the mechanism of oral tolerance. Because large amounts of autoantigen are 
necessary to skew the response towards the non-inflammatory side, a local 
environment more permissive for this type of response is desirable. Treatment with 
Lactobacillus strains that stimulate production of TGF-Jl, IL-IO and IL-4 locally in the 
gut could possibly enhance tolerance induction against autoantigens. Unfortunately, a 
Lactobacillus strain with these inducing properties has not been identified yet. Only 
L.casei tended to enhance expression of both IL-IO and TGF-Jl in the gut villi upon 
oral administration in mice, but these increases were not significant (Maassen et al., 
1999b). Down-regulation of the Thl pathway can also be beneficial. Several reports 
show that Lactobacillus strains can positively affect experimental autoimmune 
diseases, such as arthritis and diabetes. In these studies at least IFN-V was down 
regulated after oral administration of lactobacilli (Kato et al., 1998; Matsuzaki et al., 
1997a; Matsuzaki et al., 1997b). 
In food allergy 
Food allergy is thought to be caused by production of 19B against dietary antigens in 
atopic individuals, due to inappropriate generation and activation of Th2 cells. The 
Th2-type cytokine IL-4 not only induces switching of B cells to 19B-producing cells, 
but also inhibits the production of the Thl-type cytokine IFN-V (Gascan et al., 1991; 
Peleman et al., 1989; Pene et al., 1988). Conversely, IFN-V inhibits the proliferation of 
Th2 cells and suppresses the switching of B cells. JL-12 is known to stimulate Th I 
cells to produce IFN-V, resulting in inhibition of Th2-type of immune responses, but 
IL-12 is also capable of preventing Th2 responses independently of IFN-V (Kiniwa et 
ai., 1992). Lactobacilli that induce IL-12 and/or IFN-V could therefore help to prevent 
or treat 19B-mediated food allergy. From Table 4 and 5, it is clear that some strains are 
able to induce IL-12 or IFN-V, and sometimes both. When L. casei Shirota was 
administered orally, the Th2 response against OVA, which was injected i.p, was 
skewed towards a Th1 response, also reducing the OVA specific 19B response (Shida 
et al., 1998). Bven intraperitoneal administration of L. plal/tam/ll L-137 reduced 
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casein specific 19GI and 19E titers in casein fed mice (Murosaki et al., 1998). This 
indicates that lactobacilli can have a role in treatment of food allergy (Shida et al., 
1998). 
Concluding remarks 
Clearly, selected Lactobacillus strains are able to modulate immune responses by 
affecting cytokine expression ill vitro and ill vivo, thus having the potential to suppress 
infection, autoimmunity, cancer and allergy. The most prominent feature of 
lactobacilli is that most strains can induce TNF-a, probably correlating with activation 
of macrophages. Although for most tested cytokines either no induction or enhanced 
expression was found, especially the data for cytokines IL-6 and IFN-y were 
conflicting. This is probably due to the use of different mouse strains (Okitsu-Negishi 
et al., 1996), routes of administration, doses, bacterial viability and effector cells in 
individual studies. For instance, L. casei Shirota showed opposite effects in different 
experimental set-ups (Kato et al., 1998; Matsuzaki et al., 1996; 1998; Matsuzaki, 
1998). On the other hand, various Lactobacillus strains within the same experiment 
differentially affected cytokine expression, indicating that the obtained effect also 
depends on the Lactobacillus strain used (Maassen et al., 1999b; Miettinen et al., 
1996; 1998; Shida et al., 1998; Tejada-Simon et al., 1999). 
The levels of induction/reduction of cytokines vary greatly and are difficult to 
compare due to different techniques used. Furthermore, it is difficult to estimate the 
impact of up- or down-regulation of a particular cytokine ill vivo. This hampers 
accurate investigations into application of lactobacilli for prevention or treatment of 
disease. Since many pathogens enter the body via the gastrointestinal tract, it is likely 
that the local cytokine profile at those sites is decisive for the kind of response. Some 
reports show that Lactobacillus strain induced cytokine expression is directly 
correlated with disease inhibition. Further study is needed to determine the effects of 
lactobacilli at the effector sites, including a complete as possible local cytokine 
profile. The cytokine profile induced by a particular Lactobacillus strain after oral 
administration may be crucial to decide which strains can be used as a probiotic, but 
also for other applications, such as oral vaccination with recombinant Lactobacillus 
strains and recombinant Lactobacillus strains as therapeutics in autoimmune disease. 
Lactobacillus straill selectioll 
Whether oral administration of recombinant lactobacilli expressing a pathogenic 
antigen or autoantigen results in the desired immune response does not only depend on 
the level of expression, location of expression (intracellularly, surface anchored or 
secreted)(discussed below), dose of lactobacilli and frequency of administration, but 
also the Lactobacillus strain used can be of major importance (Maassen et al., 1999a; 
Pouwels et al., 1996). The large genetic and physiologic diversity of this genus in 
many properties allows selection of the most appropriate strain for oral vaccination 
purposes as well as for oral tolerance induction. As discussed in the preceding sections 
Lactobacillus strains can influence the immune response by modulation of cytokine 
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expression. In addition, Lactobacilllls strains may differ in many more properties such 
as colonization/persistence, immunogenicity and intrinsic adjuvanticity, here defined 
as the property to enhance the humoral response against a parenterally administered 
antigen. Althongh probably all Lactobacilllls strains can maintain a stable population 
in germ-free animals or can colonize the human gut when applied at very young age 
before the gut flora is established, only some strains are able to persist for a longer 
time when administered to man or animal with a normal gut flora. Concerning 
intrinsic immunogenicity, it has been shown that lactobacilli can be found in the 
Peyer's patches (Claassen et al., 1995), suggesting presentation to the mucosal 
immune system, but so far, none of the tested strains did evoke a high humoral 
immune response against itself after oral administration (Gerritse et al., 1990). In 
order to select the best suitable strains and that way enhance the effectiveness of the 
Lactobacilllls antigen delivery system for the use in vaccination and tolerization, 
several of the above mentioned properties have been investigated in this thesis. 
Vector desigll 
The expression vectors available for lactobacilli can direct the heterologous 
protein to the microenvironment (secretion), to the surface of the lactobacilli (surface-
anchored expression) or retain the heterologous protein in the cytoplasm (intracellular 
expression). The location of the heterologous antigen may influence for example 
adherence, access to enterocytes or M-cells and preferential uptake by different APC. 
As suggested in the preceding sections, Lactobacilllls strains can be used as delivery 
system in two distinct applications. They can be used as delivery system of pathogenic 
antigens in oral vaccination as well as delivery system of antoantigens in order to 
induce oral tolerance in autoimmune diseases. The success of these approaches 
depends on the appropriate presentation of the (auto)antigen at the mucosal immune 
system, leading to mucosal/systemic immune response or to systemic T cell tolerance, 
dependent on the application. Vector design may help to direct the inunune response 
towards the desired immune response. However, it is unknown in what wayan orally 
administered Lactobacilllls strain has to present the antigens to the immune system. 
There are several methods of antigen presentation possible, dependent on the design of 
the vector. 1) The antigen is secreted by the lactobacilli in the gut. 2) The antigen is 
expressed intracellularly and is released from the cytoplasm of the lactobacilli upon 
death and cytolysis. Both methods lead to soluble antigen in the gut, which normally 
induces non-responsiveness towards the antigen. 3) The antigen is expressed 
intracellularly and presented to the GALT after processing of the lactobacilli by 
antigen presenting cells. 4) The antigen is expressed on the surface of the lactobacilli 
and is presented to the GALT as a particulate antigen. Theoretically, this seems the 
best option for the induction of a good immune response against a pathogenic antigen. 
Nevertheless, the most efficient route of antigen presentation for both applications in 
combination with an appropriate Lactobacilllls strain has to be revealed by ill vivo 
experiments. 
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1.6 Introduction to chapters 
The aim of the study was to develop an antigen-specific therapy for EAE based on oral 
tolerance induction by recombinant lactobacilli. Before testing this approach in animal 
models, a suitable Lactobacillus strain had to be chosen and transformed to express 
myelin antigens. 
Chapter 2. Properties of wild type Lactobacillus strains: sirain selection for mucosal 
tolerance induction and mucosal vaccination plllposes 
Lactobacilli are attractive candidates for mucosal vaccination as well as for mucosal 
tolerance induction purposes. The large Lactobacillus genus and the diverse effects of 
its different species and strains on the immune system, necessitates careful selection of 
an appropriate strain for either of both purposes. In order to make a more directed 
Lactobacillus strain selection, several properties of wild type Lactobacillus strains 
which may have implications for induction of tolerance or immunity were 
investigated. Chapter 2.1: In this chapter the potential of recombinant lactobacilli in 
tolerance induction by oral administration of recombinant lactobacilli was shown. Just 
mixing autoantigen with a particular Lactobacillus strain did not affect the EAE 
disease course. However, oral administration of the wild type Lactobacillus strain 
alone had an adverse effect on EAE. 
Chapter 2.2: The local cytokine environment in the gut plays a role in the 
effectiveness of inducing oral tolerance or immunity. Therefore the effect of orally 
administered wild type Lactobacillus strains on cytokine profiles in the gut villi was 
determined by immunohistochemistry. Some Lactobacillus strains were able to induce 
cytokines such as IL-2, IL-Ill and TNF-a. In the same chapter the enhancement of the 
specific humoral response against a parenterally administered T-cell dependent 
antigen by orally administered Lactobacillus strains (adjuvanticity), was investigated 
in Th2-biased BALB/c mice. The Lactobacillus strains that induced the 
abovementioned cytokines also showed adjuvant activity. 
Chapter 2.3: Four of the Lactobacillus strains analyzed in chapter 2.2 were 
analyzed in a similar experimental set-up for their adjuvant activity in Thl-biased 
SJLlJ mice. In this mouse strain no adjuvant activity could be detected, but further 
analysis of the antibody responses evoked in the SJLlJ mice revealed a growth phase 
dependent effect on the IgG lIIgG2a ratio. This indicates a growth phase dependent 
skewing of T cell pathways by orally administered Lactobacillus strains. 
Chapter 3. Genetic engineering of Lactobacillus strains 
Based upon the results described in chapter 2, a choice was made which Lactobacillus 
strain to transform with myelin antigens for the use in mucosal tolerance induction 
experiments in EAE. 
Chapter 3.1: This chapter describes the development of vectors allowing 
expression of heterologous antigens by lactobacilli. It was shown that dependent on 
the vector, the heterologous proteins are indeed directed to the surface of the 
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bacterium, secreted into the environment or retained intracellulariy. Parenteral 
immunization of recombinant lactobacilli evoked specific antibody responses against 
the expressed antigens, confirming expression of the antigen by the lactobacilli. 
Chapter 3.2: Because most of the Lactobacillus strains did not readily accept 
plasmid ligation mixtures for transformation, intact plasmids needed to be purified 
from L. casei, in order to transform other Lactobacillus strains. In this chapter an easy 
and rapid method is described to isolate plasmids from lysis-resistant lactobacilli. 
Chapter 4. Mucosaltolerallce illduction with recombinantiactobacilli 
In the last experimental part of this thesis we combined the results obtained in the 
previous chapters to induce mucosal tolerance with recombinant lactobacilli. We 
selected Lactobacillus casei based on its effects on the immune system (intrinsic 
adjuvanticity, intrinsic immunogenicity, induction of cytokine profile)(chapter 2). A 
panel of recombinant L. casei expressing myelin antigens was generated and analyzed 
(chapter 3.1). A selection of recombinants was tested for its ability to reduce EAE 
(chapter 4.2). 
Chapter 4.1: Before the effectiveness of recombinant lactobacilli expressing 
myelin antigens in preventing EAE by mucosal administration could be investigated, a 
dose response analysis was performed with PLP!39.151 for the induction of EAE. This 
was done in order to select a dose of PLP!39.151 that induced medium disease severity, 
permitting modulation. 
Chapter 4.2: In this chapter we provide 'proof of principle' that it is possible to 
reduce EAE by mucosal administration of recombinant lactobacilli expressing myelin 
antigens. It was demonstrated that nasal administration of Lactobacillus extracts 
containing myelin antigens could reduce the EAE disease burden when administered 
prior to disease induction. In addition, it was demonstrated that live recombinant 
lactobacilli expressing myelin antigens were able to reduce the EAE disease burden 
when administered orally prior to disease induction. 
The nasal tolerance experiments in the Lewis rats were performed in an EAE 
model not previously used for nasal tolerance induction. In addition, we demonstrated 
that nasal administration of purified MBP could enhance the disease burden in this 
EAEmodel. 
Chapter 5. Summarizing discussioll 
The discussion stalis with the rationale behind the Lactobacillus strain selection for 
mucosal tolerance experiments in EAE. This is followed by a discussion about 
intranasal versus oral tolerance induction. In the subsequent part is discussed what 
might happen after oral administration of recombinant lactobacilli. Finally, approaches 
for future development of this approach for clinical use are discussed. 
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Chapter 2.1 
Lactobacillus as a vector for oral delivery of antigens: 
The role of intrinsic adjuvanticity in modulation 
of the immune response 
C.B.M. Maassen, K. Gerritse, R.J. Leer, D. Heemskerk, 
W.J.A. Boersma and E. Claassen 
In: Mucosal solutions; Advances in mucosal immunology, part 2, Husband AJ 
ef al. editors, 1998, The University of Sydney, Sydney, Australia 
Immune modulation by lactobacilli 
Summary 
Oral deliveJY of antigens under specific conditions induces systemic illlmuno-
tolerance. For this plllfJose non-pathogenic genetically engineered lactobacilli can be 
used as deliveJY vehicles. The intrinsic adjuvant activity of LactobaciIlus strains 
could playa role in tolerization versus induction of immune responsiveness. To 
assess whether a soluble antigen orally delivered by a particulate vehicle can 
suppress the systemic immune response, we orally administered j3-galactosidase 
expressed in Lactobacillus plantarum 80, a strain with relatively low adjuvanticity. 
This was followed by an i.p. immunization with j3-galactosidase. The pre-treatment 
led to a suppression of the anti-galactosidase antibody response, indicating that oral 
antigen deliveJy by a Lactobacillus strain with low adjuvant properties can have 
down modulatory effects. 
To assess whether ill a mouse autoimmune model lactobacilli can promote 
tolerance induction, we orally co-administered Lactobacillus casei, a strain with a 
relatively high adjuvant activity, with an encephalitogenic PLP peptide. After this 
pre-treatment of SJL mice, experimental autoimmune encephalomyelitis (EAE) was 
induced with the same peptide. This treatment did not result in tolerance, but instead 
enhanced this autoimmune disease. 
77,is study indicates that the intrinsic adjuvant activity of Lactobacillus strains 
affects the immune response in a stimulating or inhibiting manner, ill conjunction 
with the dose and character of the antigen This has implications for vaccine 
development for infectious diseases and therapy of autoimmune disease. 
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Introduction 
Recent developments have brought clinical application of the modulation of the 
immune system within reach. Application is for example the enhancement of the 
immune response for vaccines for infectious diseases, while response suppression or 
tolerance induction against autoantigens may be the goal in therapy of autoimmune 
diseases. Systemic immune responses can be modulated via the gut associated 
lymphoid tissues (GALT) through oral administration of immunogenic or tolerogenic 
proteins. Immune stimulation by oral administration of antigen is safe and simple. 
Oral vaccines are advantageous in many aspects over vaccines parenterally 
administered. The gut mucosa forms a natural site for suppression or downregulation 
of the immune response against a.o. food antigens. This property may be taken 
advantage of for the treatment of autoimmune disease. It has been shown in rats and 
mice that it is possible to prevent experimental autoimmune encephalomyelitis (EAE), 
a model for multiple sclerosis, by oral administration of myelin proteins identical to 
those used for disease induction (Hafler and Weiner, 1995; Whitacre et ai., 1996a). 
Clinical trials suggest that MS patients could benefit from oral administration of 
autoantigen (Weiner et ai., 1993). 
The complexity of the antigen may be a major factor determining tolerance 
induction versus enhancement of the immune response. Soluble proteins are more 
likely to induce tolerance, whereas particulate antigens, like antigens expressed on the 
cell surface of bacteria tend to stimulate immune responses (Mondino et ai., 1996). 
But the modulatory effects of oral antigen administration also depend on other factors 
such as size, dose, immunization regimen of the antigen, the use of adjuvants and use 
of live or dead bacteria. 
An important obstacle in mucosal immune modulation is the difficulty in 
establishing effective local dosages of the antigen or tolerogen in the gut as a result of 
the risk of proteolytic degradation of the antigen. To prevent this degradation of 
antigens in the stomach and to improve the efficiency of oral immunization, specific 
protective carrier systems can be used. Inert particles but also transformed bacteria 
expressing antigens or tolerogens can fulfill this purpose. Additional advantages of 
the latter are the local production of the antigens at the gut mucosa and the intrinsic 
adjuvanticity. However, many bacteria are potential pathogens and are therefore not 
suitable for use in humans. An attractive alternative is the use of Lactobacillus 
strains, which are gram positive commensals of the human gut and which are 
generally regarded as safe (GRAS status). In previous studies we have shown that 
orally administered lactobacilli can be very efficient antigen carriers as reflected by 
enhanced antibody responses against the hapten TNP conjugated to the lactobacilli 
(Gerritse et ai., 1990; 1991). Furthermore, gene transfer and expression systems for 
efficient production of foreign antigens by a variety of Lactobacillus species have 
been developed recently (Posno et ai., 1991b; Pouwels et al., 1992). In addition, it has 
been shown that oral administration of lactobacilli can have immunostimulating 
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effects in humans (Isolauri et al., 1995). Several dairy companies use Lactobacillus 
strains in a new generation of health foods, because of the putative health-stimulating 
properties resulting from their intrinsic adjuvanticity. It should be emphasized that the 
Lactobacillus genus consists of a wide variety of species that among others share the 
property of the production of lactic acid, but have a wide variety in fermentation 
pathways, growth characteristics and cell wall composition. Consequently, they differ 
in their intrinsic adjuvant properties, although the mechanism of adjuvanticity is not 
known. 
In this study we investigated whether oral administration of two distinct 
ulctobacillus strains can be used to positively or negatively modulate the systemic 
immune response. In the first case we used a Lactobacillus strain with low intrinsic 
adjuvanticity as a vehicle for the antigen B-galactosidase. B-galactosidase was 
administered orally either as an expression product of Lactobacillus plalltarum 80 
(intracellular) or dissolved in PBS. Antibody responses were measured after 
intraperitoneal immunization with B-galactosidase. 
In addition we investigated whether a Lactobacillus strain with high intrinsic 
adjuvanticity, L. casei, could promote systemic tolerance induction. The effect of oral 
administration of L. casei with and without co-administration of PLP139.151 prior to 
EAE disease induction with the same peptide was studied. We discuss implications of 
our data for selection of appropriate Lactobacillus strains for vaccine versus tolerance 
induction approaches. 
Materials and methods 
COllstructioll of Lactobacillus plantarum 80 producillg E. colij3-galactosidase 
For the intracellular expression of B-galactosidase by Lactobacillus plalltarum 80 
(LP80), LP80 was transformed with pCBH72. To construct pCBH72, the promoter of 
the xylR gene in pLPCR2 (Carlsson and Bratthall, 1985; Forrest, 1988) was replaced 
by a fragment comprising the promoter of the conjugated bile acid hydrolase gene of 
Lacto8bacillus plalltarum 80 (LP80)(Christaens et al., 1992) followed by insertion of 
the E. coli lacZ gene, encoding for B-galactosidase into the multiple cloning site. 
LP80 was cultured and transformed by electroporation as described previously 
(Christaens et al., 1992). LP80 transformants were selected on solid MRS medium 
supplemented with 10 flg!ml erythromycin. B-galactosidase production was confirmed 
in the lysate of LP80 transformants by standard gel electrophoresis, western blotting 
and an enzymatic assay. B-galactosidase producing and non B-galactosidase producing 
LP were designated LP80+ and LP80-, respectively. The B-galactosidase expression 
levels in LP80+ were approximately 1-2% of total protein contents. 
Oral admillistratioll ofLP80+ alld immullizatiolllVithj3-galactosidase 
To assess whether oral administration of B-galactosidase expressed intracellulary in 
Lactobacillus plallfarum 80 (LP80+) induces suppression of a systemic antibody 
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response, six groups of three female BALB/c mice (10-12 weeks of age) received 
different doses of live LPSO+ (50, 100, 500 or 1000 flg dry weight) by intragastric 
intubation. As controls, wild type Lactobacillus plantarulII 80 (1000 flg dry weight 
LPSO-) or PBS only were administered by intragastric intubation. For a continuous 
delivery of antigen during a period of ten days, lactobacilli were administered (500 
fll) five times with a two day interval. At days 3 and 31 after the last oral 
administration all mice were immunized i.p. with S flg B-galactosidase in 200 fll PBS. 
This amount is the lowest dose of antigen sufficient to mount an anti-B-galactosidase 
semm Ig plateau level response after an i.p. booster injection in low dose 
B-galactosidase primed mice (data not shown). Semm anti-B-galactosidase responses 
were determined in a direct ELISA (see below). 
Adoptive transfer of spleen cells 
To assess whether, in an alternative experimental seUing, the results which were 
obtained by oral administration of LPSO+ were an intrinsic property of the lymphoid 
cells of the systemic immune system, an adoptive transfer to naive animals was 
performed. Spleen cells from mice pre-treated as stated above were injected into naive 
irradiated mice. Mice were sacrificed by CO, euthanasia and the spleens were 
removed. Erythrocytes were removed by standard ammoniumchloride treatment. Cell 
suspensions of individual spleens (500fll) were injected i.v. into naive 5 Gy irradiated 
recipient BALB/c mice (10-12 weeks old). Two days after cell transfer the mice were 
immunized with S flg B-galactosidase in 200fli PBS i.p. The sera were screened for 
anti-B-galactosidase antibody reactivity in a direct ELISA. 
ELISA 
PVC microtiter plates were coated with B-galactosidase in PBS (5 flg/mi, 50 fll/well) 
overnight at 4 C. Subsequently free sites were blocked for 30 min at 25 C with gelatin 
(0.5 mg gelatinlmi PBS, 50 fll/well) to prevent non-specific antibody binding. After 
washing with PBS-G (0.1 mg gelatin/mi PBS), the plates were incubated for 60 min at 
25 C with dilutions of immune sera. The plates were washed with PBS-G and 
incubated with alkaline-phosphatase labelled goat anti-mouse total IgM + IgG 
antibodies (KPL, Inc., Gaithersburg) for 60 min at 25 C. The plates were washed with 
PBS-G and incubated with para-nitrophenyl phosphate (I mg/mi 10 mM 
dietanolamine,1 mM MgCI" pH 9.S) as enzyme substrate. After incubation for 30 min 
at 25 C the absorption was determined at 405 nm. 
Peptide synthesis, purification and characterization 
The synthesis of the EAE-inducing PLP-peptide was carried out with 
9-fluororenylmethoxycarbonyl (f-moc) protected amino acids, using routine solid 
phase synthesis method with an automated Milligen 9050 Continuous Flow 
Synthesizer (Millipore Co, Bedford, MA, USA). The PLP-peptide is a 13-mer amino 
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acid sequence analogous to residue numbers 139-151 of the rat PLP sequence: 
NH2.His-Cys-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe-COOH. Side-chains 
were protected as follows: asparagine: 2,4,6-trimethoxybenzyl; histidine and cysteine: 
trityl; lysine: tertiar-butoxycarbonyl. Peptide cleavage and side-chain deprotection of 
the completed peptide were performed by trifluoracid treatment (Van Denderen et al., 
1987). Peptide purification was performed according to Shively (1986). Amino acid 
composition of the synthetic peptide was confirmed by HPLC analysis according to 
the method of Janssen et al. (1986). 
Oral administration of PLPJ39.151 and Lactobacillus casei ATCC393 
To assess whether oral administration of wild type Lactobacillus casei together with 
PLP139•151 has an effect on EAE, female SJUJ mice (12-15 weeks old, 8 mice per 
group) were pre-treated by oral administration of PBS only (group A), PLP peptide 
(group B and C), Lactobacillus casei (group D) or Lactobacillus casei and PLP139. 151 
(group E and F). For a continuous delivery of antigens during a period of ten days, 
administration of suspensions or solutions (500 III per administration) was repeated 
five times at two-day intervals. PLP-peptide was administered in two amounts: 100 Ilg 
(group B and E) and 500 Ilg (group C and F). Lactobacillus casei suspensions, 
administered to mice of group D, E and F, contained 5* 10' CFU per mouse per 
administration. EAE induction was performed three days after the last oral 
administration. The mice were followed until day 43. 
EAE induction after oral pre-treatment 
EAE induction was performed by s.c. injection of 150 Ilg PLP139-151 emulsified in 
CFA (100 Ill/injection site) at two sites in the abdominal flanks. The emulsion 
contained per 100 Ill: 25 Ilg Mycobacterium tuberculosis (H37RA, Difco) in 50 III 
CFA and 75 Ilg peptide in 50 III PBS. In addition each mouse was injected i.v. on day 
o and 2, with 200 III of a Bordetella pertussis suspension containing 2* I 010 bacteria 
in PBS. The severity of EAE clinical signs was evaluated each day according to the 
following criteria: Disability scale (DAS) grade 0 = no clinical signs, grade 1 = tail 
paralysis, grade 2 = mild paraparesis and ataxia of the hind legs, grade 3 = severe 
paraparesis or ataxia of the hind legs, grade 4 = moribund, grade 5 = death due to 
EAE (Gerritse et al., 1996). 
Results 
Oral administration of a Lactobacillus strain with low adjuvant activity producing 
j3-galactosidase. 
To investigate the immunomodulating properties of lactobacilli overproducing an 
intracellularly expressed heterologous antigen, we fed BALB/c mice up to Img LP80 
which either produce B-galactosidase or not. After the first i.p. immunization of 
B-galactosidase in pre-treated mice no specific anti-B-galactosidase Ig-total serum 
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responses were observed. After the second immunization, anti-fl-galactosidase seIUm 
antibody responses were measured with a maximum at day 8 (Figure 1). A reduction 
in the anti-fl-galactosidase seIUm responses was observed after the second 
immunization with fl-galactosidase in all groups of mice orally pre-treated with 
fl-galactosidase containing lactobacilli (Figure 1). The anti-fl-galactosidase antibody 
responses of the animals which received 50, 100, 500 and 1000 Ilg transformed LP80+ 
orally, were reduced with 64%, 51 %, 27% and 39% respectively as compared to the 
anti-fl-galactosidase response measured in control animals which received identical 
doses of non-transformed LP80. In conclusion, lower doses of fl-galactosidase 
administered orally by a Lactobacillus strain appeared to have better downmodulating 
effects than higher doses. 
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Figure 1. Allti-jJ-galactosidase alltibody resp01lses after oral administration of LP80, a strain with low 
adjuvant activity. 
The anti 8-galactosidase serum antibody responses on day 0,5,8 and 14 after the second 8-galactosidase 
immunization were measured in direct ELISA. The results are expressed as the average absorbance at 405 
11m of serum dilution 1/800 of three mice per group. The animals of the four test groups received 50, 100, 
500 and 1000 JIg Lactobacillus plantarum expressing fi·galactosidase (LP80+) orally, prior to two Lp. 
fi-galactosidase immunizations spaced 30 days apart. The animals of the control groups received wild 
type Lactobacillus piallfarum (LP80-) or PBS only, prior to two i.p. fi-galactosidase immunizations. 
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Post-transfer anti-j3-galactosidase serum antibody responses 
To confirm whether the reduction of the anti-B-galactosidase antibody response in the 
groups of mice pre-treated with LP80+ was due to the intrinsic property of the 
lymphoid cells, spleen cells of these mice were transfered to naive mice. Mice which 
received spleen cells of donor mice pre-treated by oral administration of LP80+ 
showed a decreased antibody response after a subsequent injection with 
B-galactosidase in three out of four test groups, as compared to mice which received 
spleen cells from mice pre-treated with PBS. The lowest anti-B-galactosidase 
responses were found in sera from mice, which received the spleen cells of donor 
mice orally pre-treated with a low dose of Il-galactosidase producing LP80+ (lOOl1g) 
(Figllre 2). The highest anti-B-galactosidase responses were observed in sera from the 
mice which received spleen cells of donor mice pre-treated with 500l1g LP80+. These 
donor mice showed the lowest reduction (27%) in anti-Il-galactosidase antibody 
responses after the second immunization with B-galactosidase before transfer. In 
contrast to the other three groups, the anti-Il-galactosidase responses of this group of 
PBS 
o 50 100 150 
Relative titer (percent) 
Figure 2. Relative allti-jJ-galactosidase titers after adoptive trallsfer of spleen cells of mice orally 
pre-treated wit" LP80'. 
Mice received spleen cells of mice pre-treated orally with LP80+, LP80' or PBS followed by two i.p. 
inununizations of fi-galactosidase. TIle anti fi-galactosidase serum antibody responses on day 8 after 
post-transfer B-galactosidase injection were measured in direct ELISA. The average titer of the control 
recipient animals which received the spleen cells of the PBS pre-treated donor animals was set at 100%. 
The results are expressed as the average of relative titers. Standard deviations are indicated. 
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recipient mice were not reduced as compared to the responses of both control groups 
of mice. These data partially confirm that the reduction of the immune response in 
mice pre-treated orally with lactobacilli expressing B-galactosidase is due to an 
intrinsic property of the lymphoid spleen cells. 
Role of high adjuvallticity o/Lactobacillus casei ill EAE inductioll 
To investigate whether oral administration of a Lactobacillus strain with high intrinsic 
adjuvant activity can promote tolerance induction of orally administered antigen, we 
orally co-administered wild type Lactobacillus casei and PLP139-1SIo prior to EAE 
induction with the same encephalitogenic PLP peptide. Oral administration of 
Lactobacillus casei only (group D) resulted in enhanced disease, as compared to the 
cOurse of disease in animals which were not pre-treated with Lactobacillus casei (A, 
Band C) (Figure 3). Animals which were pre-treated with PBS only (group A) 
followed by EAE induction developed a moderate form of EAE, with the highest 
average DAS score (1.38) at day 31. The peak levels of the DAS scores of animals of 
groups B (1.63) and C (1.75), which were pre-treated by oral administration of 
different doses of 100 and 500 Ilg PLP-peptide respectively prior to EAE induction, 
were reached on day 34 and 32 respectively. During the entire course of the disease, 
the average DAS scores of the animals of groups B (100 Ilg PLP139-1sIl and C (500 Ilg 
PLP139-151) were slightly higher than the animals of group A (PBS) (Figure 3). The 
oral administration of PLP139-151 simultaneously with Lactobacillus casei (groups E 
[100 IlgJ) and F [500 IlgJ) resulted in enhancement of EAE, comparable to 
administration of Lactobacillus casei only (E and F vs D) (Figure 3). Peak levels of 
average DAS scores of the animals of group E (3.14) and F (3.38) were slightly higher 
compared to group D (2.71) which received Lactobacillus case; only. 
Discussion 
We showed that oral administration of B-galactosidase produced by a Lactobacillus 
strain, with low adjuvant properties, may induce a state of peripheral immune 
suppression, reflected by a reduced anti-B-galactosidase antibody response after 
parenteral immunization with B-galactosidase. This finding was confirmed in an 
adoptive transfer of the spleen cells to naive recipient mice. In contrast, the oral 
administration of a Lactobacillus strain with high adjuvanticity, together with an EAE 
inducing peptide, results in stimulation of the system immune system as is reflected 
by EAE disease enhancement. These findings demonstrate that dependent on their 
intrinsic adjuvant properties, oral administration of different Lactobacillus strains can 
have either immune stimulating or immune inhibiting effects. 
The oral pre-treatment of BALBlc mice with the intact protein B-galactosidase 
expressed within Lactobacillus pialltart/III 80, prior to i.p. immunization with 
B-galactosidase, induced a reduction in anti-B-galactosidase antibody responses. The 
observation that small amounts of orally administered antigen were more efficient in 
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Figure 3. Role of high adjllVQlllicity o/Lactobacillus casei ill EAE i1lduction 
Mice were orally pre-treated with L. case; (group D), L. easel together with PLP139-ISI (group E and F), 
PLP139-1S1 only (group Band C) or PBS only (group A) prior to EAE induction with PLPI39_1S1' Oral 
administrations \verc performed on day 0, 2. 4, 6 and 8 (arrows). EAE was induced on day 10 (asterisk). 
TIle severity of clinical signs was evaluated every day according to the criteria as described in Materials 
and methods. The clinical signs are expressed as average DAS units per group per day. 
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inducing non-responsiveness as compared to large amounts of orally administered 
antigen suggests that low zone tolerance for B-galactosidase exists (Hafler and 
Weiner, 1995). In the present experiments only a state of incomplete low zone 
tolerance was observed. This might be explained by differences in antigen processing 
of intact lactobacilli with cytoplasmic B-galactosidase and free soluble B-galactosidase 
derived from lactobacilli degraded in the gastro-intestinal tract. It is noteworthy that 
live lactobacilli were used, and therefore B-galactosidase could also have been 
produced in the gut. The fact that the antigen probably was present in both particulate 
and soluble form, might have influenced immunological (un)-responsiveness. 
Rigorously controlled conditions are required for ill vivo modulation. To be 
able to evaluate up- and down modulatory effects of Lactobacillus strains on EAE 
disease course, a dose of the encephalitogenic peptide needs to be chosen, which 
induces a medium level of disease. To determine this dose, the intensity of disease 
was evaluated in a dose-response experiment with PLP139.151 (data not shown). Oral 
pre-treatment of SJL mice with Lactobacillus casei (group D) prior to EAE induction 
resulted in a considerable enhancement of disease (Figure 3) as compared to the 
course of disease of animals which were orally pre-treated with PBS (group A). We 
expected that oral pre-treatment with soluble PL,l'139.151 peptide alone would induce 
systemic immune tolerance in SJL mice. However, we did not find any reduction of 
the disease after oral pre-treatment with PLP139. 151 (group B and C). There even seems 
to be a slight enhancement of the disease. In the experiment with B-galactosidase 
described here, it has been shown that, among other factors the dose is of importance 
for the outcome. In the EAE experiment the dose of antigen but also the treatment 
regimen could be responsible for the absence of down modulatory effects of 
PLP139. 151 . When Lactobacillus casei was co-administered with PLP139.151 (group E 
and F) prior to EAE induction, a marked enhancement of disease (Figure 3) was 
observed as compared to animals which received the PLP peptide only (group Band 
C). The severity of clinical signs was similarly enhanced when Lactobacillus casei 
were orally administered with or without peptide (group D vs E and F). Therefore the 
enhancement of disease is most likely due to the high adjuvant properties of this 
Lactobacillus strain. . 
The adjuvant properties of lactobacilli may influence whether the immune 
system is activated or tolerized, upon oral delivery of a particular Lactobacillus strain 
expressing antigen. This suggests that dependent on the aim of the specific 
application an appropriate Lactobacillus strain needs to be chosen with respect to its 
adjuvant properties. The results implicate that for tolerance induction a Lactobacillus 
strain with no or low intrinsic adjuvant activity is the best choice for antigen delivery. 
In contrast, for immune stimulating approaches, like vaccines for infectious diseases, 
Lactobacillus strains with high intrinsic adjuvanticity are better candidates. It is clear 
that some Lactobacillus strains can exert non-specific immunostimulatory effects 
(adjuvanticity) (Bloksma et al., 1979). This seems mainly due to wall components of 
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the bacteria (Henderson et al., 1996). However, lactobacilli do not produce LPS and 
the mechanism (component) of adjuvant activity of lactobacilli is still unknown. 
Because immune-stimulating effects are easier to achieve with particulate 
antigens, we have constructed vectors for lactobacilli which are able to anchor (viral) 
antigens to the cell-surface of the lactobacilli. Probably, for the best immune 
stimulating results these vectors need to be transformed into Lactobacillus strains 
with high adjuvanticity. For vaccine applications vectors expressing virus epitopes on 
the cell-surface of the Lactobacillus casei have been made. In contrast, soluble 
antigens presented at the gut mucosa normally induce tolerance. We are currently 
developing Lactobacillus constructs which are designed to secrete the antigen, which 
could be applied to treat autoimmune disease. These vectors are being transformed 
into Lactobacillus strains with low adjuvanticity. The tolerizing properties of oral 
administration of low adjuving Lactobacilllls strains excreting myelin proteins on 
EAE will be investigated. For further optimalisation of the immunizationltolerization 
protocols the expression levels of antigens expressed by the lactobacilli need to be 
controlled and standardized. 
In conclusion, the results of this study indicate that lactobacilli are promising 
candidates for the delivery of immune stimulating signals for vaccine applications as 
well as for the induction of peripheral tolerance against putative autoantigens in 
human autoimmune diseases, depending on strain characteristics and expression 
levels of the (auto)antigens. 
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Strain dependent induction of cytokine profiles in the gut 
by orally administered Lactobacillus strains 
C.B.M. Maassen, J. c.P.A. van Holten, Francis Balk, 
M.I. Heijne den Bak-Glashouwer, R.I. Leer, J.D. Laman, 
W.I.A. Boersma and E. Claassen 
Vaccine, in press 
Cytokine induction by oral administration of lactobacilli 
Summary 
Different Lactobacillus strains are frequently used in consumer food products. In 
addition, recombinant lactobacilli which contain novel expression vectors can/lOW be 
used in immunotherapeutic applications such as oral vaccination strategies and in 
T-cell tolerance induction approaches for autoimmune disease. Both for food and 
clinical applications of lactobacilli, proper selection of wild type strains is cl'llcial. 
For that plllpose, eight different common Lactobacillus strains were analysed 
with respect to mucosal induction of pro- and anti-infiamlllatOlY cytokines, IgA 
producing plasma cells in the gut, as well as systemic antibody responses against a 
parenterally administered antigen. Immunohistochemical analysis of cytokine 
producing cells in the gut villi showed /10 significant induction of the cytokines IL- I a, 
IFN- Y, IL-4 or IL-10 after oral administration of wild type Lactobacillus strains. In 
contrast, oral administration of L. reuteri and L. brevis induced expression of the 
pro-infiammatOlyfTh1 cytokines TNF-a, IL-2 and/or IL-1jJ. Oral administration of 
these two strains and L. fermentum also significantly enhanced the IgG response 
against parenterally administered haptenated chicken gamma globulin (TNP-CGG). 
The five other strains did not show this adjllvanticity. L. reuteri induced relatively 
high levels of IgG2a compared to L. murines, a /lOn-adjllving Lactobacillus strain. 
These findings imply that different Lactobacillus strains indllce distinct 
mllcosal cytokine profiles and possess differential intrinsic adjllvanticity. This 
sllggests that rational Lactobacillus strain selection provides a strategy to infillence 
cytokine expression and thereby influence immllne responses. 
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Introduction 
The capability of the mucosal immune system to act in both an immunogenic as well 
as in a tolerogenic manner protects our body against infection as well as inadvertent 
inflammation. The specific functions of mucosa-lined organs, e.g. the exchange of 
gasses (lung) and uptake of nutrients (gut), are essential and therefore the occurrence 
of destructive inflammatory immune responses at those sites is undesirable. 
Therefore, normally T-cell tolerance is induced against ingested food antigens. 
Nevertheless, the mucosal immune system is responsible for over 50% of the daily 
production of immunoglobulins (Mestecky and McGhee, 1987), reflecting continuous 
protective inmmne reactions. However, experimental induction of immune responses 
has proven difficult, as the precise nature of the parameters which determine the 
induction of such responses at the mucosa are poorly defined (Mestecky et al., 1997). 
It is likely that local cytokine profiles may favour either Th I type immunogenic 
responses or Th2 type tolerogenic responses (Gonnella et al., 1998). 
Vaccination against infectious diseases versus peripheral T-cell tolerance 
induction in autoimmune therapy upon oral antigen administration is thought to be at 
least partly dependent on particulate versus soluble nature of the antigen, respectively 
(Benson et al., 1999; Fairweather et al., 1990; Melamed et al., 1996). It has 
previously been shown that lactobacilli with surface-linked haptens can induce an 
antibody response when administered orally (Gerritse et al., 1990). For oral vaccine 
applications recombinant lactobacilli have now been constructed which express 
heterologous protein on the surface of the bacteria, which serve as a particulate 
antigen for induction of immune responses and B-cell memory (Maassen et al., 
1999a). Orally fed soluble autoantigens can induce peripheral T cell tolerance and 
thereby prevent the induction of EAE (experimental autoimmune encephalomyelitis), 
an animal model for multiple sclerosis (Higgins and Weiner, 1988; Whitacre et al., 
1991). In order to induce peripheral T-cell tolerance with the use of genetically 
engineered lactobacilli, recombinant lactobacilli have been designed to produce and 
locally secrete soluble autoantigens in medium or ill vivo (Maassen et al., 1999a). 
Lactobacilli are frequently used in dairy products because of their health 
promoting effects such as the non-specific enhancement of the immune response 
(adjuvanticity), control of intestinal infections, control of serum cholesterol levels and 
anti-carcinogenic activity (Bloksma et al., 1979). Oral administration of these diverse 
species of Gram-positive lactic acid bacteria with the generally regarded as safe 
(GRAS) status is economical and simple (Pouwels et al., 1996). Since the bacterial 
properties required for the different applications are clearly distinct, strain selection is 
very important for wild type as well as recombinant lactobacilli. Therefore, in this 
study two properties of Lactobacillus strains were investigated in order to more 
rationally select appropriate Lactobacillus strains for use in oral vaccination and oral 
tolerance induction. First, the capability of Lactobacillus strains to induce specific 
cytokines at the mucosa by oral administration was determined in BALB/c mice, 
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which are Th2-cell biased (Sun et al., 1997; Nishimura et al., 1997). Mice were 
immunized i.p. with Chikungunya vhus and fed eight different Lactobacilllls strains 
for four days. Actual ill vivo cytokine production was demonstrated 
immunohistochemically in gut tissue sections. That oral administration of an antigen 
can indeed lead to increased cytokine production in the gut has previously been 
shown with the model antigen ovalbumin (OVA) in an OVA T-cell receptor 
transgenic mouse (Gonnella et al., 1998). Here we show that oral lactobacilli can 
influence local cytokine production after parenteral immunisation with a pathogen 
(Chikungunya virus) in BALB/c mice. Second, in order to assess whether orally 
administered Lactobacilllls strains were able to non-specifically enhance the humoral 
response (adjuvanticity) and whether adjuvanticity correlated with the induced 
cytokine profiles, systemic antibody responses of mice immunised intraperitoneally 
with trinitrophenyl conjugated to chicken gamma globulin (TNP-CGG) were 
analysed. 
Materials and methods 
Bacteria 
Eight Lactobacilllls strains were used in this study. Lactobacilllls rellferi MLl, L. 
brevis MLl2, L. gasseri ML21 and L. mllrilles CNRZ were originally isolated from 
mouse. Strain L. casei ATCC 393 was isolated from cheese and strain L. plalltarllm 
ATCC 14917 was isolated from sauerkraut (Pouwels et al., 1996). The strains L. 
fermellfllm 104R and L. plalltamm NCIB 8826 were isolated from pig and human 
saliva, respectively (Pouwels et al., 1996). 
Allimals alld alltigells 
Female BALB/c mice were purc\1ased from Charles River Laboratories (Sulzfeld, 
Germany). These mice were kept under fiitertop hoods. The mice were 6-10 weeks 
old at the start of the experiments. Experiments were performed according to 
regulations in the Dutch law on animal experimentation. BALB/c mice are 
Th2-biased, favoring antibody responses (Sun et al., 1997; Nishimura et al., 1997). 
Trinitrophenyl (TNP) was conjugated to chicken gamma globulin 
(CGG)(Sigma Chemical, La Jolla, CAl according to the method described by 
Claassen and Van Rooijen (1984). TNP-CGG was used, as a soluble protein antigen, 
because the dose used without adjuvant will give a suboptimal immune response. 
Chikungunya virus was cultured and inactivated by UV according to the method 
described by Nakao and Hotta (1973). This pathogen was used since it is an ARBO 
(arthropod borne, insect vector) virus causing disease in man and animal, which is 
being widely used as a model for other ARBO vhuses (Greiser-Wilke et al., 1989). 
For the detection of cytokines the following antibodies were used. Mouse 
antibodies against human lL-l ex and lL-113 were obtained from the Instituto Ricerche 
Immunobiologiche Siena, Italy. The lL-2 specific rat MAb, S4B6, was a kind gift of 
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Dr. T. Mosmann, Department of Medical Microbiology and Immunology, University 
of Alberta, Canada (Mosmann et al., 1986). The rat MAb llBll, directed to IL-4, 
was a kind gift of Dr. W.E. Paul, Laboratory of Immunology, National Institute of 
Allergy and Infectious Diseases, NIH, Bethesda, MD (Ohara and Paul, 1985). 
SXC-I-biotin, a rat MAb against IL-IO, was obtained form Pharmingen (San Diego, 
CA). The murine Mab DB-I directed to IFN-y and rabbit selUm against TNF-a were 
both obtained from Dr. P.H. van del' Meide from the Biomedical Primate Research 
Centre (BPRC), Rijswijk, The Netherlands. All antibodies were crossreactive with 
their murine counterparts, but not with eachother. Goat anti Mouse-IgA-HRP 
(horseradish peroxidase) was obtained from KPL (Gaithersburg, MD). Streptavidin-
HRP was obtained from Life Technologies (Gaithersburg, MD) and Swine anti 
Rabbit-Ig-HRP from Dako AlS (GlostIUP, Denmark). 
Oral administration of Lactobacillus strains 
All strains were cultured in MRS broth (Difco, Detroit, MI) at 37°C until the OD69Q 
was 1.1 (end log phase). The cells were harvested by centrifugation at 4000g for 20 
min at 4°C, washed twice with PBS and once with 0.2M NaHCO,. Before use, the 
cells were resuspended in 0.2M NaHC03 buffer (pH 8.4) to compensate for the acidic 
gastric environment. Each mouse received approximately 1010 CFU lactobacilli via the 
oral route. Administration was performed intragastrically. 
Adjuvant activity of orally administered Lactobacillus strains 
Eight different Lactobacillus strains were orally administered to groups of 3 mice for 
4 consecutive days. On the first day the mice were also immunized intraperitoneally 
(i.p.) with 25J.1g TNP-CGG in PBS. Oral administration of lactobacilli was repeated 
on days 21, 22, 23 and 24. The booster immunisation with TNP-CGG was performed 
on day 21. SelUm was collected on day 7 and 14 after prime and booster 
immunizations. Specific antibodies against CGG and TNP were detected by ELISA. 
ELISA 
Polyvinyl chloride (PVC) microliter plates (Titertek, Flow Laboratories, Irvine, 
Scotland) were coated with CGG (5J.1g1mI, 50J.lllwell) or TNP-BSA (5J.1g1mI, 
50J.ll/well) overnight at 4°C. To block non-specific antibody binding the plates were 
incubated for 1 hour with 0.2% gelatine in PBS (50J.lllwell) at room temperature. 
Subsequently the plates were incubated for 1 hour at 25°C with dilutions of 
TNP-CGG induced anti-sera and preimmune sera to correct for background reactivity. 
After washing, the plates were incubated with either alkaline phosphatase-labelled 
goat-anti mouse IgG or anti-IgM (H+L)(KPL). For the detection of CGG specific 
IgG 1 or IgG2a antibodies, rabbit anti-mouse IgG 1 or rabbit anti-mouse IgG2a 
antibodies (ICN Immunobiologicals, Costa Mesa, CA) were used respectively, 
followed by 1 hour incubation with alkaline phosphatase-labelled swine anti-rabbit Ig 
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antibodies (Dako NS). After addition of the substrate paranitrophenyl phosphate, the 
absorbance was read at 405nm. An IgG I monoclonal antibody directed against CGG 
was used as reference for detection of IgG I CGG specific antibodies on each ELISA-
plate. A polyclonal mouse serum containing high levels of IgG2a antibodies specific 
for CGG was used as reference in the ELISA's to detect IgG2a specific antibodies 
against CGG. Sera of mice immunized with TNP-CGG in specol (water-in-oil 
adjuvant) served as reference serum for relative concentrations of IgG specific 
antibodies against TNP and CGG. 
Relative concentrations of IgG I, IgG2a and total IgG were calculated after 
subtraction of the absorbance of preimmune sera at the corresponding dilutions. The 
linear part of the reference curve was used to perform linear regression. Only those 
measurements of the test sera falling within the same absorbance range as reference 
samples used for regression (with comparable slope), were used for the calculation of 
the relative concentrations of IgG I, IgG2a and IgG in arbitrary units (a.u.). 
Immllnohistochemical detection of cytokine prodllcing cells in gilt villi indllced by 
lactobacilli 
Eight different Lactobacilllls strains were orally administered to groups of 3 mice on 
days 0, 2, 4 and 6, in order to obtain a high continuous level of administered 
lactobacilli in the gastrointestinal tract during the experiment. On day 0 the mice were 
also immunized i.p. with 25J.1g UV-inactivated Chikungunya vitus in PBS. One day 
after the last feeding the mice were euthanized. The first 10 cm of the small intestine 
containing the most Peyer's patches were taken out and rinsed in PBS. Swiss rolls 
were made by rolling up the small intestine around a match stick, whereby the 
terminal end is on the center of the role and the "stomach" end is on the outside. 
Subsequently, these swiss roles were frozen in liquid nitrogen. 
Mouse cytokines were detected as described before (Herzenberg et al., 1997). 
Briefly, frozen sections (-20°C) of 8 J.lm were thaw-mounted on silane coated glass 
slides and kept overnight under high humidity at RT. The next day, slides were 
air-dried for 1 hour and fixed at room temperature in acetone containing 0.02% H20 2• 
After air-drying for at least 10 minutes, sections were incubated with pre-determined 
optimal dilutions of primary reagents overnight at 4°C, in humidified atmosphere. 
Primary reagents were diluted in PBS containing 0.1% BSA. Incubations with 
secondary reagents diluted in PBS containing 1 % BSA were done during 1 h at room 
temperature under high humidity. Between the incubation steps slides were washed 
with PBS. Biotinylated antibodies followed bij streptavidin-HRP were used for 
detection of IL-Ia, IL-1P, IL-2, ILA, IL-10 and IFN-y. TNF-a was detected with 
swine anti rabbit-Ig-HRP conjugate. IgA containing plasmacells were directly 
detected with goat anti mouse-IgA-HRP. Incubation with AEC (3-amino-9-
ethylcarbazole) substrate for 10 minutes was used to reveal HRP activity (bright red 
precipitate) (Jeurissen et al., 1997). After washing, slides were counterstained with 
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hematoxylin and embedded with glycerol/gelatin. Primary antibody/reagent omission 
control stainings were pelformed for the different reagents used. 
Quantitation was performed by counting cytokine positive cells by light 
microscopy. Comparable areas of gut villi were scored for positive cells by two 
independent observers blinded to treatment. The average number of positive cells per 
five villi per mouse was determined. Significance of differences between all groups 
were determined by a single factor anova. Only the significant differences of the 
Lactobacillus fed groups as compared to the NaHC03 fed group i.p. immunized with 
virus are indicated. 
Statistical alia lysis 
A single factor ANOV A was used to analyse the data. Since per group all mice were 
kept in one cage, it is allowed to use the t -test to calculate the least significant 
differences. When p<O.05 the difference was interpreted as significant. This approach 
was used to compare the total IgG antibody responses, the IgG lIIgG2a ratios and the 
number of cytokine positive cells. 
Results 
Adjuvallt activity of orally admillistered Lactobacillus straills 
In order to examine whether there is a difference between distinct Lactobacillus 
strains in their ability to influence the humoral immune response when administered 
orally to BALB/c mice, which are Th2-cell biased (Sun et al., 1997; Nishimura et al., 
1997), eight different strains were tested. Seven days after booster immunisation TNP 
and CGG specific IgG titers were determined in sera of mice treated according to the 
immunisation protocol. No differences could be detected between the levels of IgM 
antibodies against CGG and TNP 7 days after prime and booster immunization. 
Differences in specific IgG titer were interpreted as adjuvant effects of Lactobacillus 
strains (Figure 1). Although most of the tested strains did not show any effect as 
compared to the control group immunized with TNP-CGG which received NaHC03 
orally, L. reuteri significantly enhanced the specific CGG antibody response (p<O.Ol). 
L. reuteri appeared to be significantly different from all groups, except from L. brevis 
(significance not indicated in Figure 1 B). When the same sera were tested for the 
presence of TNP specific antibodies, again L. reuteri (p<O.OI), but also L. brevis 
(p<O.OI) and L. fermellfum (p<O.05) showed significant enhancement of the humoral 
response as compared to the TNP-CGG immunized group of mice which orally 
received NaHC03 only (Figure 1A). This indicates that some orally administered 
Lactobacillus strains, but not others, can non-specifically enhance the humoral 
response against a parenterally immunized antigen (adjuvanticity). 
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Figure 1. Adjuvant activity of orally admillistered Lactobacillus straius. 
The effect of orally administered Lactobacillus strains on the antibody response against the thymus 
dependent antigen 1NP-CGG administered intraperitoneally was analyzed by ELISA. The mice received 
a Lactobacillus strain or NaHC03 only orally on 4 consecutive days. On the first day the mice were also 
immunized i.p. with 1NP-CGG in PBS. From day 21 on this protocol was repeated. The left panel shows 
the mean IgG antibody response ± SEM against lNP per group in arbitrary units 7 days after the second 
immunization. 111e right panel shows the JgG antibody response ± SEM against the carrier protein CGG. 
Only significant differences compared to the NaHCOJ group are indicated by asteriks. No antibody 
responses were detected in mice orally fed NaHCOJ and inununized with PBS (data not shown). 
*: p<O.05, ** : p<O.O I, plafll.: planfamm 
IgOIIIg02a ratio after oral administration o/Lactobacillus strains 
It was demonstrated that the quantity of the antibody response evoked against the 
parenterally immunized antigen CGG-TNP could be enhanced by some of the orally 
administered Lactobacillus strains. Since it is generally accepted that the IgG 1 
response reflects activity of Th2 CD4+ T-cells and IgG2a is a reflection of 
Thl-activity (see Martin and Lew, 1998; O'Garra, 1998 and references therein), the 
difference in the quality of the immune response was determined by analysing those 
antibody isotypes. The IgG I and IgG2a responses against CGG were detected after 
oral administration of 4 Lactobacillus strains. The antibody responses were expressed 
as IgGI/IgG2a ratios (Figure 2). Only the antibody response against CGG was 
detected since the IgG2a responses against TNP were in most cases too low to be 
calculated. Oral administration of L. reuteri and L. plallfal'll/ll NCIB induced 
relatively high IgG2a levels against CGG when compared to the control group which 
was fed buffer only, although the differences did not reach significance. The reduced 
IgG l/IgG2a ratio was significant compared to oral administration of L. /IIurilles, 
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which slightly increased the IgG IIIgG2a ratio. The IgGl/IgG2a ratio induced by L. 
1Il1irilles was also significantly higher than after parenteral immunization of 
CGG-TNP in specol, a water-in-oil adjuvant. The ratio detected after oral 
administration of L. casei was comparable to the ratio of the control group fed buffer 
and the group fed L. IIlllrilles. 
NaHCO, 
NaHCOyadjuvant 
L. mllrines * 
L, casei 
L. plan/arum NCIB 
L. reuteri 
o 3 6 9 12 15 
IgGlflgG2a ratio of response against CGG (a.u.) 
Figure 2. /gGl//gG2a ratio of aflli·CGG resp01lse after oral administration o/Lactobacillus strains. 
The effect of 4 orally administered Lactobacillus strains on the IgGlfIgG2a ratio of the response against 
coa was analyzed by ELISA. The mice received a Lactobacillus strain or NaHCOJ only orally on 4 
consecutive days. On the first day the mice were also immunized i.p. with TNP~CGG in PBS. A control 
group was fed NaHCO, and inununized i.p. with TNP-CGG in specol (NaHCOYadjuvant). From day 21 
on this protocol was repeated. Seven days after the second immunization the IgG 1 and IgG2a responses 
against COO were calculated in arbitrary units with the use of reference curves. The mean IgG lIIgG2a 
ratio per group ±SEM is shown. *: p<O.05 compared to the groups fed L. plan/arum NC1B, L. rellteri and 
the group immunized with TNP-CGG in adjuvant. 
Immllnohistochemical detection of IgA and cytokines ill gut villi 
To investigate whether orally administered Lactobacillus strains are able to induce 
cytokines and IgA at the mucosa, BALB/c mice were immunized i.p. with 
Chikungunya virus and fed wild type lactobacilli for four days. Seven days after 
administration of the inactivated pathogen the animals were sacrificed and frozen gut 
tissue sections were analysed for IgA and cytokine production. In Figure 3A the 
production of IgA in this primary immune response is shown in a complete cross-
section of the duodenum including a Peyer's patch (lower right corner). In al1 animals 
we could find massive amounts of IgA in the B (plasma) cells located central1y in the 
villi (Figure 3B). Hardly any antibody producing B-cells were seen in the Peyer's 
patches. As Figure 3B shows, the lamina propria lymphocytes were the ones 
exclusively involved in antibody production. No IgA containing cells were seen in the 
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Figure 3. ImlllllllohistoclIemicai detectioll of IgA alld cylokine-producillg cells ill gut villi 
A) IgA producing cells in the duodenum of a mouse imrnunised with Chikungunya virus. 
B) Lamina propria plasma cells stained for IgA of a mouse fed with L. reuler; and immunised with 
Chikungunya virus. 
C) Absence of IL.2 producing cells in gut villi stained for IL-2 of a mouse inununised with PBS and 
red NaRCO,. 
D) IL-2 producing cells in gut villi of a mouse immunised with Chikungunya virus and fed NaHCOJ• 
E) 1NF-o: producing cells in the lamina propria of a mouse fed L. reuter; and immuniscd with 
Chikungunya virus. 
F) Localisation ofTNF-cx positive cells in submucosa of mouse described in E. 
Some of the positively stained cells are indicated by arrows. For color figures see the original paper. 
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outer rim of the villi. Figure 3B also gives a clear visual indication of the maximum 
number of cells per villus (8-10) that can be observed for both IgA production as well 
as for cytokine production by T-cells (9-12, see also Figure 3E). 
The background number of positive cells was different for all cytokines, as 
shown in a quantitative way in Figure 4. Figure 3C demonstrates that for IL-2 no 
cytokine producing cells are found when the animals are given NaHC03 orally and 
PBS intraperitoneally (no virus). It should be noted that sections on the same glass 
slide included positive tissue controls (van den Eertwegh et al., 1991) for IL-2. 
Brown (not red) rims circumfering the villi were found in all samples stained for IL-2 
with AEC (for revelation of horseradish peroxidase activity), even in the absence of 
IL-2 positive cells, representing non-specific staining. 
After intraperitoneal immunisation with Chikungunya virus, but without oral 
pretreatment with lactobacilli, IL-2 positive cells could be demonstrated in the lamina 
propria of the villi (identical to the localisation pattern of IgA) as indicated by arrows 
(Figure 3D). As is clear from Figure 3D the cells were not always homogeneously 
distributed over the tissue when relatively small numbers (0.2-2 on average per villus) 
are found. 
When antigen was given in conjuction with oral lactobacilli, the number of 
cytokine producing cells increased in a strain-dependent manner (Figure 4 alld 5). 
Most cytokine producing cells (±10 per villus) were found for TNF-cx in L. reuteri 
treated animals as shown in Figure 3E. 
In the submucosa, where Brunner's glands are located, TNF-cx was also found 
in the endothelial cells after oral administration of L. reuteri (Figure 3F). This 
localisation pattern was not observed for any of the other cytokines studied. 
Quantitative analysis of cytokine producillg cells ill gut villi induced by lactobacilli 
In order to investigate whether Lactobacillus strains are able to differentially induce 
cytokines at the gut mucosa after oral administration in Chikungunya-immunized 
mice, the frequency of cytokine producing cells was determined. The levels of IgG 
and IgM antibodies against Chikungunya virus in sera obtained at sacrifice, were too 
low to be correlated to the found cytokine profiles. The cytokines IL-lcx, IL-IB, IL-2, 
IL-4, IL-IO, lPN-y and TNF-cx were immunohistochemically analysed by counting 
the number of cytokine producing cells in gut villi. The background level of positive 
cells differed for each cytokine. Of the cytokines tested, only ILA was hardly 
detectable in all treatment groups, despite the fact that positive control tissue, 
(TNP-ficoll reactive spleen) contained numerous IL-4 producing cells (van den 
Eertwegh et al., 1991; 1993). The rest of the tested cytokines can be roughly divided 
into two groups. Some cytokines are not induced by oral administration of any of the 
tested Lactobacillus strains when compared to the control group which 
wasimmunized i.p. with virus and orally received NaHC03 only (group NaHC03) 
(Figure 4). Other cytokines are induced by one or more Lactobacillus strains (Figure 
5). Cytokines that were not induced are IL-Icx, IL-4, lPN-V and IL-IO. A low level of 
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Figure 4. Quantitative analysis of background cytokille produci1lg cells. ill gilt villi. 
A quantitation on the immunohistochemically stained sections from mice immunized with Chikungunya 
virus and fed different Lactobacillus species was performed. Animals in the control groups were fed 
NaHCO) only and were immunized with TNP~CGG (NaHC03 group) or PBS (no antigen), Sections of 
the duodenum were stained for the cytokincs IL.-Ia, IFN-y and IL.-IO. The mean number of positive cells 
per five villi per group ± SEM is shown. 
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Figure 5. Quantitative allalysis of cylokille.producillg cells ill gilt villi induced by lactobacilli. 
A quantitation on the immunohistochemically stained sections from mice immunized with Chikungunya 
virus and fed different Lactobacillus species was performed. Animals in the control groups were fed 
NaHCO, only and were immunized with TNP-CGG (NaHCO, group) or PBS (no anligen). Seclions of 
the duodenum were stained for the cytokines IL-16. lNF-a and fL..2. The mean number of positive cells 
per five villi per group ± SEM is shown. Only significant differences compared to the NaHCOJ fed group 
are indicated by asterisks. *: p<O.05, **: p<O.Ol 
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IFN-y and IL-Ia positive cells could be detected in all mice, but there was no 
significant difference with the NaHCOJ fed group (Figure 4). For IL-IO we observed 
that i.p. immunisation with virus only (group NaHCOJ) increased the frequency of 
IL-IO producing cells above background (no virus), although this difference did not 
reach significance (Figure 4). No further enhancement by oral administration of 
lactobacilli was observed. Only L. casei tended to further increase IL-IO producing 
cells as compared to the virus immunized group which received NaHCOJ orally 
(group NaHCOJ), but this increase was not significantly different either. The group of 
cytokines that can be induced by oral administration of wild type Lactobacillus strains 
consists of IL-IB, IL-2 and TNF-a (Figure 5). An enhancement of TNF-a levels in 
the gut villi could be detected after oral administration of all of the tested 
Lactobacillus strains, except for L. fermelltum, when compared to the group fed 
NaHCOJ only (group NaHCOJ)(Figure 5). L. wiled and L. brevis both showed an 
approximately IS-fold increase in the number of TNF-a positive cells. Like TNF-a, 
IL-2 is already induced in the gut by parenteral immunisation with Chikungunya virus 
alone (compare group 'no vitus' with group 'NaHC03)(see Figure 3D), but is 
significantly further increased by oral administration of L. reuteri and L. brevis 
(Figure 5). L. reuted is also able to induce IL-IB (Figure 5). Clearly, there are 
Lactobacillus strains which are able to induce an inflammatory cytokine profile 
(L.reuteri, L. brevis). 
Discussion 
This study shows that orally administered wild type Lactobacillus strains can induce 
differential cytokine profiles' in the gut of Th2-biased BALB/c mice. The 
Lactobacillus strains L. reuteri and L. brevis induce several of the proinflanunatory 
andlor Thl cytokines IL-IB, IL-2 and TNF-a but not anti-inflammatory Th2 cytokines 
such as IL-IO and IL-4 (Figure 4). These same Lactobacillus strains were able to 
significantly enhance the systemic antibody response against a parenterally 
immunized antigen. In the current dogma, Th I cells stimulate IgG2a antibodies 
production regulated by IFN-y, whereas IgG I antibodies are induced under control of 
the Th2 cytokine IL-4. Analysis of the antibody isotypes induced after oral 
administration of L. reuteri revealed that high IgG 1 as well as high IgG2a levels could 
be detected. However, after oral administration of L. reuteri the IgG IIIgG2a ratio of 
antibodies directed against CGG were (significantly) lower than the IgG IIIgG2a 
ratios after oral administration of buffer or non-adjuving Lactobacillus strains. These 
results indicate that L. reuteri and probably also L. brevis are inducers of the cellular 
as well as humoral responses. Most of the tested Lactobacillus strains did not affect 
the systemic humoral immune response and showed antibody levels similar to the 
control group that orally received NaHCOJ only. A possible explanation is that these 
strains act as natural gut commensals of the BALB/c mice and do not disturb the 
existing immune status. This is in accordance with the observation that lactobacilli are 
not or hardly immunogenic (Maassen et al., 1999c). Possibly, the Lactobacillus 
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strains that induce IL-2 and high levels of IL-IB and TNF-a and enhance the humoral 
immune response do evoke an immune response against themselves, leading to local 
inflammation. It should also be kept in mind that mucosal cytokine induction may not 
be directly linked to systemic antibody secretion. That there can be a relation between 
mucosal cytokine production and systemic antibody responses has been demonstrated 
by e.g. Marinaro et al. (1999) and Shi et al. (1998b). 
Most cytokines are differentially regulated, which may result for instance in the 
presence of the Th1 cytokine IL-2 without the presence of IFN-y, which is also a Th1 
cytokine (van den Eertwegh et al., 1992). In addition, due to different kinetics of 
expression of the cytokines, analysis at another timepoint may show induction of 
other cytokines, such as IFN-y. Also IL-1a and IL-1B appear to be under separate 
transcriptional control, which may lead to expression of one form of IL-l without the 
other form (Dinarello, 1998). 
Most Lactobacillus strains induce TNF-a, although there is a strain dependent 
difference in the number of TNF-a containing cells which is induced. This has also 
been seen after parenteral injection of cell wall components of L. casei, where L. 
casei components led to coronary arteritis due to activation of macrophages, which 
produced mainly IL-l and TNF-a (Lehman et ai., 1988; Okitsu-Negishi et ai., 1996; 
Tomita et al., 1993). III vitro, an increased production of IL-1 and TNF-a or IFN-y by 
macrophages exposed to various strains of Lactobacillus could be demonstrated, as 
well as enhanced phagocytosis (Perdigon et ai., 1986; Rangavajhyala et al., 1997; 
Kitazawa et al., 1994). From these studies, it seems that components in the cell wall 
of lactobacilli are responsible for this activation. That this is not necessary due to the 
peptidoglycan, a major cell wall component of Gram-positive bacteria, was 
demonstrated by de Ambrosini et al. (1996) who showed that after oral administration 
of peptidoglycan of four different Gram-positive bacteria only the L. casei cell wall 
preparation could activate macrophages. Although no double staining was performed 
to determine which cells produce the detected cytokine, due to results obtained in 
other studies it is likely to assume that the induced TNF-a and IL-1B are produced by 
macrophages. Whether also IL-lO was produced by macrophages can not be excluded. 
TNF-a containing cells were located in the villi like all other cytokine producing 
cells. In addition to the TNF-a positive cells in the villi, TNF-a was also found to be 
produced by cells in the submucosa after oral administration of L. reuteri, but not 
after administration of other Lactobacillus strains. Also in humans, with appendicitis, 
TNF-a can be found in the submucosa (Wang et al., 1996). 
Although inflammatoryrrh1 cytokine inducing Lactobacillus strains and 
non-cytokine inducing strains were identified, our panel did not contain a Th2 
cytokine inducing strain despite the fact that a Th2-biased mouse strain was used. 
Only L. casei tended to induce IL-lO and TGF-B. Although TGF-B was clearly found 
to be high for L. casei and L. Jill/rilles, the TGF-B data in general were not always 
clear to interpret and are therefore not shown. IL-IO and TGFE have 
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immunosuppressive effects on Thl cells and are thought to be involved in oral 
tolerance (Miller et al., 1992b). An IL-lOrrGF-J3 cytokine profile in the lamina 
propria can be found in ovalbumin (OVA) T cell receptor transgenic mice after oral 
administration of OVA, leading to T-cell tolerance towards OVA (Gonnella et al., 
1998). From our panel of Lactobacillus strains, no Lactobacillus strain emerged, 
inducing a local cytokine environment permissive for oral tolerance induction. 
As mentioned above, orally administered lactobacilli can activate macrophages. 
The known tumor-suppressive activity of lactobacilli is thought to be due to the 
cytotoxic action of TNF-cx and IL-l produced by macrophages (Kato et al., 1994; 
Nanno et al., 1989; Pool-Zobel et al., 1996; Matsuzaki et al., 1990; 1996; Perdigon et 
al., 1995). It seems that most of the tested Lactobacillus strains do have this 
anti-tumor property, but not all. Also many orally administered Lactobacillus strains, 
like L. casei, L. reuferi, L. bulgaricus and L. acit/ophilus seem able to protect against 
infections (Alak et al., 1997; De Simone et al., 1988; Kabir et al., 1997; Perdigon ef 
al., 1990; 1991; Wagner et al., 1997). Intrinsic properties of different Lactobacillus 
strains can playa role in the effectiveness of the treatment. Therefore, the choice of 
the Lactobacillus strain is of major importance. Properties that can playa role are the 
capability to induce cytokines in the gut and stimulate antibody responses 
(adjuvanticity), but also adhesion and colonization properties of the strains. Even the 
growth phase of the strain can be of importance, since we have shown that log phase 
versus stationary phase cultures differentially influence the IgG IIIgG2a ratio of 
systemic antibody responses against protein antigen dependent on the growth phase 
(Maassen et al., 1999c). 
Lactobacilli can also be used for oral vaccination and immunotherapeutic 
purposes in autoimmune diseases. Therefore, recombinant lactobacilli were developed 
which express bacterial or viral antigens on the cell surface (Maassen et al., 1999a). 
These immunogenic particles can be used as oral vaccines. In contrast, the soluble 
autoantigen secreted by other recombinant lactobacilli probably will induce peripheral 
T-cell tolerance and protect against experimental autoimmune diseases like 
experimental autoimmune encephalomyelitis (EAE), an animal model for multiple 
sclerosis (Maassen et al., 1999a). For oral tolerance induction with a recombinant 
Lactobacillus strain secreting autoantigens, a wild type strain without adjuvanticity 
but able to induce Th2 cytokines might be optimal. Such a strain did not emerge from 
the current analyzed panel. On the other hand, the Lactobacillus strains L. rellferi and 
L. brevis are good candidates for the expression of immunogenic antigens for oral 
vaccination purposes since they may stimulate innate, cellular and humoral immune 
responses. 
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Growth phase dependent skewing of IgG11IgG2a ratio 
Summary 
Lactobacillus strains with probiotic activity are major constituents of nwnerous 
common food products. Due to their 'generally regarded as safe' -status, Lactobacillus 
strains can also be genetically engineered for lise ill oral immunotherapeutic 
applications, such as vaccination and T lymphocyte tolerance induction in 
autoimmune disease. 
1n the current study we demonstrate that the growth phase of orally 
administered individual Lactobacillus strains can differentially affect systemic activity 
of T helper cell type 1 (Thl) and T helper 2 (Th2) pathways supporting antigen-
specific antibody formation (lgG2a versus IgG1 subclass, respectively). Mice were 
orally fed different wild type Lactobacillus strains in log phase or stationOl), phase 
and immunized intraperitoneally with a T-cell dependent protein antigen. Sera were 
evaluated for the ratio of antigen-specific IgG I and IgG2a antibodies. Stationary 
Lactobacillus murines and Lactobacillus casei cultures, but not two other 
Lactobacillus strains, evoked significantly higher IgG111gG2a ratios than log phase 
cultures, implying increased activity of the Th2-patlnvay. Despite normal variation in 
antibody responses against TNP-CGG among individual mice, a high correlation was 
found between the IgG1 and IgG2a responses of mice within experimental groups. 
This differential activation of Th-pathways is likely due to growth phase-dependent 
differences in bacterial cell composition. 
As growth phase-dependent skewing ofT-cell pathways may inadvertently affect 
allergic and (auto)-immune responses, the current findings strongly caution against 
unidimensional views on the oral administration of individual Lactobacillus strains for 
probiotic or immunotherapeutic pwposes, but also suggest additional possibilities for 
immune modulation. 
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Introduction 
The genus Lactobacilllls belongs to the family of Lactobacteriaceae, also known as 
lactic acid bacteria, a group of microorganisms that have been used for centuries in 
bio-processing and preservation of food and feed. Some fermented dairy products 
containing Lactobacillus species are believed to have certain health promoting 
properties for humans. This assumption was originally based upon Metchnikoff's 
theory (Metchnikoff, 1908) that harmful effects of undesired bacteria can be overcome 
by establishing a new balance between intestinal bacteria, through ingestion of 
lactobacilli or fermented products made by these organisms. Research carried out 
during the last few decades has resulted in additional claims of health andlor 
nutritional benefits for humans and animals associated with the consumption of 
fermented milk products. Such claims include; control of intestinal infections, control 
of serum cholesterol levels, enhancement of immune responses (adjuvanticity), and 
anti-carcinogenic activity (Perdigon et ai., 1995; Pouwels et ai., 1996). 
Because lactobacilli are commensals of the gut and are generally regarded as 
safe (GRAS-status)(Maassen et ai., 1999a), lactobacilli are good candidates for use as 
production and delivery hosts of heterologous proteins in food but also health care 
products. Genetically engineered lactobacilli expressing bacterial or viral proteins on 
the cell surface can potentially be used as oral vaccines (Maassen et aI., 1999a). On 
the other hand, Lactobacillus recombinants secreting tolerogenic autoantigens can be 
used to induce systemic peripheral T-cell tolerance by oral administration for 
treatment of autoimmune disease (Maassen et al., 1999a). 
Due to the diversity of species within the Lactobacillus genus not each 
Lactobacillus strain possesses (all) of the above mentioned health stimulating 
properties. For instance, it has been shown that Lactobacillus strains differ in their 
ability to enhance the humoral immune response (adjuvant activity) and that they 
induce distinct cytokine profiles in the gut after oral administration (Maassen et ai., 
1999b). This implies that strain selection is a crucial issue for the use of wild type 
Lactobacillus strains in food products, but also when recombinant lactobacilli are to 
be used to promote different types of immune responses such as vaccination, T-cell 
tolerance induction and treatment of allergy. 
Most inunune responses are centrally regulated by the activity of CD4-positive 
T helper (Th) cells. In mice and humans, two functionally polarized responses of Th 
cells can be distinguished mediated by Thl versus Th2 cells (reviewed by Romagnani, 
1997). The distinction depends on the profile of cytokines which these Th cell subsets 
secrete. Thl cells produce proinflammatory cytokines like interleukin 2 (IL-2), IL-12, 
tumor necrosis factor alfa (TNF-a) and interferon gamma (IFN-y). Th I cells promote 
cellular immune responses including macrophage activation, delayed type 
hypersensitivity (DTH) and cytotoxicity. Thl cells positively contribute to the 
humoral (antibody) response to a limited extent by supporting the production of the 
IgG2a antibody subclass, but they inhibit production of several other subclasses like 
IgG 1. Although the Th I pathway is crucial to protection against many pathogens, it 
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may also be the predominating type of response in chronic inflammatory autoimmune 
diseases like multiple sclerosis and insulin-dependent diabetes mellitus (Romagnani, 
1997; Laman et 01., 1998b; O'Garra, 1998). 
Th2 cells produce !LA, !L-S and !L-I0, which are generally regarded to be 
anti-inflammatory. These cytokines are involved in stimulating strong antibody 
production by B cells (e.g. IgG I, IgM and IgE), stimulation of eosinophils and mast 
cells, as well as deactivation of macrophages. Dominant Th2 responses may contribute 
to diseases such as atopic allergy. In animal studies, the IgG llIgG2a ratio is an 
accepted and convenient marker for differential Th2-Thl reactivity (see O'Garra, 
1998; Martin and Lew, 1998 and references therein). 
A multitude of approaches to skew T helper cell pathways to treat human 
diseases is under intense investigation (Weiner, 1997). When oral biotherapy with 
wild type Lactobacillus strains or genetically engineered recombinants (Maassen et 
01., 1999a) is considered, the way these strains impinge on T helper pathways is an 
important factor determining successful application. Therefore, the aim of the present 
study was to establish whether orally administered individual Lactobacillus strains can 
differentially affect T-helper cell pathways as reflected in IgG 1 (Th2) versus IgG2a 
(Th 1) antibody responses against systemically administered exogenous protein 
antigen, and whether such T-helper cell skewing is dependent on the growth phase of 
the lactobacilli. 
Materials and Methods 
Allimais alld Lactobacillus straills 
Female SJL mice (Erasmus University Rotterdam, The Netherlands) were kept under 
filtertop hoods in a DII facility with free access to mouse chow and acidified water 
(pH 2.8). Experiments were performed according to regulations in the Dutch law on 
animal experimentation. 
The Lactobacillus strains L. reuteri MLl and L. murilles CNRZ were originally 
isolated from mouse. The strains L. casei ATCC 393 and L. pialltarum NCIB 8826 
were originally isolated respectively from cheese and human saliva. 
Cuituring of Lactobacillus strains 
All Lactobacillus strains were cultured overnight, in 5 ml MRS broth followed by 15 
mI MRS broth (Difco, Detroit, MI), before inoculation in 500ml MRS broth (1:50). 
The cultures were grown to late log phase (6 hours) or stationary phase (16 hours). 
The cells were harvested, washed twice with PBS and once with 0.2M NaHC03• This 
extensive washing was performed to ensure no secreted Lactobacillus products were 
present in the suspension. Before use the cells were resuspended in 0.2M NaHC03• 
From this suspension a sample was taken for plating on MRS broth plates for the 
calculation of the number of colony forming units (CPU) as well as to rule out 
contamination. 
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Oral administration of Lactobacillus strains and immunisation schedule 
To investigate the effect of orally administered lactobacilli on the humoral immune 
response, mice orally received wild type lactobacilli, prepared as described above, on 
four consecutive days. Each animal received approximately 10 '0 CFU per intragastric 
administration. On the first day the mice were also immunized intraperitoneally with 
25 ;tg of the hapten trinitrophenyl (TNP) conjugated to the thymus dependent antigen 
chicken gamma globulin (CGG) (Sigma Chemical, La Jolla, CA). One control group 
was immunized with TNP-CGG in a water-in-oil adjuvant, specol (Bokhout et al., 
1981), which resembles Freund's incomplete adjuvant. From day 49 onwards oral 
administration of lactobacilli as well as intraperitoneal immunisation with TNP-CGG 
was repeated as above. This day was chosen as titers had declined to below 50% of 
maximal values. Blood samples were taken before the start of the experiment and 
every 7 days. 
Semi-quantitative ELISA 
Serum titers of CGG and TNP specific antibodies after immunisation with TNP-CGG 
were determined by ELISA. Polyvinyl chloride (PVC) microtiter plates (Titertek, 
Flow Laboratories, Irvine, Scotland) were coated with CGG (5;tg/ml, 50;tl!well) or 
TNP-BSA (5;tg/ml, 50;tllwell) overnight at 4°C. Non-specific antibody binding was 
blocked by incubation with 0.2% gelatin in PBS (50;tllwell) for I hour at 25°C. 
Subsequently the plates were incubated for I hour at 25°C with dilutions of TNP-CGG 
induced antisera and preimmune sera to correct for background reactivity. For the 
detection of IgG antibodies specific for CGG or TNP, alkaline phosphatase-labelled 
goat anti-mouse IgG (KPL, Gaithersburg, MD) was used. For the detection of CGG or 
TNP specific IgG 1 or IgG2a antibodies, rabbit anti-mouse IgG 1 or rabbit anti-mouse 
IgG2a antibodies (ICN lmmunobiologicals, Costa Mesa, CA) were used respectively, 
followed by 1 hour incubation with alkaline phosphatase-labelled swine anti-rabbit 19 
antibodies (Dako AlS, Glostrup, Denmark). After addition of the substrate 
paranitrophenyl phosphate, the absorbance was read at 405nm. An IgG 1 monoclonal 
antibody directed against CGG was used as reference for detection of IgG and IgG 1 
CGG specific antibodies on each ELISA-plate. A polyclonalmouse serum containing 
high levels of IgG2a antibodies specific for CGG was used as reference in the 
ELISA's to detect IgG2a specific antibodies against CGG. The reference used in all 
TNP-specific ELISA's was a polyclonal mouse serum with high levels of IgG 1 and 
IgG2a TNP-specific antibodies. 
Relative concentrations of IgG I, IgG2a and total IgG were calculated after 
subtraction of the absorbance of preimmune sera at the corresponding dilutions. The 
linear part of the reference curve was used to perform linear regression. Only those 
measurements of the test sera falling within the same absorbance range as reference 
samples used for regression (with comparable slope), were used for the calculation of 
the relative concentrations of IgG 1, IgG2a and IgG in arbitrary units (a.u.). 
To detect antibody responses against Lactobacillus murines after oral 
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administration, PVC plates were coated with fragmented L. murilles (50ng/mI, 
50llllwell). The fragments were obtained by sonification of cells harvested after 
overnight growth in MRS broth. The following incubation steps and development 
were performed as described for total IgG. SenUll obtained after intraperitoneal 
immunisation of mice with L. casei in adjuvant (Difco's complete adjuvant, Difco) 
was used as reference. 
Statistical alia lysis 
A single factor ANOV A was used to analyse the data. Because the groups of mice 
were too large to be held in one cage, it was calculated whether there were differences 
between cages holding mice of the same group. Since this was not the case, the t-alfa 
for student's t-test could be used to calculate the least significant differences instead of 
the F-alfa of the F-test. When p<O.05 the difference was interpreted as significant. 
This approach was used to compare the total IgG antibody responses and the 
IgGI/IgG2a responses of the groups on one day (Figure I and Figure 2). When the 
IgGI/IgG2a ratio's were compared over time (7, 14 and 21 days after the second 
immunisation), linear regression was performed on the data of each individual animal. 
The same procedure as used for the single data points was applied to the regression 
lines (Figure 5). Differences between the intercepts indicate different IgG l/IgG2a 
ratio's. Distinct slopes indicate difference in change of the ratio's over time. Linear 
regression was performed to calculate the correlation lines in Figure 4. 
Results and Discussion 
Four wild type Lactobacillus straills do IIOt ellhallce systemic alltibody respollses 
In order to investigate whether different Lactobacillus strains have different intrinsic 
adjuvanticity (defined as the capability to non-specifically enhance the antibody 
response), four wild type Lactobacillus strains were orally administered to SJLlJ mice 
(n=5). SJLlJ mice are biased towards the Th I pathway and are susceptible to induction 
of experimental autoimmune diseases such as EAE (experimental autoimmune 
encephalomyelitis), a model for multiple sclerosis. The bacteria were grown to log 
phase (6h) or stationary phase (l6h) to investigate whether the intrinsic adjuvanticity 
is growth phase dependent. The mice received one of the wild type Lactobacillus 
strains, L. plal/tarum NelS, L. reuteri, L. /IIurilles or L. casei in NaHC03 orally on 
four consecutive days. The control groups received NaHCO, only. On the first day, 
the mice were also immunized i.p. with TNP-CGG in PBS. One control group was 
immunized with TNP-CGG in adjuvant. The immunisation with TNP-CGG as well as 
the oral administration of lactobacilli was repeated from day 49 onwards. Total IgG 
antibody responses against CGG were determined in sera collected 14 days after the 
second immunisation (Figure 1). A reference curve was used to calculate the arbitrary 
units (a.u.). None of the tested Lactobacillus strains exhibited intrinsic adjuvanticity in 
SJL mice, as no significant differences between groups fed Lactobacilllls strains and 
the control group immunized with TNP-CGG in PBS and fed with NaHCO, only were 
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seen. These data are consistent with results obtained with log phase Lactobacillus 
strains in the Th2-biased BALB/c mouse strain, except for L. reuteri (Maassen et a/., 
1999b). This strain did enhance the antibody response against CGG in BALB/c mice. 
In addition, no significant differences between log and stationary phase lactobacilli fed 
groups were present in SJUJ mice, indicating that in this Thl-biased mouse strain, the 
growth phase of these Lactobacillus species does not affect adjuvant activity. As 
expected, the control group immunized with TNP-CGG in adjuvant showed a 
significant and strong increase in CGG-specific antibody levels when compared to all 
other groups (p<O.OI). Total IgG responses against TNP were lower but comparable to 
the anti-CGG responses. 
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Figure 1. Four wild type Lactobacillus strains do lIot enha1lce systemic alltibody respo1lses 
20 
Total IgG antibody responses against eGG were determined in sera of mice immunized Lp. with 
lNP-CGG in PBS (n::;5). One control group was irnl!lunized with 1NP-CGG in adjuvant. TIle mice 
received wild Iype lactobacilli in NaHCO) orally on four consecutive days. The lactobacilli were grown 
to log phase (white bars) or stationary phase (black bars), The control groups received NaHCOJ buffer 
only (hatched bars). The immunisation with TNP-CGG as well as the oral administration procedure was 
repeated from day 49 onwards. Results (± SEM) obtained with sera collected 14 days after this second 
immunisation are shown. A reference curve was used to calculate the arbitrary units. 
Two wild type Lactobacillus straills skew the IgGlllgG2a ratio depelldellf all growth 
phase 
Although no significant differences occurred in the total IgG response of mice fed log 
phase or stationary phase cultures of the same Lactobacillus strain, the antibody 
response might be qualitatively different. It is generally accepted that the IgG I 
response reflects activity ofTh2 CD4+ T-cells, where IgG2a results from Thl-activity 
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(see O'Garra, 1998; Martin and Lew, 1998 and references therein). Therefore the IgGI 
and IgG2a responses against CGG were calculated for sera obtained 14 days after the 
second immunisation and were expressed as the IgG l/IgG2a ratio (Figure 2). Oral 
administration of a stationmy phase culture of L. casei or L. murines lead to a 
significantly higher IgG 1/IgG2a ratio than log phase bacteria of the same strain 
(p<O.Ol). Although L. pianta/'llm NelB induced a similar pattern of IgGlIIgG2a 
ratio's, the difference did not reach significance. L. reuteri did not show a difference 
in IgG l/IgG2a ratio between log and stationmy phase cultures. Because of the 
differences found between Lactobacilllls strains, it can be concluded that this isotype 
skewing is growth phase- as well as bacterial strain-dependent. Although the anti-TNP 
IgG2a responses in many cases were too low to calculate the IgG lIIgG2a ratio, the 
ratio's that were calculated showed a similar trend as the ratio's calculated for 
anti-CGG (data not shown). 
Adjuvant Oral Growth phase 
NaHCO,l 
+ NaHCO, ~ 
tog tl ] n.s. L. plalil. NelB 
stationary r-
tog ] 
stationary n.s. 
h-, log ::::1p<O.OI 
stationary 
h log ::::1p<O.OI 
stationary 
I , 
L. reuteri 
L. mllrilles 
L. case; 
0 5 10 15 20 25 
IgG l/IgG2a ratio of response against CGG (a.u.) 
Figure 2. Two wild type Lactobacillus strains skew the IgGlIIgG2a ratio dependellt 011 growth phase 
Mice (n::::5) were immuniscd Lp. with TNP-CGG in PBS and fed with wild type Laclobacillus strains in 
log (white bars) or stationary phase (black bars), The control groups orally received NaHCOJ only 
(hatched bars) and were immunised i.p. with TNP-CGG in PBS or adjuvant. The IgGI and IgG2a 
responses were calculated in arbitrary units with the use of reference curves. TIle ratio between IgGl and 
IgG2a antibodies specific for CGG was calculated for sera obtained 14 days after the second 
immunisation with TNP~CGG (±SEM). Significance of differences observed between groups of mice fed 
log or stationary phase cultures of the same Lactobacillus strain is indicated. 
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No systemic alltibody respollse agaillst L. murines after oral admillistratioll 
From the previous experiments it was clear that some Lactobacillus strains are able to 
skew the Thl and Th2 response dependent on their growth phase. In addition to L. 
casei, also L. murilles showed a growth phase-dependent difference in IgG lIIgG2a 
ratio. L. murilles was selected for further investigation. One of the rationales to use 
lactobacilli for oral vaccination or other therapeutical purposes is the fact that they are 
commensals of the human gut (perdigon et al., 1986; Pouwels et al., 1993) and are 
generally regarded as safe (GRAS-status). In addition, they should be 
non-immunogenic reflected in an inability to evoke antibody responses against 
themselves. To evaluate this in the current experimental setting, a similar experimental 
design as in Figures 1 and 2 was used. Total IgG and IgM responses of SJLlJ mice 
(n=8) against L. murilles were determined by ELISA in pooled sera obtained 21 days 
after the second intraperitoneal immunisation with TNP-CGG and oral administration 
of L. /Ilurilles. Figure 3 shows that, as expected, the treatment protocol did not induce 
IgG responses against L. murilles itself, nor IgM (data not shown). In contrast, when 
separate mice were immunized intrapelitoneally with L. Illllrilles in adjuvant as a 
positive control group, high IgG responses against L. murilles itself occurred. These 
data confirm that oral administration of L. murilles does not induce antibody responses 
against the bacteria, and imply that growth phase-dependent skewing of the TNP-CGG 
specific IgGIlIgG2a ratio is not related to an antibody response against the bacteria. 
pre~immune serum 
positive control 
NaHC03 
L. mllrilles 
L. llIurilies stationary 
o 0.5 1.5 
Total IgG response against L. murilles 
(OD,o,) 
2 
Figure 3. No systemic alltibody response against L. murines after oral administration 
TIle total IgG antibody response against L. 11I11rilles was determined after oral administration of the 
lactobacilli to mice (11::::8) in sera obtained 21 days after the second immunization with 1NP-CGG. The 
anti-L. mllrilles antibody response is indicated in absorbance at 405 om of a 1: 100 dilution of the pooled 
sera. Pooled pre-immune serum was used as negative control serum and serum obtained from mice 
immunized i.p. with L casei in adjuvant was used as reference serum. 
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L. murines of differellt growth phases illdllce distillct bllt cOllstallt IgG 1I1gG2a ratio's 
The skewing of IgGlIIgG2a ratio's as depicted in Figllres I and 2 was further 
confirmed in the experiment described above (Figllre 3). The total IgG responses 
against eGG and TNP were similar to the data presented in Figllre I, although the 
total IgG response against eGG after oral administration of L. /lllIrilleS in stationary 
phase to mice (n=8) was more pronounced (data not shown). From the previous 
experiments (Figllres 1 and 2) it was apparent that the IgG I/IgG2a ratio is 
independent of the level of the total IgG response. This raised the question whether the 
IgG IIIgG2a ratio is also independent of the level of the IgG I and IgG2a response per 
animal, i.e. whether the ratio is constant. Therefore, in Figllre 4 the IgG I response of 
individual animals is depicted against the IgG2a response of the same animal, with 
each circle representing an individual animal. Because comparable observations were 
made for time points 7, 14 and 21 days, only data are shown from gronps which 
received L. /lllIrilleS in log or stationary phase 21 days after the second immunization. 
5 ,------------------------------" 
• 
• L tuurines 
log phase . 
o L-______________ ~ ____________ ~ 
o 1 2 
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Figure 4. L. murines of different growlh phases induce distillct but COllstallt /gGl//gG2a ratio's 
Mice (n=8) were fed L. lIIurilles in stationary or log phase. Sera obtained 21 days after the second 
immunisation with 1NP-CGG were tested for IgG 1 and IgG2a antibody responses against CGG. JgG I 
and JgG2a responses are indicated in arbitrary units which were calculated with the use of reference 
curves. TIle IgG2a response of two animals in the group fed log phase L. 111llrifles was too low to be 
calculated. These mice were excluded from the analysis to prevent undue further emphasis on the existing 
clear difference between the groups. Each circle represents an individual animal. Mice fed log phase L. 
11Iurilles arc indicated by 0 and mice fed stationary phase L. 11I11rilleS are indicated by •. The correlation 
lines were calculated by linear regression. The variance is 0.67 for the group fed log phase L. Ilillrilles and 
0.85 for the group fed stationary phase cultures. R= 0.43 for the group fed log phase cultures and R= 2.43 
for the group fed stationary phase cultures. 
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Two conclusions can be drawn from this figure: First, there is a strong correlation 
between the IgG 1 and IgG2a response of each individual animal within an 
experimental group (variance = 0.67 for the group fed log phase cultures and variance 
= 0.85 for the group fed stationary phase cultures), despite considerable differences in 
IgG 1 and IgG2a responses between the animals. This strong correlation indicates that 
the IgG l/IgG2a ratio of individual animals within an experimental group is highly 
comparable. This was demonstrated not only for the groups fed L. murilles but also for 
the control groups fed buffer only. Second, the different slopes of the correlation lines 
of the groups fed log phase (R=0.43) or stationary phase (R=2.43) L. murilles indicate 
that the IgG IIIgG2a ratio's between those groups are different (see Figure 2 and 
Figure 5), confirming that the growth phase of orally administered lactobacilli 
differentially affects T-cell pathways. 
IgG subclass skewillg by statiOi/lIIY phase L. murines decreases but persists over time 
In order to investigate whether the antigen specific IgGlIlgG2a ratio's persist over 
time, the ratio between IgG I and IgG2a antibodies specific for CGG was calculated 
for sera obtained at 7,14 and 21 days after the second intraperitoneal immunisation of 
mice (n=8) with TNP-CGG. Figure 5A shows the mean IgG I/IgG2a ratio of responses 
against CGG in mice fed L. murilles in log phase and Figure 5B L. lIlurilles in 
stationaty phase. When the ratio's were compared over time, the group fed L. murilles 
in log phase showed a significantly lower IgG IIIgG2a ratio than the stationary phase 
fed group (intercept difference with p<0.05). This is consistent with the data presented 
in Figure 2. Furthermore, the IgGIIIgG2a ratio decreased significantly with time 
when L. murilles in stationary phase were administered (R= -1.04), in contrast to a 
comparable IgGlIlgG2a ratio over time when L. IIlllrilles in log phase was given (R= 
-0.07) (slope difference with p<0.05). This change in IgG I/IgG2a ratio over time was 
not seen in the control groups (R=0.06 for the buffer fed group and R=0.02 for the 
group immunized with TNP-CGG in adjuvant). 
Perspectives 
This study shows that orally administered individual Lactobacillus strains are able to 
differentially affect CD4-positive T helper-cell pathways supporting systemic antigen-
specific antibody production. Stationary phase cultures skewed T-cell responses to the 
Th2 pathway as reflected by increased production of the IgG 1 subclass. This skewing 
was evident even while the Thl-biased SJLlJ mouse strain was used. The most likely 
explanation for these findings is the occurrence of growth phase-dependent differences 
in bacterial cell wall composition, for which there is ample prior evidence, including 
proinfiammatOlY compounds (Davies et al., 1991; Derre et al., 1999; Graumann et al., 
1999; Henderson et al., 1996; Hu and Coates, 1999). Another not mutually exclusive 
explanation is that log phase versus stationary lactobacilli differentially affect 
dendritic cell populations (DCI versus DC2), which govern directional activation and 
.polarization ofT-cell subsets during antigen presentation (Rissoan et al., 1999). 
75 
Growth phase depelldent skewillg of IgGIIIgG2a ratio 
A 6 
5 
4 
3 
~ g 2 
8 
.~ 
~o 0 
~ 
Ii}< 
Log phase L. IllUrilieS 
T T T 
7 14 21 
B g r---------------------------------
'5 6 
2 
o 
7 14 
Stationary phase 
L. murilles 
21 
Time after second immunisation (days) 
Figure 5. IgG subclass skewing by statiollary phase L lJIurilles decreases but persists over time 
TIle ratio of IgGI and IgG2a antibodies specific for eGa was calculated for sera obtained 7, 14 and 21 
days after the second inununisation. 
(A) IgGl/IgG2a ratio of response against CGG in mice fed L. IIIltril/es in log phase (±SEM). 
(B) IgG llIgG2a ratio of response against eGG in mice fed L. l1Iurilles in stationary phase (±SEM). 
TIle IgGllIgG2a ratio decreased significantly (p<O.OS) over time when L. I1lflr;neS in stationary phase was 
fed (R::; -1.04), in contrast to a similar IgGllIgG2n ratio over time when L mllrilles in log phase was fed 
(R= -0.07). 
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Growth phase dependent skewing of T helper cell pathways has important 
consequences for industrial application of Lactobacillus strains, as skewing may affect 
desired probiotic activities of food products. With respect to inununotherapeutic 
applications, including genetically engineered lactobacilli, our data caution that oral 
administration may inadvertently promote autoimmune or allergic reactions. However, 
this property of some Lactobacillus strains may also offer promising opportunities for 
immune modulation. Oral vaccination strategies (Clements, 1997; Robinson et ai., 
1997) may exploit skewing properties to enhance T helper cell pathways dependent on 
the desired protective response, for example induction of cell mediated immunity 
versus antibody production, or preferential induction of specific functional IgG 
subclasses (e.g. differential complement fixation by IgGI versus IgG2a). Oral 
Lactobacillus administration strategies for peripheral T cell tolerance induction as a 
treatment of autoimmune disease (Maassen et ai., 1999a; Weiner, 1997) may benefit 
from skewing towards Th2 responses, whereas reduction of Th2 activity is required in 
treatment of allergy. 
The current findings strongly emphasize the need for rational Lactobacillus 
strain selection and detailed evaluation prior to application in food or health care 
products, and imply that the bacterial growth phase is a crucial parameter allowing 
additional manipulation of immune responses by oral administration of lactobacilli. 
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Chapter 3.1 
Instruments for oral disease-intervention strategies: 
recombinant Lactobacillus casei expressing tetanus toxin 
fragment C for vaccination or myelin proteins for oral 
tolerance induction in multiple sclerosis 
CB.M. Maassen, J.D. Laman, M.I. Heijne den Bak-Glashouwel~ 
F.I. Tielen, J.CPA van Holten, L. Hoogteijling, C Antonissen, 
R.I. Leer, P.B. Pauwels, WJ.A. Boersma and D.M. Shaw 
Vaccine 17: 2117-2128, 1999 
Recombinant lactobacilli as antigen carrier 
Summary 
Lactobacillus strains possess properties that make them attractive candidates as 
vehicles for oral administration of therapeutics. In this report we describe the 
constl'llction and analysis of recombinant Lactobacillus casei applicable in oral 
vaccination against an infectious disease (tetanus) and in oral tolerance induction for 
intervention in an autoimmune disease, multiple sclerosis. 
Recombinant Lactobacillus casei which express slllface-ancJlOred teta/llIs toxin 
jragmel/t C (1TFC) were generated. Quantitative analysis by flow cytomefly 
demonstrated a high level of cell wall-bound expression of 1TFC and immllllOgenicity 
was demonstrated by parel/teral immunisation with whole cell extracts of the 
recombinants. 
A series of expression vectors was constructed to secrete human myelin basic 
protein (hMBP) or IIMBP as a fusion protein with fJ-glucuronidase from Escherichia 
coli. These heterologous products produced by L. casei were detected in the growth 
medium and parenteral immunisation with this medium evoked antibodies against 
hMBP, confirming that secretion indeed had occurred. 
Based on the different localisation of the heterologous proteins, lactobacilli 
expressing slllface-anchored 1TFC are ideally suited for the induction of antibody 
responses, whereas lactobacilli that secrete myelin proteins can be used for the 
induction of peripheral T-cell tolerance. In conc/usion, the specific technology 
described here al/ows the construction of a wide array of safe live recombinant 
lactobacilli which //lay prove to be useful in oral intervention strategies for the 
prevention of infectious diseases or treatment of alltoimmune diseases. 
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Introduction 
Among the acquired disorders of the central nervous system (CNS) are infectious and 
autoimmune diseases. For the prevention of infectious diseases, oral vaccines possess 
a variety of advantages over parenterally administered vaccines (Czerkinksy and 
Holmgren, 1995). Similarly, as an intervention in autoimmune diseases, autoantigens 
can be administered orally to restore peripheral T-cell tolerance. Active vaccination as 
opposed to the induction of T-cell tolerance following oral administration of antigens 
is considered to be crucially dependent on the particulate or soluble nature of the 
antigen delivered to the intestinal tract (Brandtzaeg, 1996; Gebert et al., 1996). 
Therefore, in the current study, we have developed various recombinant Lactobacillus 
strains which differ in the form of expression of the antigen, facilitating either surface-
anchored or secreted heterologous antigen expression. 
It has long been recognized that feeding of soluble proteins can result in a state 
of immunological non-responsiveness termed oral tolerance (Strobel et al., 1983; 
Mowat, 1985). This natural feature of the gut mucosa can be exploited to generate 
tolerance towards autoantigens. We have previously shown that oral tolerance to 
B-galactosidase can be induced with L. pialltarulIl transformed to express 
B-galactosidase (Maassen et al., 1998a). In this context, it has been reported that oral 
administration of MBP can result in inhibition of experimental autoimmune 
encephalomyelitis (EAE) in Lewis rats, a model for multiple sclerosis (MS)(Higgins 
and Weiner, 1988; Bitar and Whitacre, 1988). 
The mucosal surfaces of the intestinal tract are designed for the uptake of 
nutrients. Immune responses towards dietary antigens are unwanted and therefore 
suppressed and as a result it is very difficult to evoke systemic immune responses 
following delivery of antigens to the mucosal surfaces. Enhanced immunogenicity 
following oral administration is achieved by presenting antigen to the immune system 
in association with inert particles, bacteria (Challacombe and Tomasi, 1980) or live 
viral vectors (reviewed for vaccinia by Moss (1996». Due to the many advantages of 
oral vaccination, the 'Children's Vaccine Initiative' (CVI) of the World Health 
Organization (WHO) supports the development of a new generation of vaccines that 
can be administered orally. 
Lactobacillus species are members of the diverse group of Gram-positive lactic 
acid bacteria that are generally recognized as safe (GRAS). These bacteria are 
potentially food grade, a status corroborating their particular suitability for oral 
therapeutical applications. Presentation of antigens on the surface of lactobacilli is 
attractive for vaccine design, especially because the peptidoglycan layer of some 
strains appears to exhibit natural immuno-adjuvanticity (perdigon et al., 1991; 
Boersma et al., 1994; Link-Amster et al., 1994; Pouwels et al., 1996). The chemical 
coupling of the hapten trinitrophenyl (TNP) to the surface of lactobacilli has resulted 
in the induction of significant TNP-specific antibody responses following oral 
immunization (Gerritse et al., 1990). In contrast to immunogenic applications of the 
strains expressing the antigen at the cell surface, recombinant lactobacilli that secrete 
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(auto)antigens locally in the gastrointestinal tract may also be used for the induction of 
peripheral T-cell tolerance following oral administration. 
Here we describe the construction of recombinant L. casei expressing tetanus 
toxin fragment C (TTFC) on the cell surface. Tetanus is an infectious disease affecting 
the CNS of which over 400.000 children die worldwide each year. Infection with 
Clostridium tetani results in the production of tetanus toxin, which enters the CNS via 
the blood, leading to muscle cramping and eventually to death. TTFC is a non-toxic 
but immunogenic 47kDa fragment of the tetanus holotoxin heavy chain which is 
capable of inducing protective antibody responses, and hence TTFC is a rational 
choice for inclusion in a subunit (Fairweather et ai., 1990; Robinson et ai., 1997). In 
this study we examine the expression of TTFC by recombinant L. casei using both 
immunochemistry and flow cytometry analysis. The immunogenicity of the 
transformed cells was evaluated following parenteral immunisation. 
For oral tolerance induction, L. easei recombinants expressing myelin antigens 
were constructed. Multiple sclerosis is a T cell mediated autoimmune disease of the 
CNS that affects the myelin sheath, which insulates the nerve axons. EAE 
(experimental autoimmune encephalomyelitis), a model for MS, can be induced in 
several animal species by imunization with myelin antigens such as MBP. Two 
vectors were created directing secretion of the encephalitogenic/tolerogenic compound 
hMBP or hMBP fused to B-glucuronidase. In this study we report the analysis of the 
MBP recombinants and the immunogenicity of the hMBP secreted by transformed 
L.casei following immunisation of mice with concentrated growth medium. 
Consequently, based on this generic technology a wide array of recombinant 
lactobacilli can be designed for application in oral intervention strategies for the 
prevention and treatment of infectious as well as autoimmune diseases. 
Materials and methods 
Bacterial strains and vector constmction 
The E. coli strain DHSa (Hanahan, 1983) was used as host strain for the construction 
of shuttle vectors. L. casei (ATCC 393) was cultured in MRS broth (Difco 
Laboratories, Detroit, MI). General molecular cloning, PCR techniques and 
transformation of Lactobacillus casei were carried out essentially as described 
elsewhere (Sambrook et al., 1989; Posno et al., 1991a). 
A series of TTFC expression vectors was constructed, based upon the 
constitutive Idh (L-( + )-Iactate dehydrogenase gene) promoter of L. easei and 
regulatable amy (a-amylase gene) promoter of L. amylovoms, as described previously 
(Pouwels et ai., 1996). The TTFC gene, kindly provided by Dr. A. Mercenier 
(Transgene, Strasbollrg, France), containing a BamHI site at its 5' end was extended 
by PCR at the 3' end using designed primers in order to obtain XllOI and NcoI sites. A 
BamHI-NcoI DNA fragment was cloned into the multiple cloning site (MCS) of 
pTUAT (Figure]). The pTUT/pTUAT vector series were developed for convenient 
analysis of DNA sequences and to simplify construction of the desired DNA fragment 
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Figure 1. pTUTlpTUAT vectors /0 simplify clolling DNA fragments illto Lactobacillrn expression 
vectors 
TIle pTUAT (Figure IA) and pTUT (Figure IB) vector series are based on the pOEM-3 vector (promega, 
Madison, WI). In brief, the multiple cloning site (MCS) of pOEM-3 was replaced by sequences 
encompassing a fragment flanked by NotI sites containing the ldll gene transcription terminator 
sequences, the uMA gene encoding J3-glucuronidase and the transcription terminator sequence of the L. 
plalltarum cbh gene. In case of pTUAT the B-glucuronidase open reading frame (ort) sequence was fused 
in frame with that of a sequence encoding the sequences responsible for the anchoring of prtP of L casei 
ATCC 393.111C MeS, which is direct in front of the uidA gene sequence, contains several restriction sites 
including Bamffi and Nco!. 
into the pLP400lS00 series of LactobacilluslE.coli shuttle vectors (Pouwels et al., 
1996). Subsequently, the BaIllHI/Nhe! fragment containing TTFC-lIidA was 
exchanged with the BaIllHI/Nile! fragment of the expression-secretion vectors of the 
pLP400lS00 series. In the pLP40l-TTFC/U expression vector TTFC is fused to the 
marker gene uidA, which encodes B-glucuronidase. This expression vector is under the 
transcriptional control of the promoter and secretion signal sequence of the regulatable 
amylase gene of L. alllylovol'lls (aIllY). The fusion TTFC-uidA open reading frame is in 
frame with a sequence coding for the cell wall anchor sequence of the Pl'tP gene of 
L.casei in order to expose the synthesized product at the cell surface of the bacterium. 
The pLPSOl expression vector resembles the pLP40l expression vector, however 
expression is under the transcriptional control of the constitutive ldll promoter and 
translocation is facilitated by fusion of the orf to the secretion signal sequences of the 
prtP gene of L. casei. By digestion with XhoI the uidA gene sequencewas removed 
resulting in expression vectors pLP40l-TTFC and pLPS01-TTFC (Figure 2). 
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Figure 2. Lactobacillus expression vectors for secretioll or slIr!ace-allcllOred expression of 
heterologous pro/eills 
(A) pLP401-TfFC vector mediating surface-anchored expression of TTFC under control of the 
regulatable amylase promoter. (B) pLP501-TIFC vector mediating surface-anchored expression of TfFC 
under control of the constitutive lactate dehydrogenase promoter. (C) pLP402-hMBP vector mediating 
secretion of hMBP under control of the regulatable amylase promoter. (D) pLP402-hMBP/u vector 
mediating secretion of hMBP fused to 6-g1ucuronidase under control of the regulatable amylase promoter. 
Pamy = promoter sequence of the a-amylase gene of L amy/ovonts. ssAmy = sequences encoding secretion signal 
(36aa) of Ihe a-amylase gene of L casei and the N-tenninus (26aa) of a-amylase gene of L casei. P1dh = promoter 
sequences of the Idh gene of L casei. ssPrt = sequences encoding secretion signal (33aa) of the prt P gene of L. easei 
and the N-tenninus (36aa) of the prt P gene of L. easei. Anchor = anchor peptide (U7aa) encoding sequence of L. 
easei. Tan = Imnscription tenninator sequence of Ihe ebh gene of L plantart/Ill 80. VidA = sequences encoding 15-
glucuronidase. rep = repA gene of plasmid p353-2 from L pelltosis. el)' = crythromycine resistance gene. amp = 
ampicilline resistance gene. on = origin of replication (ori+ =ori E. coli, ori- = ori Lactobacillus). 
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A series of expression vectors was constructed to secrete human MBP or hMBP fused 
to uidA under transcriptional control of the amy promoter, in a similar fashion as used 
for the TIFC vectors. The 513 bp DNA coding for human MBP (ATCC clone 
M13577) was extended at its 3' end with a BspHI site and at the 5' end with a BglIT 
site using PCR. The BglII - BspHI MBP DNA fragment was cloned in pTUT (Figure 
1), following digestion of pTUT with Ball/HI and NcoL Subsequently, the BglWNheI 
fragment containing the insert was exchanged with the BamHI/NheI fragment of 
pLP402 creating pLP402-hMBP/u (Figure 2D). Digestion with X/wI removed the 
uidA gene, resulting in the vector containing only hMBP (Figure 2C). The 
pLP4001500 vectors are stable in E. coli due to the presence of the Idll terminator 
(Tldh)(pouwels et al., 1996). After removal of the Tldh terminator by NotI digestion, 
ligation of the vectors juxtaposed the heterologous protein encoding sequences in 
frame with the first few codons of the translation initiation region present downstream 
of the promoter sequences, allowing heterologous gene expression in Lactobacillus 
species (Figure 2). 
Expression analysis of heterologous gene products 
For expression analyses, recombinant L. casei containing the vectors pLP401 and 
pLP50 I expressing TIFC (designated pLP40 1-TTFC and pLP50 1-TTFC) or 
containing the vector pLP402 expressing hMBP or hMBP fused to B-glucuronidase 
(designated pLP402-hMBP and pLP402-hMBP/U) were routinely prepared from 
glycerol stocks by two consecutive overnight (o/n) cultures without aeration of a 1:50 
dilution in MRS medium containing 5 flglml elythromycin. 
Transformants with expression vectors containing the constitutive Idh promoter 
were subsequently grown in antibiotic selective MRS medium or Lactobacillus 
carrying medium (LCM)(Efthymiou and Hansen, (962) containing 1% glucose (w/v) 
at 37"C, using a I :50 dilution of the last o/n culture. In order to induce expression of 
the heterologous proteins in transformants containing plasmids under the 
transcriptional control of the regulatable a-amy promoter, cells were grown in 
mannitol (1% w/v) supplemented LCM or modified MRS medium (ruMRS) (1% w/v 
proteose peptone, 0.5% w/v yeast extract, 0.2% w/v meat extract, 0.1 % v/v Tween SO, 
37mM sodium acetate, O.S ruM magnesium sulfate, 0.24 ruM manganese sulfate, S.S 
ruM diammonium citrate in O.1M potassium phosphate buffer [pH 7.0)). Cells were 
harvested at defined time points, pelleted by centrifugation and suspended in 
phosphate buffered saline (PBS). Cell extracts were obtained from the bacteria by 
sonicating the cells four times on a 30 sec on/30 sec off cycle using an MSE Soniprep 
150 sonicator at 10 amplitude microns (Sanyo Gallenkamp PLC, Leicester, UK), to 
release both cytoplasmic and cell wall-bound proteins. After centrifugation the soluble 
fraction was used for immunoblot analysis. 
To detect heterologous proteins secreted into the medium, the culture medium 
was collected after spinning down the cells and filtered through a 0.2 flm filter to 
remove the remainder of cells. After addition of 0.2mglml trypsin inhibitor (Sigma 
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Chemical, La Jolla, CA) the culture medium was freeze-dried and concentrated 
approximately 200-fold in PBS. Dilutions of these concentrated media are used for 
immunoblot analysis. Proteins in cell extracts or culture medium were separated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE)(7.5, 10 or 14% acrylamide, 
400 mM Tris pH 8.8) and lun in a 25 mM Tris, 192 mM glycine buffer (pH 8.3) at 
200V for 45 minutes. Protein was transferred electrophoretically onto nitrocellulose 
using a Bio-Rad Miniprotean II blotting unit (Bio-Rad Laboratories, Hercules, CA). 
Immunoblots were incubated with optimally diluted rabbit anti-TTFC (Calbiochem-
Novabiochem International, San Diego, CA), rabbit anti-hMBP or rabbit anti-p-
glucuronidase antiserum. Antibodies against hMBP and p-glucuronidase were induced 
by immunization of New Zealand White rabbits with human MBP and B-
glucuronidase in complete adjuvant containing Mycobacterium tuberculosis H37Ra 
(Difco Laboratories). The second incubation step was performed with swine anti-
rabbit Ig-HRP (Dako NS, Glostrup, Denmark). The immunoblots were incubated with 
ECL detection reagents (Amersham Life Science Ltd, Buckinghamshire, UK). A light 
sensitive film (Kodak X-omat) was exposed to the blots for a variety of time periods 
before development. In all immunoblots, recombinant TTFC antigen (List Biological 
Laboratories, Campbell, CA), bovine MBP (purified according to Deibler et al., 1972) 
or B-glucuronidase (Sigma Chemical) were used as references for the immuno-
reagents. Culture medium of various recombinant L. casei strains expressing fusion 
proteins with B-glucuronidase were used as controls for secretion or lack of secretion 
of heterologous proteins into the culture medium in immunoblot experiments. 
pLP402-HNU, which secretes the 111-120 peptide of hemagglutinin of influenza 
(HA 111-120) fused to p-glucuronidase, was used as a positive control for secretion 
(Hackett et al., 1985). Surface-expressed TTFC fused to B-glucuronidase 
(pLP40 1-TTFCIU) and intracellularly expressed TTFC fusion protein 
(pLP503-TTFCIU) are examples of heterologous proteins that are not directed to the 
medium and were utilized as negative controls. The amount of soluble heterologous 
hMBP-B-glucuronidase was calculated by comparison of several dilutions of extracts 
of transformants with a reference of purified B-glucuronidase in immllnoblot analysis 
making use of Bio-ID V6.32 software (Vilber Lourmat, Marne la Vallee, France). 
FlolV cytomelly analysis 
At defined time points bacteria were prepared for analysis by FACScan. Cells were 
washed twice with FACS fluid (FF), Facsflow™ (Becton-Dickinson, San Jose, CA) 
with 1 % BSA and 0.1 % sodium azide. Cells were resuspended in 200fll FF containing 
optimal dilutions of antibodies specific for TTFC, MBP or p-glucuronidase and 
incubated for one hour at 4°C. Cells were again washed twice in FF. Bound antibody 
was detected by incubation with fluorescein isothiocyanate-conjugated (FITC) labeled 
goat anti-rabbit immunoglobulin G (Jackson Immunoresearch Laboratories, West 
Grove, PA) at a dilution of 1: 1500 for lh at 4°C. Cells were then washed twice prior to 
analysis on a flow cytometer (FACScan™, Becton-Dickinson). CellQuest® software 
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was used for analysis of the data. A gate was set for events representing lactobacilli as 
detennined by cytograms of forward and side scatter to enable exclusion of debris. 
Control strains were wild type L. casei or recombinant strains expressing an irrelevant 
protein harvested in the same growth phase. For control stainings normal rabbit selUm 
was used or the antigen-specific primary antibody was omitted. For each sample, data 
was collected for 10,000 or 20,000 gated events. TIle fluorescence obtained from 
bacterial cell suspensions was represented by fluorescence histograms and mean channel 
intensities were calculated. 
For quantification of surface expression, L. casei pLP401-TrFC cells were 
analysed by examining TrFC antibody binding at the point of antibody saturation. This 
precise determination of fluorescence levels at the point of saturation of binding sites was 
achieved empirically following the generation of a titration curve for the TrFC-specific 
polyclonal antibody. 
The conversion of measured fluorescence intensities into values representing 
the number of TrFC molecules accessible for binding on the surface (ABC) was 
undertaken using the Quantum25® FITC Kit calibration beads (Flow Cytometry 
Standards, Leiden, The Netherlands). To enable quantitative estimates of the numbers 
of antibodies bound pel' cell, peak channel data generated from the calibration beads 
was regressed against the defined values of molecules of equivalent soluble 
fluorochrome (MESF) possessed by each bead population. Because of the broader 
distribution of channel intensities for stained cells, extrapolation of the MESF value 
for pLP40 1-TTFC vectors was then undertaken using the mean channel fluorescence 
intensity obtained at antibody saturation of the lactobacilli presenting TrFC on the 
cell surface. Following corrections for fluorochrome/protein (F/P) ratios in the 
anti-rabbit FITC conjugate (second) step an estimation of numbers of surface 
molecules available for binding on the smface of the recombinant lactobacilli was 
made. 
Parellferal illllllunisationwith L. casei recombinants 
In order to demonstrate the immunogenicity of the expressed heterologous proteins, mice 
were immunized parenterally with cell extracts or concentrated growth medium of the L. 
casei recombinants. Cell extracts of the recombinants pLP401-TTFC and pLP501-TTFC 
were obtained as described above. Three BALB/c mice per group were immunized s.c. 
with an emulsion of 112.5/11 total cell extract and 137.5/11 Difco's complete adjuvant 
with M. tuberculosis H37Ra (Difco Laboratories). Concentrated culture medium from 
the recombinants pLP402-hMBP and pLPhMBP/u was used for immunisation. Three 
SJUJ mice per group were immunized s.c. with 250/11 concentrated culture medium 
emulsified in Difco's complete adjuvant or i.p. in incomplete adjuvant (Difco 
Laboratories). The immunisation procedure was repeated 28 days after the fn'st 
immunisation. SelUm was collected for analysis in ELISA every seven days. 
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TTFC alld MBP specific ELISA 
To test serum for the presence of anti-TTFC or anti-MBP antibodies, Nunc immuno 
plates (Life Technologies, Gaithersburg,MD) were coated with tetanus toxoid (RIVM, 
Bilthoven, The Netherlands)(5J.lglml, 50J.lllwell) in 0.05M carbonate-bicarbonate 
buffer (pH 9.6) or guinea pig MBP (5J.lglml, 50J.ll/well) in PBS overnight at 4°C. 
Non-specific binding was blocked by incubation with 3% BSA in PBS (150J.ll/well) 
for I hour at 37°C. Subsequently the plates were incubated for 1 hour at 37°C with 
dilutions of sera of mice immunized with cell extracts or culture medium of L. casei 
recombinants and preimmunization sera to correct for background reactivity. For the 
detection of IgG antibodies specific for TTFC or MBP, alkaline phosphatase-labelled 
goat anti mouse IgG (V) (KPL, Gaithersburg, MD) was used (lh, 37°C). After addition 
of the substrate 4-nitrophenylphosphate, the absorbance at 405nm was read at several 
time points. Endpoint titer was defined as the highest dilution which gives an 
absorbance above twice the absorbance with normal mouse serum. 
Results 
TTFC-e>.pressillg recombillallt L. casei 
Construction of TTFC-expressing L. casei transformants 
To enable the constl1lction of TTFC-expressing L. casei vectors, the 1329bp DNA 
coding for TTFC was cloned into the Lactobacilllls expression vectors pLP401 and 
pLP501 (Fig lire 2). The pLP401 vectors drive expression via the regulatable ((-amy 
promoter and include the secretion signal and N-terminus of the amylase gene of L. 
amylovol'lls. The pLP501 vectors contain the promoter sequence of the Idll gene of L. 
casei and include the secretion signal and N-terminus of the prtP gene of L. casei. 
Both the pLP401 and the pLP501 vectors contain the anchor sequence of the prtP 
gene of L. casei, resulting in expression of the TTFC-anchor protein at the cell 
surface. Candidate vectors were consltucted in E. coli DHSa hosts and after removal 
of the Idll terminator introduced in L. casei by eiectroporation. 
Immunoblot analysis of TTFC-expressing L. casei transformants 
Expression of TTFC was demonstrated by immunoblot analysis using a rabbit 
polyclonal TTFC-specific antiserum (Figllre 3A). Cell extracts were prepared of the L. 
casei transformant carrying pLP401-TTFC approximately 8 hours (log phase) after 
inoculation in LCM supplemented with mannitol at OD690= 0.6. Expression of TTFC 
in the pLP501-TTFC strain, in which expression is driven by Pldh, is not particularly 
time dependent (data not shown). This confirmed the constitutive expression by 
pLP50 1-TTFC during growth, whereas in transformants containing pLP40 1-TTFC, 
TTFC synthesis was induced by derepression of the ((-amy promoter following 
replacement of glucose in the growth medium by mannitol. Expression was 
demonstrated to be optimal at the end of the log phase (OD690=0.6). Figllre 3A 
demonstrates that the amount of TTFC product present in pLP50 1-TTFC (falle 2) is 
higher than in pLP401-TTFC (falle 4). The TTFC products of both vectors are larger 
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than the purified TTFC (falle 5) due to additional elements such as the anchor 
sequence. The apparent molecular weight of these TTFC products on immunoblot is 
approximately 7S kDa. In extracts of either of the transformants types a variety of 
breakdown products was observed. This in contrast with pLPS03-TTFC transformants 
which retain the TTFC product intracellularly. The breakdown products of this 
recombinant are less abundant (Figure 3A, lalle 6). This difference in breakdown 
products between anchored/secreted products and intracellular products holds hue for 
all pLP400/S00 vectors constructed so far. L. casei transformed with the 
pLP401lpLPSOl vectors with irrelevant sequences demonstrated no corresponding 
heterologous product expression (Figure 3A, lalle 1 alld 3). 
L. casei producillg MBP alld MBP fusioll products 
For oral tolerance induction Lactobacillus transformants containing expression vectors 
with which secretion of heterologous proteins can be achieved were constructed. DNA 
encoding human MBP was cloned into the expression vector pLP402 in frame with or 
without the sequence of p-glucuronidase (Figure 2CID). These pLP402 plasmids drive 
the expression via the regulatable a-amy promoter and contain the secretion signal 
and N-terminus of the amylase gene of L. amylovol'l/s. 
Expression of both fusion products was demonstrated in extracts by 
imrnunoblot analysis using antiserum against hMBP (Figure 3B, lalle 3 alld Figure 
3C, lalle 3). HMBP fused to fi-glucuronidase was also detected after incubation of the 
immunoblots with anti-p-glucuronidase serum (Figure 3D, lalle 1). Semi-quantitative 
analysis yielded a calculated amount of 1- I.S% MBP-p-glucuronidase fusion protein 
as a percentage of total protein. 
Secretioll of MBP alit! MBP fusioll producfS illfo the medium 
Culture medium used for the propagation of the recombinant lactobacilli was analysed 
in order to detect whether the cells secreted MBP or MBP fusion proteins. Using 
immunoblot analysis of cell extracts, the time point of optimal expression was 
determined to be 12 hours after initiation of growth in mannitol-supplemented mMRS 
medium (OD690=1.1). The fusion protein hMBP fused to p-glucuronidase was 
detectable in SO-fold concentrated medium (=7S0/11 medium) in low concentration 
using the p-glucuronidase specific anti-serum (Figure 3C, lalle 3). The breakdown 
products, which are abundantly present, are specific for fi-glucuronidase. This 
indicates that the product is, at least partially, secreted. The fusion product of hMBP 
with fi-glucuronidase could not be detected in the media when anti-hMBP serum is 
used (data not shown). Other secreted fusion proteins could be detected in the 
medium, such as the influenza peptide fused to fi-glucuronidase of L. casei 
pLP402-HAIU (Figure 3D, lalle 4). That this product is probably intact can be 
concluded from the fact that the MW of this product is higher than secreted 
fi-glucuronidase from the L. casei pLP402/u recombinant (Figure 3D, lalle 8). During 
the secretion process the signal sequence is cleaved off.. Therefore, the secreted 
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(A) E'pressioll of TTFC by recombillallts ca/'l)'illg pLP401-TTFC (lalle 4) or pLP501-TFFC (lalle 2). 
When the culture reached an optical density of 0.6 at 690 nm after derepression of the a-amy promoter, 
cell extracts were prepared and analysed by immunoblot. Nitrocellulose membranes were stained with 
serum specific for TfFC. Purified TfFC was used as positive control (lane 5) and cell extracts of wild 
type L. case; carrying an pLP501 vector with an irrelevant insert (lane 1) Of a pLP401 vector with an 
irrelevant insert (lane 3) were used as negative controls. pLP503-TfFC, which retains the TfFC product 
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products are smaller than the heterologous proteins detected in the cell extracts, as can 
be seen by comparison of the cell extract (Figure 3D, lane 7) with medium of L. casei 
pLP402/u (Figure 3D, lane 8). In concentrated culture medium from two control 
recombinant L. casei strains which expressed irrelevant antigens fused to 
B-glucuronidase either intracellular (pLP503-TI'FCIU) (Figure 3D, lane 5) or 
anchored to the bacterial surface (pLP401-TIFCIU) (Figure 3D, lane 6), no 
heterologous proteins were detected using antiselUm specific for p-glucuronidase, as 
expected. This indicated that the positive signals obtained with the medium samples of 
the recombinants are unlikely to result from leakage or lysis of cells. 
Although the large hMBP-B-glucuronidase protein is not efficiently secreted, 
the much smaller hMBP product from the pLP402-hMBP transformant was secreted 
well. This product was clearly demonstrated in 25 fold-concentrated culture medium 
on a immunoblot incubated with anti-hMBP selUm (Figure 3C, lane 2). All medium 
samples have the property that they lUn in a wide pattern (Fig 3D, lane 3, 4 and 8), but 
they show vety wide and diffuse bands in the region of the smaller proteins (Figure 
3C, lane 2). As a negative control pLP402/u, which secretes only B-glucuronidase, did 
not show a specific reactivity, as expected (Figure 3C, lane 4). 
Flow cytollletric analysis and selection 
Flow cytometry analysis of surface association of TI'FC 
Presentation of the TI'FC antigen on the surface of L. casei transfOlmed with plasmids 
pLP401-TIFC or pLP50I-TI'FC was demonstrated by FACScan analysis of 
recombinant lactobacilli. TI'FC gene expression by L. casei was analysed using a 
polyclonal rabbit TI'FC-specific antiselUm in the period of 4 to 9 h following the onset of 
intraccllularly. is shown in lane 6. (B) Expression of IIMBP fused to fl-glucutollidase by recombinallls 
can)'illg pLP402-hMBP/U. At an optical density of 1.1 at 690 11m, cell extracts were prepared and 
analysed by immunoblot. Nitrocellulose membrane was stained with serum specific for hMBP. Purified 
bovine MBP was used as positive control antigen (lane 1) and a cell extract of L. case; expressing 
n·glucuronidase (pLP402·U)(lane 2) was used as a negative control. (C) E.'pression of hMBP in cell 
extracts (llld ill culture medium. Cell extracts (lane 3) and culture medium (lane 2) of L. case; 
recombinants pLP402-hMBP were analysed by immunoblot for the presence of heterologous hMBP. 
Nitrocellulose membrane was stained with serum specific for hMBP. Purified bovine MBP was used as 
positive control antigen (lane 1) and a cell extract (lane 5) and concentrated culture medium (lane 4) of L. 
easei with pLP402-U were used as negative controls. (D) Detectioll of secreted fi-g/Ucllfollidase fusion 
products. At an optical density of 1.1 at 690 nm, cell extracts and culture medium were prepared for 
analysis by immunoblot. Nitrocellulose membrane was stained with serum specific for B-glucuronidase. 
Lane I showed hMBP-B-glucuronidase in a cell extract from pLP402-hMBPIU. Lane 2 is kept empty, to 
be sure that the secreted product in medium from pLP402-hMBP/U in lane 3 can not be due to overflow. 
Lane 4 and lane 8 show the secreted products in medium from pLP402-HNU and pLP402-U 
respectively. Lane 5 and 6 showed the concentrated media of pLP503-TfFC (intracellular TfFC) and 
pLP401.TfFC (anchored TfFC) respectively. In lane 7, pLP402·U extract was analysed. Purified 
B-glucuronidase was used as positive control antigen in lane 9. 
a= heterologous anchored TTFC, b= intracellular TIFC, c= purified TfFC, d= hM:BP-B-glucuronidase, C=: purified 
MBP, f= non-secreted hMBP, g= secreted hMBP, h =secreted HA-B.glucuronidase, i= non-secreted B-glucuronidase, 
j= secreted 3-glucuronidase, k= purified 3-glucuronidase. Sizes of the low range marker are indicated in kDa. 
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growth. Data obtained 7 h after inoculation are presented (Figure 4A). Mean flnorescence 
levels observed with pLPS01-TIFC after staining with non-immune rabbit selUm were 
used as control (Figure 4A). A higher level of surface-anchored exposure of TIFC under 
control of the ldh promoter (pLPSO 1-TIFC) in comparison to that of the 
surface-anchored exposure of TIFC under control of the a-cuny promoter 
(pLP401-TYFC)(pouwels and Leer, 1993) was indicated by the distinct mean channel 
fluoresence intensities of the two recombinants at an equivalent time point. Similar 
results were obtained at other time points (results not shown). 
Quantitation of the number of TIFC molecules present on the cell slllface 
To estimate the mean number of TIFC molecules present on the sUiface of the cell, mean 
channel intensities obtained following staining of L. casei pLP40 1-TYFC and L. casei 
pLPS01-TIFC with anti-TIFC were used for calculation. As shown in Table I, after 7 
hours of growth approximately 3.9x103 and 1.4x103 TIFC molecules were found on the 
surface of the pLPSO 1-TIFC and pLP401-TIFC recombinant L. casei, respectively. 
Table 1. Quantitafioll of the Ilwnber of7TFC molecules expressed Oil the cell slIJiace 
of recomb;'Wlll L easei. 
Cells 
pLP401-TfFC 
pLP501-TIFC 
Mean channel 
fluorescence 
21 
55 
MESF 
4282 
12170 
FIP ratio 
3.1 
3.1 
Surface-molecules / 
per cell 
1.4*10' 
3.9*103 
Analysis of secreted hMBP and hMBP fusion products 
In order to determine whether it is possible to detect epitope-specific sequences 
associated with the cell wall of heterologous proteins which are directed to be 
secreted, transformants secreting MBP and MBP fusion proteins were analysed by 
flow cytometry, at time points of optimal expression as determined by immunoblot 
analysis (data not shown). The cells were incubated with specific antiselUm against 
p-glucuronidase or against MBP. Wild type L. casei as well as L. casei transformed 
the vector pLP402-U, which secreted p-glucuronidase, were used as controls. As 
shown in Figure 4B and 4C, it was possible to detect myelin proteins fused to 
fl-glucuronidase associated with the cell surface by flow cytometry. Significant levels 
of hMBP-p-glucuronidase (mean channel fluorescence = 13.S channels) could be 
detected using anti-p-glucuronidase selUm as compared to the wild type L. casei 
(mean channel fluorescence ~ 2.S). Using anti-MBP serum, the hMBP fusion protein 
(Figure 4C) and hMBP (Figure 4D) only could also be detected, although the level of 
surface expression of hMBP only was very low (mean channel fluorescence = 8.1 
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versus 5.1 of pLP402-U). The increase in fluorescence intensity of pLP402-MBPIU 
compared to the control recombinant pLP402-U, which only secretes fl-glucuronidase 
(mean fluorescence = 15.5 respectively 7.7 channels) (Figllre 4C) was slightly less 
than the increase in fluorescence intensity of the control strains and the recombinant 
pLP402-MBPIU detected with anti-fl-glucuronidase (Figllre 4B). 
A B 
J 
c D 
Figure 4. Flow cylomelry allalys;s of Lactobacillus casei recombinants 
~U'~02 h'JIlP:\J 
(¥I(,fi-;''-'o!'.;=;j~Hl 
(A) Sill/ace-association of 1TFC. TIFC was detected on the cell surface of Lactobacillus case; 
recombinants with pLP401·TfFC (a·amy promoter) or pLP501·TfFC (ldh promoter) by incubation of 
cells with rabbit antibodies specific fOf TIFC and stained with FITC labelled goat anti-rabbit serum. 
Recombinant pLP501-TfFC incubated with normal rabbit serum (NRS) was used as negative control. (B) 
SlIIface-association of MBP·/J-gillcllrollidase /lsillg antiserum agaillst fJ-gluwrollidase. Lactobacillus 
casei recombinants secreting MBP-p-glucuronidase (pLP402-MBPIU) showed surface-association when 
the cells were incubated with rabbit antibodies against P-glucllronidase and stained with FITC labelled 
goat anti-rabbit serum. Wild type Lactobacillus casei (wO incubated with serum specific for 
B-glucuronidase and pLP402-MBPIU incubated with normal rabbit serum (NRS) were used as negative 
controls. (C) Smface-association of hMBP-j3-glucurDllidase using hMBP specific antiserum. 
pLP402-MBPIU recombinants were incubated with rabbit antibodies directed against MBP and stained 
with FITC labelled goat anti-rabbit serum. Recombinant L. easei secreting p-glucuronidase only 
(pLP402-U) incubated with serum specific for hMBP and pLP402·MBP/u incubated with normal rabbit 
serum (NRS) were used as negative controls. (D) Swface-association of hMBP using hMBP specific 
antiserum. pLP402-hMBP recombinants were incubated with rabbit antibodies directed against hMBP 
and stained with FITC labelled goat anti-rabbit serum. Recombinant L. casei secreting l3-glucuronidase 
only pLP402-U) incubated with serum specific for hMBP and pLP402·hMBP incubated with normal 
rabbit serum (NRS) were used as negative controls. 
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ImlllllllOgellicity of heterologous proteills expressed by L. casei 
To determine whether the heterologous TTFC proteins expressed by L. casei 
recombinants pLP401-TTFC and pLP501-TTFC were immunogenic, BALB/c mice 
were immunized with total cell extracts of these recombinants. Immunogenicity of 
TTFC construct pLP50 I was demonstrated in a tetanus toxoid specific ELISA within 
14 days after the second immunization with an IgG endpoint titer of 103.2 (LoglO) for 
the rooled mice sera. The TTFC construct pLP401-TTFC showed an endpoint titer of 
10'· (LoglO) 21 days after the second immunization. 
SJLlJ mice were immunized with cell-free culture medium of L. casei 
recombinants pLP402-hMBP and pLP402-hMBP/u to demonstrate immunogenicity as 
well as secretion of the heterologous proteins into the medium. Immunogenicity of 
secreted MBP was shown by IgG endpoint titers of 1023 (LoglO) for pLP402-hMBP 
and 1029 (LoglO) for pLP402-hMBP/u after 21 days with negligible values at 14 days. 
None of the selected control recombinants (i.e. L. casei pLP402/u) induced MBP or 
TTFC antibodies, as expected. 
Discussion 
In this study we describe the construction and characterisation of Lactobacillus 
expression/delivery vectors as potential vaccines or therapeutics for diseases of the 
central nervous system. Essentially, similar vectors are designed for use of two distinct 
applications; live oral vaccines to actively immunise versus live oral therapeutics to 
restore peripheral T cell tolerance in autoimmune disease. The distinct effects are 
facilitated through the precise location of the antigen; surface-anchored antigen-
expression for the vaccine application versus antigen secretion into the local 
environment for tolerance induction (Brandtzaeg, 1996; Gebert et al., 1996). 
Two plasmids were constructed to enable surface-anchored expression of 
TTFC. The expression is under transcriptional control of the constitutive Idh promoter 
(pLP501-TTFC) or under the control of the a-amy promoter (pLP401-TTFC), which 
is repressed in the presence of glucose. For application in vaccine strategies, the 
number of molecules of the antigen present on the cell-surface is considered important 
for immunogenicity. Flow cytometry has previously been used to determine the 
composition of bacterial cultures, in which each bacterial species has its own 
characteristic 'signature' (Pinder et al., 1990). In addition, heterologous proteins have 
also been demonstrated on the surface of other recombinant Gram-positive bacteria 
such as Staphylococcus xylosus (Samuelson et al., 1995). Flow cytometry, to our best 
knowledge, has not been used before to detect heterologous proteins associated with 
the Lactobacillus surface. We have shown that this technology allows an estimation of 
the relative number of molecules expressed on the cell wall by individual cells. In the 
utilisation of a polyclonal antibody we assumed that each TTFC molecule is bound by 
only one antibody molecule, enabling the relative measurements between recombinant 
lactobacilli. With this strategy it was demonstrated that for L. casei pLP50 1-TTFC, 
under control of the constitutive Idh promoter, the number of TTFC molecules per 
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cell, present on the Lactobacilllls cell wall is three times higher than observed for L. 
casei pLP40 1-TIFC which expresses TIFC under the control of the regulatable 
a-amy promoter. The difference in expression level can be explained by the fact that 
the promoter sequences used have different transcription activities (pouwels et at., 
1996). The different secretion signals (proteinase versus amylase) inherent to the 
vectors may also lead to higher translocation efficiencies in the pLP501-TIFC 
recombinant and may result in elevated levels of TIFC on the cell wall accessible for 
binding by antibody (Pouwels and Leer, 1993; Hols et at., 1997). The difference in 
level of expression/surface association may also account for the higher levels of TIFC 
specific antibodies found after parenteral immunisation with total cell extracts of L. 
casei pLP501-TIFC as compared to pLP401-TIFC. Although both recombinant 
strains appear to be immunogenic, the results argue for the use in vaccine applications 
of recombinant strains utilising the constitutive promoter. The breakdown products 
present in extracts obtained from either the pLP401 or pLP501 recombinants, which 
are not as abundantly present in extracts obtained from pLP503 recombinants 
maintaining the heterologous proteins intracellular, may well be due to activity of 
proteases present at the surface of the bacterium or in the medium. 
Vectors for the use in oral tolerance studies preferably should secrete the 
tolerogen (Brandtzaeg, 1996; Gebert et at., 1996). Therefore, two vectors that secrete 
hMBP (pLP402-hMBP) or hMBP fused to Il-glucuronidase were constlUcted and 
analysed. Although secretion of both products was demonstrated in immunoblot 
analysis using protein samples prepared from the culture medium, there was a clear 
difference in the levels of secretion. The quantity of hMBP-Il-glucuronidase fusion 
protein actually present in the culture medium was very low, and the product 
apparently was digested into two main products. However, this fusion product was 
detectable by flow cytometry using either anti-MBP or anti-Il-glucuronidase 
antibodies. This suggests that although the protein is translocated over the membrane, 
it did not undergo signal peptide cleavage or was degraded by extracellular proteases. 
When cleavage does not occur within the encephalitogenic epitopes, the secreted 
protein could still maintain its tolerogenicity. Association of the mature form of 
translocated heterologous proteins with the cell wall has been described for Gram-
positive bacteria (Suanders et at., 1987; Simonen and Paiva, 1993; Wells et at., 1993). 
The smaller hMBP protein without Il-glucuronidase is much more efficiently secreted 
than hMBP fused to Il-glucuronidase. Following analysis of this recombinant by flow 
cytometry, we only found a very low surface-association of hMBP. Apparently, this 
product is indeed quite efficiently secreted into its environment. We have shown that 
protein secretion into the medium from recombinants transformed with vectors using 
the same secretion signals (pLP402-hMBP, pLP402-hMBPIU, pLP402-HAlU, 
pLP402-U) does not occur at similar levels. These differences probably arise from 
biochemical properties of the protein itself (e.g. size, hydrophobicity, conformation). 
In addition, varying sensitivities of each protein for proteases may affect the amount 
of protein found in the medium. Introduction of pLP402-MBPIU in alternative 
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Lactobacillus strains may result in an increase of the level of secretion of this 
particular protein. 
Immunisation of mice with concentrated culture medium of the hMBP 
recombinants evoked MBP-specific antibodies, from which it could be concluded that 
the heterologous proteins were immunogenic and secreted into the medium. However, 
the antibody levels induced by medium containing the hMBP-B-glucuronidase fusion 
protein were higher than the levels induced by medium containing hMBP. 
Host strain selection is a factor that may impact significantly on the capacity to 
successfully induce antibodies or restore peripheral T-cell tolerance by oral 
administration. Recently, Lactobacillus strains have been identified that persist for 
extended periods in the intestinal tract of mice (D.M. Shaw, unpublished) as well as in 
humans in comparison to the prototype L. casei, and this property may improve 
efficacy of oral vaccination and of tolerance induction considerably. We have 
previously shown that induction of oral tolerance can be induced with L. piantal'll/ll 
transformed to express p-galactosidase (Maassen et ai., 1998a) and mucosal antibody 
responses can be induced with orally administered trinitrophenyl-Lacfobacillus 
acidophilus conjugates (Gerritse et ai., 1991). 
In conclusion, the generic technology described here allows the construction of 
a multitude of safe recombinant lactobacilli which may prove advantageous in oral 
intervention strategies for the prevention and treatment of infectious and autoimmune 
diseases of the central nervous system. Currently, recombinant lactobacilli expressing 
TIFC or viral antigens are tested in animal models for their ability to induce specific 
antibodies after oral administration. Whether orally administered recombinant 
lactobacilli secreting myelin antigens are capable of inducing peripheral T-cell 
tolerance is currently investigated in mouse and rat BAE-models for multiple sclerosis. 
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A rapid and safe plasmid isolation method for 
efficient engineering of recombinant lactobacilli 
expressing immunogenic or tolerogenic epitopes 
for oral administration 
C.B.M. Maassen 
Journal of Immunological Methods 223: 131-136, 1999 
Rapid alld safe plasmid isolationmethodfor lactobacilli 
Summary 
Recombillallt lactobacilli are beillg developed which call be used as expression alld 
delivelY vectors of heterologous antigens in oral vaccillatioll alld other therapeutic 
applicatiolls. Because most Lactobacillus strains do not accept ligation mixtures, 
sufficielltly pure plasmid DNA lIeeds to be isolated from L. casei to trallsform other 
Lactobacillus strains. The isolation of plasmid DNA from Gram-positive lactobacilli is 
complicated by the resilience of the peptidoglycan layer. Here a rapid, safe and 
efficient method is described that combilles ellzymatic breakdown of the cell wall alld 
purification of the plasmid by commercially available DNA-billding columlls. For the 
lysis-resistallt Lactobacillus casei straill, this method yields high levels of pure 
plasmid DNA that call be used for common molecular techniques, such as digestion 
alld transformation, with high efficiellcy. 
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Introduction 
Lactobacilli are lactic acid bacteria, which are founs as conunensals of the human gut. 
Lactobacilli are increasingly being used in food products. In addition, pharmaceutical 
applications are being developed, such as genetically engineered lac'tobacilli as oral 
vaccines and for oral T-cell tolerance induction for the treatment of autoimmune 
diseases such as multiple sclerosis (MS) (pouwels et al., 1996; Maassen et al., 1999a). 
Currently, in our laboratory, recombinant lactobacilli which express viral and 
microbial heterologous antigens on the cell surface are orally administered for the 
induction of antibodies in mice. Lactobacilli which secrete autoantigens such as 
myelin basic protein (MBP), are administered orally for the induction of peripheral 
T-cell tolerance in a mouse model for MS (experimental autoimmune 
encephalomyelitis, EAE). 
Because most Lactobacillus strains do not accept ligation mixtures, the DNA 
required to transform these strains needs to be isolated from Lactobacillus casei 
ATCC 393, which can be transformed with ligated DNA. For efficient transformation 
of Lactobacillus strains, highly pure DNA is required. Current isolation techniques 
used to obtain large quantities of plasmid DNA consist of a cell lysis method followed 
by alkaline lysis, phenol-extraction and cesium chloride gradient centrifugation. The 
major obstacle in these isolation procedures is the efficient lysis of the Gram-positive 
cell wall. This can be achieved by mechanical or enzymatic procedures (Klaenhammer 
and Sutherland, 1980; Posno et al., 1991a; Frere, 1994; Reinkemeier et al., 1996). 
Lactobacillus plasmid DNA obtained after alkaline lysis and phenol-extraction 
contains contaminating chromosomal DNA and cell wall debris. Therefore additional 
cesium chloride equilibrium density gradient centrifugation is necessaty to obtain 
plasmid DNA of high purity suitable for electroporation (Sambrook et al., 1989). The 
procedure is time-consuming (2-3 days) and requires the use of toxic chemicals. 
As a consequence, there is clearly a need for a more rapid, high yield isolation 
method to obtain plasmid DNA from lactobacilli, which does not require the use of 
hazardous agents. The aim of this study was to develop a simple method that yields 
large amounts of pure plasmid DNA from several different Lactobacillus strains, 
including lysis-resistant strains such as L. casei. Furthermore, this method should be 
more rapid than methods such as cesium chloride gradient centrifugation and has the 
advantage that no hazardous agents such as phenol and ethidium bromide need to be 
used. This method would simplify the development of recombinant lactobacilli, which 
can be used in various therapeutic applications. 
Materials and methods 
Plasmid isolation 
Recombinant Lactobacillus strains were cultured overnight in 500 ml MRS (Difco 
Laboratories, Detroit, MI). Lysis of the lactobacilli was performed essentially as 
described by Posno et al. (199Ia). The cells were harvested by centrifugation at 4000g 
for 20 min. The cells were washed twice in 25 ml 20 mM Tris/HCI buffer pH 8. The 
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pellet was suspended in 20 ml Tris/HCI (20 mM/pH 8) with 5 mg/ml hen egg white 
lysozyme (Boehringer Mannheim GmbH, Mannheim, Germany) and 20 ml of 24% 
polyethylene glycol 20,000 (F1uka Chemie AG, Buchs, Switzerland). After 2 h of 
incubation at 37"C, the cells were centrifuged and washed again with TrislHCI (20 
mM/pH 8). After discarding the supernatant the cells were taken up in the solution 
buffer E1 of the commercial kit (Jetstar plasmid maxi kit, Genomed GmbH, Bad 
Oeynhausen, Germany). The manufacturer's protocol, comprising alkaline lysis and 
subsequent neutralization with potassium acetate, was followed. After precipitation of 
the proteins present in this solution, the resulting DNA solution was applied to the 
provided column. After washing, the DNA was eluted with the buffer provided. 
Finally, the DNA was concentrated by alcohol precipitation and dissolved in 200 III 
TE buffer (10 mM TrislHCI pH 8, 1 mM EDT A). Digestion of the isolated DNA and 
analysis by agarose gel electrophoresis were carried out essentially as described by 
Sambrook et al. (1989). 
Electroporation of Lactobacillus strains 
Electroporation of L. casei was conducted as described by Posno et al. (1988), slightly 
adjusted from the method described by Chassy and Flickinger (1987). Electroporation 
of L. plantarum 256 was essentially performed as described for L. plallfa/'/(m 80 by 
Josson et al. (1989). Briefly, an overnight culture of L. plantarum 256 was diluted 
(1/50) in MRS broth and incubated anaerobically at 37°C. The cells were harvested in 
the mid-log phase, washed twice with "MilliQ" water, and washed once in 30% (w/v) 
PEG-IOOO. The cells were resuspended in 30% PEG-IOOO in 1/50 of the original 
culture volume. Plasmid DNA (lllg) was mixed with 100111 of the cell suspension in a 
disposable electroporation cuvette with an interelectrode distance of 0.2 cm. A single 
pulse of 8500 V!em2 was delivered (lOOn parallel resistor and 25 IlF capacitance 
settings, Gene Pulser and Pulsecontroller from Bio-Rad). Following the pulse, the cell 
suspension was diluted with 900 III MRS broth and incubated for 2 h at 37°C. 
Transformants were selected by plating the cells on MRS agar plates containing 
erythromycin. Transformants were visible after approximately 48 h. 
bmmlllobiot analysis of Lactobacillus transformants 
Immunoblots were performed in order to investigate the expression of heterologous 
proteins by L. casei and L. plantarum transformants. To induce expression, cells were 
grown in modified MRS medium (mMRS) (1 % w/v proteose peptone, 0.5% w/v yeast 
extract, 0.2% w/v meat extract, 0.1 % v/v Tween 80, 3.7mM sodium acetate, 0.8mM 
magnesium sulfate, 0.24mM manganese sulfate, 8.8mM diammonium citrate in 
potassium phosphate buffer (pH 7.0) containing 1 % w/v mannitol) at 37°C, using a 
1/50 dilution of an overnight culture. Cells were harvested in exponential phase, 
pelleted by centrifugation and suspended in phosphate buffered saline (PBS). Cell 
extracts were obtained from the bacteria by sonicating the cells four times on a 30 sec 
on/3D sec off cycle using an MSE Soniprep 150 sonicator at 10 amplitude microns 
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(Sanyo Gallenkamp PLC, Leicester, UK), to release both cytoplasmic and cell 
wall-bound proteins. After centrifugation the soluble fraction was used for 
immunoblot analysis. Proteins in cell extracts (30llg) were separated by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), (7.5% acrylamide for the UreB 
transformants and II % acrylamide for the MBP/u transformants, 400 ruM Tris pH 
8.8) and run in a 25 ruM Tris, 192 ruM glycine buffer (pH 8.3) at 200V for 45 min. 
Protein was transferred electrophoretically onto nitrocellulose using a Bio-Rad 
Miniprotean II blotting unit (Bio-Rad Laboratories, Hercules, CA). Immunoblots blots 
were incubated with polyclonal rabbit anti-H. pylori (Simoons-Smit et al., 1996) or 
rabbit anti-MBP serum. The second incubation step was performed with swine 
anti-rabbit Ig-HRP (Dako AlS, Glostrup, Denmark). The immunoblots were incubated 
with ECL detection reagents (Amersham Life Science Ltd, Buckinghamshire, UK). A 
light sensitive film (Kodak X-omat) was exposed to the blots for 1 min before 
development. 
Results and Discussion 
Isolation 0/ plasmid DNA/rom L. casei recombinants 
Two recombinant Lactobacillus casei strains were used to demonstrate the advantages 
of this novel plasmid isolation method. The first L. casei recombinant contained a 
vector (pLP402-MBP/U)(Pouwels et al., 1996) with an insert coding for myelin basic 
protein (MBP), which is a central nervous system protein thought to be involved in the 
pathogenesis of multiple sclerosis. The heterologous MBP protein is fused to the 
marker protein l3-glucuronidase. Because this fusion protein will be secreted, these 
transformants can be used for oral tolerance induction in an animal model for multiple 
sclerosis (EAE). The second Lactobacillus casei recombinant contained the vector 
pLP401-UreB (pouwels et ai., 1996) with an insert encoding UreB, a subunit of the 
urease enzyme of Helicobacter pylori. The UreB-product is expressed on the cell 
surface, because the vector also contains an anchor sequence. UreB transformants 
have proposed for use in oral vaccination experiments and plasmid DNA from both 
recombinants were isolated with the present novel isolation procedure. The ratio of 
A260 over A280 of the purified DNA was approximately 1.8, indicating that the DNA 
was indeed highly purified. The yield obtained from a 500 ml culture was 
approximately 200 Ilg of plasmid DNA. This is similar to the amounts of DNA usually 
obtained with the classic method using alkaline lysis and cesium chloride DNA 
banding. 
Restriction analysis o/isolated plasmid DNA 
Two vectors isolated from the highly lysis-resistant Lactobacillus casei were digested 
with two restriction enzymes at the same time. The vector pLP402-MBP/u was 
digested with the restriction enzymes Bamffi and PVIII for 2 h at 37"C. The vector 
pLP401-UreB was digested with two other enzymes, PstI and NheI. Both constructs 
were fully digested, confirming the high purity of the plasmids (Figure I). 
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Figure I. Restriction analysis of plasmids isolated from L. casei 
TIle vector encoding the urease subunit B of H. pylori was digested with PstI and 
NlleI (lane 1). The vector encoding myelin basic protein fused to 6-g1ucuronidase 
was digested with BamID and PvuI (Jane 2). For each restriction enzyme only one 
site was present. Lane 3, molecular weight DNA ladder. 
Transformation of isolated plasmid DNA to other Lactobacillus strains 
To assess whether the plasmids isolated by this method were sufficiently pure for use 
in transformation, the plasmids pLP402-MBPfU and pLP401-UreB were transformed 
to L. casei and L. plantal'llm 256 by electroporation. Transformation efficiencies of 
106_107 transformants per flg plasmid DNA were obtained for L. casei and 105_106 
transformants per flg DNA for L. plantaruIII. These efficiencies are equal to those 
obtained with plasmid DNA purified by CsCI gradient centrifugation. This suggests 
that the plasmid DNA is highly pure and that limited breakdown of the DNA occurs. 
Expression of heterologous proteins by L. casei and L. plantarum 
In order to demonstrate that the L. casei and L. plantal'llm transformants are able to 
express heterologous proteins, extracts of these transformants were analysed by 
immunoblotting. After electroporation of the isolated plasmid DNA, the transformants 
were grown under conditions that permit expression of the heterologous proteins to 
occur. After 8 h of culture the cells were harvested and extracts were made. The 
soluble fraction of the extracts was analysed for expression by inununoblotting. 
Figure 2A shows the expression of UreB in L. casei containing pLP401-UreB (lane 3) 
as compared to wild type L. casei (lane 2) which, as expected, does not show any 
expression. UreB can also be demonstrated in L. plantarum pLP401-UreB extracts 
(lane 4). Wild type L. plallfarulIl is negative for UreB (lane 5). As a positive control 
recombinant UreB (66kDa) isolated from E. coli was used (lane 1). UreB from L. 
caseilL. plantart/III is larger (82kDa) due to the presence of signal peptide and anchor 
sequences. Expression of MBP fused to B-glucuronidase is demonstrated in Figure 2B. 
Lane 3 shows the expression by L. casei pLP402-MBPfU and lane 4 shows the 
expression in L. plantarulIl pLP402-MBPfU. Again the wild type strains were used as 
negative controls (lane 2 = L. casei, lane 5 = L. plantal'llll/ 256). The size difference 
between the heterologous MBP, which runs at 85kDa (lane 3 and 4), and purified 
guinea pig MBP (21kDa)(lane 1) is mainly due to the fusion of the heterologous MBP 
with B-glucuronidase. The additional bands present in the lanes with heterologous 
proteins result from cross-reaction of the polyclonal rahbit sera with Lactobacillus 
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antigens when those bands are also present in the corresponding wild type lane. All 
bands of smaller size, which are not due to such cross-reactivity, are breakdown 
products of the heterologous proteins. These results clearly demonstrated that 
Lactobacillus strains transformed with plasmids isolated using the present method are 
able to express the heterologous proteins that are encoded on the plasmids. 
A 
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Figure 2. 
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(A) IJlJmlmoblot analysis o/Lactobacillus Irallsjormallts expressing UreB 
MBP-
a-glucuronidase 
Lane I, positive control of recombinant UreB isolated from E. coli. Lane 2, wild type L. casei. Lane 3, L. 
case; containing pLP401-UreB. Lane 4, L. planta1'll1ll containing pLP401-UreB. Lane 5, wild type L. 
'plallfarum. TIle immunoblot was incubated with anti-H. pylori serum. 
(B) 1I1111l111l0blot analysis of Lactobacillus trallsjonllallts expressi1lg MBP 
Lane I, purified MBP. Lane 2, wild type L. casei. Lane 3, L. casei containing pLP402.MBPfU. Lane 4, L. 
plan/omit! containing pLP402-MBPIU, Lane 5, wild type L. plal/farum. The immunoblot was incubated 
with anti-MBP semm. 
Plasmid isolation from Lactobacillus plantarum 256 
In order to investigate whether this method is more generally applicable to various 
Lactobacillus strains, plasmid DNA from L. plalltarulIl 256 transformed with the MBP 
containing plasmid was re-isolated as described above. Plasmid DNA was also 
isolated from L. plantartlm 256 transformed with a plasmid encoding tetanus toxin 
fragment C (pLP40 1-TTFC), which was isolated using a classic method followed by 
cesium chloride gradient centrifugation (posno et at., 1988). Figure 3 shows that, from 
this Lactobacillus strain also, plasmid DNA could be isolated using this method. 
Breakdown of plasmid DNA, as reflected by the DNA smear in Figure 3, can 
probably be diminished when the incubation time with lysozyme is shortened, because 
the stringent lysis protocol for L. casei was also used for L. plantarum. 
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Figure 3. Plasmids isolated/rom L. plalltarum 256 
TIle vectors pLP402-MBP/u (lane I) and pLP401-TfFC (lane 2) were isolated 
from L. plantarum 256 with the method described above and analysed on a 1% 
agarose gel. Lane 3, molecular weight DNA ladder. 
In conclusion, this new method for the isolation of plasmid DNA from lysis-resistant 
lactobacilli has major advantages over the classic method that requires phenol-
extraction and cesium chloride gradient centrifugation. This new method takes 
approximately five hours to perform instead of approximately two days, does not 
employ highly toxic reagents, is considerably cheaper and is easy to perform. This 
method provides high yields of pure DNA, which can be used for restriction analysis, 
transformation and other molecular techniques. This plasmid isolation technique is 
also applicable to other Gram-positive bacteria, and will improve the efficient 
engineering of biotechnologically and therapeutically useful lactobacilli recombinants 
for oral administration. 
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Antibodies against CDi54 and CD44 block EAE 
Summary 
Interactions between /l1O/IOIIl/clear cells are required for the formation of 
injlammatOlY infiltrates in the CNS and the activation of cellular effector functions 
provoking demyelination in MS. Membrane-expressed costimulatOlY molecules are 
cl'/lcia/ to such interactions. We therefore investigated whether two costimulatOl)' 
molecules, CD40L (CDi54, expressed on activated CD4-positive Tcells) and selected 
CD44-variant isoforms (expressed on activated CD4-positive T cells), are targets for 
immunotherapy in MS. TI,e model of experimellla/ autoimmune encephalomyelitis 
(EAE) induced in SJL-mice by immunization with a peptide derived from the 
proteolipid protein (PLP139-151) was optimized to address these questions. A previous 
obse/vation that anti-CD40L (CDI54) monoclonal antibodies can effectively prevent 
EAE in this model was confirmed, and extended by demonstrating that CD40 is 
expressed by cells of the monocytic lineage infiltrating the spinal cord. In vivo 
treatment with antibody against the standard isoform of CD44 (CD44s or CD44H) did 
not affect disease burden In contrast, combined treatment with antibodies against the 
isoforms CD44v6, v7 and viO, which are thought to be involved in injlammatOl)' 
processes, reduced the disease burden considerably. In addition, CD44vlO-eJ.pressing 
cells were detected in the spinal cord. These data support the idea that CD40-CD40L 
interactions form a target for immunotherapy of MS, and indicate that cells expressing 
CD44v6, v7 andlor vIO-containing isoforms have such potential as well. 
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Introduction 
Temporary and cumulative neurological dysfunction of multiple sclerosis (MS) 
patients results from chronic autoinunune inflammatory events within the central 
nervous system (CNS), leading to edema, demyelination of nerve axons, and axonal 
loss. Perivascular and periventricular inflammatory infiltrates of mononuclear cells 
containing mostly macrophages and CD4+ T-cells most probably affect these three 
processes, but the effector mechanisms involved have been elusive thus far. The 
formation of such infiltrates and activation of cellular effector mechanisms requires 
intercellular communication mediated by soluble mediators such as cytokines, as well 
as costimulatory (accessory) molecules on the cell surface. 
Immunotherapy of MS with antibodies directed against costimulatory molecules 
such as CD40L, CD80/CD86 and CD44-isoforms, may affect one ore more of the 
following events: (i) Peripheral activation of autoreactive T-cells; (ii) Adhesion, 
blood-brain barrier transmigration, and migration of mononuclear cells within the 
CNS; (iii) Peripheral or local (CNS) cellular activation events, leading to further 
(co)-stimulation of T-cells, and/or induction of cytokines, chemokines and proteolytic 
enzymes. In the current study, the co-stimulatOlY CD40L and CD44-isoform 
molecules were evaluated as candidate targets for therapy, in a mouse EAE model. 
We have previously shown that CD40-CD40L interactions are involved in EAE 
and MS, and that this interaction is indeed a target for therapy of MS (Gerritse et al., 
1996). CD40 is expressed on antigen presenting cells, such as dendritic cells, 
macrophages, microglia, endothelial cells and B cells. Interaction with CD40L 
expressed by activated, antigen-experienced CD4+ T-cells can trigger a wide array of 
effector functions of both the antigen presenting cell and the T cell itself (Laman et al., 
1996). In human MS autopsy brain, CD40 is expressed on the surface of monocytic 
cells within mononuclear infiltrates of the CNS. Functionally, we have demonstrated 
that development of EAE in SJL mice immunized with the proteolipid protein (PLP) 
peptide residues 139-151 can be prevented by treatment with anti-CD40L monoclonal 
antibody (Gerritse et al., 1996). Finally, we have demonstrated that CD40 and CD40L 
are expressed in the CNS of marmoset monkeys with demyelinating EAE in relation 
to expression of pro-inflammatory and anti-inflanunatory cytokines (Laman et al., 
1998c). This novel model is useful for the evaluation of human-specific 
immunotherapeutics. 
In view of the proposed roles of differential CD44-isoform expression in tumor 
metastasis and chronic (autoinunune) inflammation, we hypothesized that CD44 
variant isoforms are also involved in the development of MS and EAE (Rosenberg et 
al., 1995; GUnthert, 1996). 
CD44 (formerly also called Pgp-I, gp90Hennes and H-CAM) has been 
implicated to act in processes such as pattern formation in embryogenesis, formation 
of the CNS, hematopoiesis, lymphocyte homing and activation, tumor dissemination 
and inflammatory reactions (Kaayk et al., 1997). CD44 is an 80-250 kDa type I 
(extracellular N-terminus) transmembrane glycoprotein, encoded by only one gene. 
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Due to the complex RNA splicing mechanism of CD44 and post-translational 
modifications, about a thousand CD44-isoforms can potentially be generated. In 
practice, about one hundred different functional isoforms have been identified to date. 
The combination of structural features of CD44-isoforms allows high versatility in a 
wide array of cellular adhesion and activation events under physiological as well as 
pathological conditions. The CD44H (hematopoietic) or CD44s (standard) isoform is 
expressed widely, but no clear functional defects are apparent in CD44s knockout 
mice. CD44-variant isoforms, however, are only expressed on haematopoietic 
precursor cells, transiently during activation, and on memory cells. The 
pro-inflammatory cytokines TNF-alpha and IFN-gamma upregulate CD44 expression. 
Multiple ligands exist for CD44s, including hyaluronate, fibronectin, osteopontin, and 
collagen types I and IV, which are all components of the extracellular matrix (Lesley 
et al., 1993). By virtue of glycosylation and heparan sulfate side chains, CD44v3 
isoforms can also capture and concentrate cytokines as well as other soluble 
components, and present these to neighboring cells. The functions of CD44 and its 
variants still remain unknown, and putative ligands for these molecules await 
identification. 
The aim of the current study was to provide further evidence for the 
involvement of CD40L in EAE, and to establish whether CD44-variant isoforms could 
also form a target for therapy in MS. The model of EAE induced in the SJL-mouse by 
immunization with PLP139-151 peptide was further optimized to address these questions. 
Materials and methods 
Allimals 
Female SJL-mice were bred and maintained under SPF-conditions with free access to 
0.9 MRAD-irradiated pelle ted food (Hope Farms, Woerden, The Netherlands) and 
acidified water (pH 2.2) at the animal facility of the Department of Immunology, 
Erasmus University Rotterdam. This mouse strain is derived from the original SJLlJ 
(Jackson) line, and has a low microbiological burden as assessed by routine screening. 
This strain is characterized by low IgE levels in na'ive mice and animals display 
markedly more docile behavior than the original line. All experiments were performed 
with animals of 8-12 weeks old, at TNO-PG in Leiden, according to regulations in the 
Dutch law on animal expedmentation. 
EAE-indllctioll 
EAE was induced by immunization with PLP139- 151 peptide and additional treatment 
with Bordetella pertllssis to affect blood-brain barrier integrity. This is a classic and 
widely used EAE-model in mice. Animals develop paralytic disease 10-11 days after 
disease induction and recover spontaneously around day 20 (Kono et al., 1988; Sobel 
et al., 1990; Gerritse et al., 1996). Animals also show weight loss up to 25% 
concurrent with paralytic disease. On day 0, animals were injected subcutaneously 
with 50-100 micrograms (or other doses in the ill vivo titration experiments) of peptide 
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(sequence HSLGKWLGHPDKF), divided over the four flanks, with 50 microliter per 
site. The peptide in PBS was mixed at I: I in Difco complete adjuvant (Difco 
3113-60-5, with Mycobacterium tuberculosis H37RA). At day I and 3, animals 
received intravenous injections with 10'0 heat-killed Bordetella pertussis bacteria from 
the vaccine preparation used for vaccination of humans (National Institute of Public 
Health and Environmental Protection, BiIthoven, The Netherlands). Clinical disease 
was monitored daily from day 7 onward by weighing the mice, and by grading 
symptoms of paralysis using an internationally accepted clinical scoring scale, ranging 
from 0 to 5 (0 = no disease, 0.5 = tail paresis or partial paralysis, I = complete tail 
paralysis, 2 = paraparesis: limb weakness and tail paralysis, 2.5 = partial limb 
paralysis, 3 = complete hind- or front limb paralysis, 3.5 = paraplegia, 4 = 
quadriplegia, moribund,S = death due to EAE). 
Treatment lVith antibodies against costimulatory lIlolecules 
To intelfere with development of EAE, animals were treated intraperitoneally with 
protein A-purified monoclonal antibody preparations from the day of immunization 
onward. For CD40L, this treatment has previously been shown to effectively prevent 
EAE, even when treatment was started shortly before onset of clinical signs (Gerritse 
et al., 1996). For CD44-variant isoforms such experiments have not been reported yet. 
In the current study, anti-CD40L treatment was performed to confirm previous 
findings, and to extend these by analysis of spinal cord mononuclear cell infiltrates for 
expression of CD40. In addition, anti-CD40L treatment served as an internal treatment 
control for the anti-CD44 isoform experiments. Animals were treated by i.p. injection 
of 250 microgram of antibody against CD40L and CD44s on day 0, 2 and 4, or on day 
0, 2, 4 and 6 with a combination of antibodies against CD44 v6, v7 and vl0. This 
protocol was based on previous experiments where anti-CD40L successfully 
prevented EAE (Gerritse et al., 1996). The rat IM-7 antibody (IgG2b) directed against 
the mouse CD44s isoform was used, as well as mouse antibodies against isoforms v6 
(LN 6.1), v7 (LN 7.1) and vlO (LN 10.1). These antibodies are further referred to as 
anti-v6, anti-v7 and anti-vlO. CD40 was detected by means of FGK-45 (Rolink et al., 
1996). As the blocking antibody against CD40L is raised in hamster, hamster 
immunoglobulin (Hig) was used as a negative control antibody lacking blocking 
activity (Noelle et al., 1992). 
[mlllunohistochelllisfly 
To evaluate expression of CD40, CD40L and CD44-variant isoforms in the CNS of 
animals used in the experiments above, immunohistochemistry was pelformed on 
frozen sections from brain and spinal cord of mice, using biotinylated preparations of 
the antibodies mentioned above, according to standard methods with previously 
described modifications (Gerritse et al., 1996; Laman et at., 1998c). 
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Results 
In vivo titratioll of PLP/39.151 
Animal models for EAE and other autoimmune diseases are notoriously sensitive to 
minute changes in a wide array of variables, including the origin, age, sex, hormonal 
and microbiological status of the animals, as well as the dose and composition of the 
disease-inducing antigen, and of the adjuvant used. In addition, for modulation 
experiments in such animal models, it is a prerequisite that the dose of antigen and the 
level of clinical disease are carefully balanced to be able to detect both disease-
reducing and disease-aggravating effects of treatment. In other words, the lowest dose 
of antigen inducing a 100% incidence of disease should be used, and not a higher dose 
inducing plateau-levels of disease, obscuring modulatory effects of experimental 
treatment. For that reason, the EAE PLP139. 151 peptide was titrated ill vivo in SJL-mice 
to accurately determine the optimal dose allowing modulation by treatment with 
antibodies or by oral feeding of Lactobacillus strains genetically engineered to express 
myelin antigens for mucosal T cell tolerance induction (Maassen et al., 1999a). Table 
1 shows two independent ill vivo titration experiments performed. Both the disease 
incidence and the level of disease of individual mice need to be considered. As is clear 
from comparing the upper and lower panel of the Table, peptide doses of over 25 
microgram induce a 100% disease incidence. The low dose of 3.125 microgram of 
peptide is ineffective in inducing disease. The 6.25 microgram dose does induce 
disease, but only in a single animal out of three, with a delayed onset 
Table 1. In vivo titration of 'he e1lcephalitogenic PLPIJ9.151 peptide 
Peptide dose (~g) Incidence Mean day of onset ±SDa Mean max, score ±SDb 
25 3/4 11.3±1.5 2.7±O.3 
50 4/4 1O.5±0.6 3.3±O.3 
75 4/4 1O.5±0.6 3.4±O.3 
100 4/4 1O.5±1.0 2.6±1.l 
0 0/4 
3.13 0/3 
6.25 1/3 16c I' 
12.5 3/4 13.0±1.7 2.2±1.0 
25 3/3 11.0±0.0 3.3±O.3 
50 212 11.5±O.7 3.3±O.4 
100 4/4 11.3±1.0 3.4±1.2' 
200 3/4 11.0±0.0 3.0±O.0 
400 4/4 IO.S±0.5 3.3±O.5 
SOO 3/3 11.3±0.6 3/3±0.3 
Two independent experiments using partially overlapping dose ranges, are shown in the upper and lower 
part of the table. amean day of disease onset of animals with clinical signs, bmean maximal disease score 
of animals with clinical signs. Cdata of a single individual animal with clinical signs. uone animal in this 
group died ofEAE (clinical score 5). 
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and a lower disease score than that of animals receiveing higher doses. 12.5 
microgram induces disease in three out of four animals, of which two have disease 
scores comparaple to animals treated with higher peptide doses. Doses of 25 
microgram and higher lead to a 100% incidence. Interestingly, the higher doses of 
peptide (even up to 800 microgram per mouse) did not lead to death from EAE. Only 
one animal in the 100 microgram dose group died of EAE (clinical score of 5: lower 
panel). This is clearly a desirable aspect of a model for MS, in which death due to 
acute inflammation of the CNS is not typical at all. On the basis of these results, a 
dosage of 50-100 microgram peptide was considered to be optimal for use in 
subsequent experiments, resulting in a 100% incidence of disease. 
Prevention of EAE by antibodies against CD40L alld CD44-variant isoforms 
To assess whether the standard form of CD44 (CD44s) is involved in development of 
EAE, animals were treated with a specific antibody (IM-7). Control animals were 
either treated with an irrelevant antibody (disease control group) or with anti-CD40L 
(blocking of disease control group). Although the irrelevant antibody did not interfere 
with disease as expected (Figure 1, top panel) and anti-CD40L antibody blocked 
disease effectively (middle panel), the monoclonal antibody against CD44s did not 
affect disease burden (lower panel)(Gerritse et al., 1996).This indicates that either 
treatment was not effective in the regimen used, or that the standard isofonn CD44s is 
not involved in development of EAE. As it has been claimed that specific isoforms of 
CD44 are involved in (autoimmune) inflammatory disorders such as colitis and 
arthritis, we next investigated whether CD44v6, v7 and vlO have a role in 
development of EAE in this model. Therefore, animals were treated with a 
combination of three different monoclonal antibodies against the CD44 isoforms v6, 
v7, and vlO on days 0, 2, 4 and 6 after EAE-induction. As can be seen in Figure 2, 
animals treated with the irrelevant antibody developed disease and recovered 
spontaneously, following normal disease kinetics (top panel). According to 
expectation, anti-CD40L antibody again effectively blocked development of EAE in 
this administration regimen (middle panel). Interestingly, administration of antibodies 
against v6, v7 and vlO considerably reduced EAE disease burden (lower panel). 
Importantly, one out of four animals was totally protected, and a second one only 
displayed minimal clinical symptoms for a period of three days versus eight days in 
the controls. The other two animals developed disease at a regular level, consistent 
with the all-or-none character of the model as was found in the in vivo titration 
experiments described above. 
ImmunohistocilemistlY 
To assess whether CD40, CD40L and CD44-variant isoforms are expressed within 
mononuclear cell infiltrates within the CNS, brain and spinal cord tissue of the 
animals from the experiment was evaluated in situ by immunohistochemistry. As 
animals were sacrificed after resolution of the disease, it should be kept in mind that 
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Four SJL mice per group were treated with PLP139-151 peptide to induce EAE. On days 0, 2 and 4 after 
immunization they received intrapedtoneal injections with irrelevant control antibody (top panel: disease 
control group), anti·CD40L antibody (middle panel: disease blockade control group), or anti·CD44s 
antibody IM-7 (lower panel). Graphs show averages of four mice, with the line indicating the weight of 
the animals as a percentage of the start weight, and the bars represent clinical signs of disease, scored on a 
scale from 0 to 5 (see Materials and methods section). 
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Figure 2. Treahllellt witll auti-CD44 v6, v7 alUl vlO reduces EAE disease burdell 
Four SJL mice per group were treated with PLPI39-ISI peptide to induce EAE. On days 0, 2, 4 and 6 after 
immunization they received intraperitoneal injections with irrelevant control antibody (top panel: disease 
control group), anti-CD40L antibody (middle panel: disease blockade control group), or anti-CD44 v6, v7 
and vI 0 antibody (lower panel). Graphs show averages of four mice, and are organized as described in 
the legend to Figure 1. 
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only late-stage infiltrates were analysed. In general, the infiltrates within the CNS of 
animals treated with anti-CD44-variant antibodies or anti-CD40L antibodies were 
markedly reduced in number and size compared to animals treated with irrelevant 
antibody (data not shown), indicating that antibody treatment directly or indirectly 
interfered with the local inflammatory process. CD40L-positive cells were only 
occasionally found within the infiltrates (not shown), consistent with findings in 
human MS brain (Gerritse et al., 1996). However, we demonstrated for the first time 
that CD40 is clearly and abundantly expressed in mononuclear cell infiltrates of the 
mouse spinal cord (Figllre 3a). Similar to the situation in human MS autopsy brain 
and marmoset EAE brain, CD40 was abundantly expressed by cells with intracellular 
Figure 3. Expression of CD40 alld CD44 isofonlls ill tlte !Jpillai cord 
Control antibody-treated animals from the experiment shown in Figure 3 were sacrificed after resolution 
of disease and frozen spinal cord tissue analyzed by immunohistochemistry for expression of CD40, 
CD40L and CD44 isofonns using the respective specific monoclonal antibodies (see Materials and 
methods). (A) Abundant expression of CD40 by cells present within perivascular mononuclear cell 
infiltrates in the spinal cord. Star indicates vessel. Bar indicates 15 micrometer. (B) CD40 is expressed on 
the surface of cells (examples indicated by arrowheads) by cells in the perivascular mononuclear cell 
infiltrates. Some of the CD40~positive cells belong to the monocytic lineage as indicated by the activity of 
intracellular acid phosphatase, a lysosomal enzyme (examples indicated by stars). Bar indicates 20 
micrometer. (C) Abundant expression ofCD44s by mononuclear cells within the spinal cord of an animal 
treated with control antibody, as detected by antibody JM~7. Bar indicates 50 micrometer. (D) Expression 
of the CD44vlO isoform (red) within the spinal cord of an SJL~mouse treated with control antibody 
(examples indicated by arrowheads). Bar indicates 10 micrometer. 
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acid phosphatase activity, characteristic for cells of the monocytic lineage (Figure 
3b)(Laman et al., 1998c). Single CD40-positive cells were also present (again similar 
to human MS and marmoset EAE), which might represent B cells or other antigen 
presenting cells lacking detectable acid phosphatase activity. Furthermore, cells with 
clear acid phosphatase activity but lacking CD40 expression were found too, 
indicating that local conditions do not necessarily induce CD40 expression of cells of 
the monocytic lineage. CD44s was clearly present within mononuclear cell infiltrates 
as can be seen in Figure 3e. In addition, expression of CD44vlO, but not v6 or v6, by 
cells within the infiltrates could be demonstrated in the CNS of animals treated with 
irrelevant antibody after resolution of the disease (see Figure 3d), indicating that this 
isoform is indeed expressed in the target organ. 
Discussion 
This study confirms previous findings that anti-CD40L treatment can prevent EAE 
induced by PLPIJ9-151 in SJL-mice, and extends this concept by showing that CD40 is 
expressed abundantly in the spinal cord by infiltrating mononuclear cells. In addition, 
it is shown that combined treatment with antibodies against the CD44 variant isoforms 
v6, v7 and vlO reduces EAE disease burden, and that CD44s and CD44vlO are 
expressed by inflammatory cells in the spinal cord. 
Although CD40-CD40L interactions have initially been described with respect 
to physiological T-B cell communication, it has now become clear that these 
interactions are also involved in B cell-driven autoimmune disease, and in 
autoimmune diseases driven by T cells and macrophages such as EAE in SJL-mice 
(Durie et al., 1994; Gerritse et al., 1996; Laman et al., 1996; Mohan et al., 1995). In 
addition, CD40-CD40L interactions are relevant for the chronic inflammatory process 
underlying atherosclerosis (Laman et al., 1997). We have previously proposed that the 
CD40-CD40L interaction is a target for immunotherapy of MS (Gerritse et al., 1996). 
Further support for this idea is provided by data in the current study showing that 
CD40 is expressed in the spinal cord of SJL-mice, mostly on the membrane of 
infiltrating cells of the monocytic lineage characterized by intracellular acid 
phosphatase activity. This is fully concordant with what was described previously for 
human MS autopsy brain and marmoset monkeys (Callithrix jaec!llIs) with 
demyelinating EAE, a recently developed model for MS allowing evaluation of 
human-specific reagents (Gerritse et al., 1996; Laman et al., 1998c). The local 
expression of CD40 strongly suggests that HLA class II-restricted antigen presentation 
is ongoing, and that effector functions of macrophages expressing CD40 can also be 
triggered by CD40L-expressing activated CD4+ T cells. III vitro, such T 
cell/macrophage interactions can lead to production of nitric oxide, pro-inflammatory 
cytokines (including interleukins 1, 8, 12 and TNF-alpha), and matrix 
metalloproteinases (MMP-9: gelatinase B), which are all compounds thought to be 
involved in the immunopathogenesis of MS as well as other chronic inflammatory 
diseases (Laman et al., 1997). 
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In view of the role of CD40-CD40L interactions in MSIEAE, and data on the 
involvement of CD44-variant isoforms in inflammation, we hypothesized that specific 
variant isoforms of CD44 might be involved in development of MS and EAE as well. 
Interestingly, it has been shown previously that CD40-CD40L interactions can activate 
CD44s expression ill vitro, thereby functionally linking these receptor-coreceptor 
systems (Guo et 01., 1996). CD44-isoforms could be involved in the process of 
leukocyte extravasation (DeGrendele et 01., 1997) and trans-blood-brain barrier 
migration, as well as cellular interactions within perivascular and periventricular 
infiltrates, triggering effector functions that evoke MS and EAE-pathology (Wittig et 
01., 1997). The concept that CD44-directed therapy may have promise for treatment of 
MS is supported by studies describing successful CD44-directed immunotherapy of 
experimental tumor formation, colitis and the inflammatory autoimmune disease 
arthritis (Mikecz et 01.,1995; Verdrengh et 01.,1995; Brennan et 01., 1997; Croft et 01., 
1997). 
Our ill vivo treatment experiments with an antibody against CD44s (IM-7: see 
Figure 1) might argue against an involvement of the CD44s molecule, despite its 
expression on cells within infiltrates of the CNS. However, it cannot be excluded at 
this stage that factors inherent to the current experimental setting have influenced the 
findings, such as high and ubiquitous expression of CD44s on diverse cell types, 
limiting the amount of antibody available for blocking migration or effector functions 
of mononuclear cells effecting clinical disease. In addition, antibody characteristics 
such as affinity and functional capabilities of the Fc-portion of this IgG2b molecule 
may limit its blocking efficacy. In contrast, combined treatment with antibodies 
against v6, v7 and vlO effectively prevented development of EAE in half of the 
animals (Figure 2). CD44 isoforms (by staining with IM-7 antibody) and CD44v1O 
separately (by staining with a specific antibody) were found to be expressed in the 
spinal cord of animals treated with the control antibody (Figure 3). Clearly, it needs to 
be addressed whether treatment with antibodies against v6, v7 and v 10 can prevent 
disease individually. Also, further evaluation of in situ expression of the isoforms in 
relation to disease stage is required. 
What activities of CD44 might specific antibodies be blocking to prevent EAE? 
In comparison to other chronic inflammatory diseases, the insight into the roles of 
CD44-variant isoforms in EAE and MS is limited as yet. It has been described that 
CD44 is expressed within the CNS of SJL-mice with EAE by CD4+ T-cells of the 
activated memory/effector cell phenotype known to effect disease (Zeine and Owens, 
1992). Possibly, CD44-expression by activated T-cells supports passage over the 
blood-brain barrier, but it is also conceivable that CD44 mediates activation of cellular 
effector functions within the mononuclear cell infiltrates in the CNS (Merrill et 01., 
1992). CD44 also participates in binding ofT cells to astrocytes (Haegel et 01.,1993). 
Current experimentation is focusing on expression of CD44-isoforms in human 
MS and marmoset EAE brain, and on the role of selected isoforms in EAE in 
SJL-mice. To this end, both treatment with single isoform-specific antibodies and 
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isoform knockout mice are being used. In due course, such experiments should 
provide further insight into the mechanisms of CD44-involvement in inflammation of 
the CNS, as well as into the feasibility of CD44-isoform directed immunotherapy of 
MS. 
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Reduced EAE after mucosal administration of recombinant lactobacilli 
Summary 
Oral administration of autoclIltigens is potentially a safe and convenient way to 
induce peripheral T cell tolerance in autoimmune diseases like multiple sclerosis. To 
increase the efficacy of oral tolerance induction and obviate the need for purification 
of human myelin proteins, we use genetically modified lactobacilli that locally secrete 
the antigell. A panel of recombinant Lactobacillus strains was constructed which 
secrete myelin proteins and peptides, including human and guinea pig MBP and 
PLP139•151• In this study we examined whether these Lactobacillus recombinants are 
able to induce oral and nasal tolerance in an animal model for multiple sclerosis, 
experimellfal autoimmune encephalomyelitis (EAE). Lewis rats and SJUJ mice 
received soluble cell extracts of Lactobacillus transformants intranasally three times 
prior to induction of EAE. For the induction of oral tolerance, rats and mice were fed 
live transformed lactobacilli for 20 days. Ten days after the first oral administration 
EAE was induced. Intranasal administration of extracts containing gpMBP or 
MBP72-85 significantly inhibited EAE in Lewis rats. Extracts of control tram/ormants 
did not reduce EAE. Live lactobacilli expressing guinea pig MBP72-85 fused to }J-gluc 
were also able to significantly reduce disease burden when administered orally, in 
collfrast to total guinea pig MBP. Also in SJUJ mice Lactobacillus constructs tended 
to reduce disease after oral or nasal administration. In conclusion, these experiments 
provide proof of principle that lactobacilli expressing myelin antigens reduce EAE 
disease burden after mucosal administration. Optimization of myelin expression 
levels and administration regimens will further increase efficacy of peripheral T-cell 
tolerance induction in rodents. 
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Introductiou 
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous 
system (CNS) that leads to destlUction of CNS myelin. It is widely assumed that MS is 
an autoimmune disease mediated by CD4+ T -cells of the T helper 1 subset. The 
current therapies available for MS are non-specific, may have toxic side effects or can 
not be used in long term treatment. Therefore, antigen-specific therapies to silence or 
delete autoreactive T-cells are preferred. In animal models for MS (EAE, experimental 
autoimmune encephalomyelitis), induction of peripheral T cell tolerance can be 
achieved by injection of large doses of soluble myelin antigens intravenously or 
intrathymically (Goss el al., 1994; Khoury el al., 1993; reviewed by Liblau el al., 
1997). Also systemic administration of altered peptide ligands (APL) or MHC-II-
peptide complexes can suppress EAE in an antigen-specific manner (reviewed by 
Liblau el al., 1997). For use in humans a disadvantage is that some of these therapies 
need to be tailored to the HLA haplotype of individual patients. During disease T cell 
responses against more epitopes of the myelin will develop (epitope spreading), which 
further complicates these approaches. 
A promising antigen-specific therapy is the induction of peripheral T-cell 
tolerance by mucosal administration of autoantigen (mucosal tolerance). Three main 
mechanisms have been described; anergy, deletion and active suppression. When 
anergy (non-responsiveness of autoreactive T-cells) (Karpus el al., 1996; Whitacre el 
al., 1991) or deletion (Chen el al., 1995a) are the mechanisms of peripheral T-cell 
tolerance induction, the autoantigen needs to be known. This can be circumvented 
when active bystander suppression is induced (e.g. ai-Sabbagh el al., 1994; Anderton 
and Wraith, 1998; Higgins and Weiner, 1988; Miller el al., 1991). A local Th2rrh3 
(e.g. Chen el al., 1994) environment or a suppressive CD8+ T-cell subset (Lider el al., 
1989; Chen et al., 1995b) can suppress the inflammatory autoimmune response. 
Mucosal tolerance by oral and nasal administration has been achieved with several 
different myelin antigens in distinct EAE models (e.g. Anderton and Wraith, 1998; 
Bitar and Whitacre, 1988; Higgins and Weiner, 1988; Li el al., 1998). 
In the Lewis rat, EAE can be induced by immunisation with guinea pig spinal 
cord homogenate (gpSCH), myelin basic protein (MBP) or proteolipid protein (PLP) 
emulsified in complete Freund's adjuvant (CFA). The dominant encephalitogenic 
epitope of MBP in the Lewis rat is MBPn.85 (Hashim, 1977; Mannie el al., 1985). 
EAE induced with this peptide is mediated by CD4+ T lymphocytes. A second MBP 
epitope that is encephalitogenic for Lewis rats has been localized to residues 86-98 
(Offner el al., 1989; Sun el al., 1992). However, this peptide is only weakly 
encephalitogenic requiring higher doses to elicit clinical signs (Gould and Swanborg, 
1993). This secondmy encephalitogenic peptide of MBP in the Lewis rat is the major 
encephalitogenic MBP peptide in SJUJ mice, but 100% disease incidence is hard to 
achieve, even with high peptide doses (Kono el al., 1988; Sakai et al., 1988). EAE in 
SJUJ mice can be induced by immunization with SCH (e.g. ai-Sabbagh el al., 1996), 
MBP (e.g. Fritz el al., 1983) or PLP139. 151 (e.g. Laman el al., 1998a). 
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In all these models oral tolerance induction leading to reduction of the disease hurden 
was demonstrated. Of increasing interest is the induction of mucosal tolerance by 
nasal application of autoantigen. Several groups have now reported that nasal 
administration of autoantigens or peptides derived from self as well as foreign 
antigens can induce peripheral T cell tolerance, thereby protecting animals from the 
induction of autoimmune disease (Dick et ai., 1994; Li et al., 1998; Liu et al., 1998; 
Metzler and Wraith, 1993; Staines et al., 1996; Tian et al., 1996). Nasal tolerance 
induction has not been reported yet in MBP"_'5 EAE in Lewis rats, the rat model used 
in this study. Some studies have shown that the nasal route is more effective than the 
oral route, requiring significantly lower antigen doses (Ma et al., 1995; Metzler and 
Wraith, 1993). The mechanisms by which nasal administration of soluble antigens 
suppress autoimmunity are poorly understood. A number of studies has suggested that 
nasal administration of soluble antigens can lead to peripheral T-cell tolerance by 
processes of active suppression, such as immune deviation (i.e. shift from Th 1 to Th2 
response) or induction of regulatOlY TGF-B producing Th3 cells (aI-Sabbagh et al., 
1996a; Bai et al., 1997; Li et ai., 1998; Ma et ai., 1996; Tian et ai., 1996). Li et al. 
showed that, like in oral tolerance, dose-dependent mechanisms are involved in nasal 
tolerance induction. Nasal administration of 5 doses of only 6J-lg gpMBP led to 
complete prevention of EAE in Lewis rats, probably due to an active suppression 
mechanism. In contrast, nasal tolerance induction by administration of 600J-lg gpMBP 
probably induced anergy (Li et ai., 1998). 
Mucosal administration of autoantigens is velY effective in animal models in 
preventing autoimmune disease, but in humans chronic disease often has been 
established. In some experimental autoimmune models it is possible to treat ongoing 
disease (Anderton and Wraith, 1998; Benson et ai., 1999). The efficacy of these 
treatments is crucially dependent on dosing and scheduling (Meyer et ai., 1996). For 
several autoimmune diseases in humans therapy by oral administration of antigen has 
been attempted. Although some trials were promising, no clear positive results were 
obtained (e.g. Barnett et al., 1998; Weiner et ai., 1993; Nussenblatt et al., 1997). For 
MS, one of the problems is the fact that the autoantigen is still unknown, a problem 
that does not exist in animal models. Another major problem is the purity and the 
amount of antigen that needs to be obtained. In the human MS trial, bovine myelin 
was used. From animal studies it is known that heterogeneous antigen mixtures such 
as myelin are less effective in inducing oral tolerance than single protein antigens such 
as MBP (Benson et ai., 1999). In addition, very high doses are required in oral 
tolerance induction, partially due to breakdown of antigen in the stomach. In order to 
overcome a number of these problems, we use genetically modified lactobacilli that 
secrete the antigen locally in the gut. The use of these recombinant lactobacilli is 
probably safer than purified myelin, because there is no risk of administering viruses 
or prions co-isolated with myelin. A panel of recombinant Lactobacillus strains was 
constructed which secrete myelin proteins and pep tides, including human and guinea 
pig MBP and PLP139_151 (Maassen et ai., 1999a). cDNAs of a number of 
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encephalitogenic myelin proteins and pep tides were cloned, because encephalitogenic 
antigens have been demonstrated to be efficient tolerogens (e.g. Liu et al., 1998; 
Karpus et al., 1996). 
Lactobacilli are Gram-positive lactic acid bacteria which are frequently used in 
dairy products because of their health promoting effects such as the non-specific 
enhancement of the immune response (adjuvanticity), control of intestinal infections, 
control of serum cholesterol levels and anti-carcinogenic activity (Bloksma et al., 
1979). Oral or nasal administration of these diverse species of lactic acid bacteria with 
the generally regarded as safe (GRAS) status is cost-effective and simple (Pouwels et 
al., 1996). Since individual Lactobacillus strains are clearly distinct, strain selection is 
very important. We have chosen L. casei for recombinant autoantigen expression, 
because this strain possibly favors tolerance induction in the gut by inducing TGF-fl 
and IL-IO expression (Maassen et al., 1999b), while the bacterium itself is not 
immunogenic and does not enhance the humoral immune response to exogenous 
protein antigen in a non-specific manner (Maassen et al., 1999c). 
Our data show that Lactobacillus recombinants can prevent EAE by oral and 
nasal administration, and that in at least one model, nasal administration enhances 
EAE. 
Materials and methods 
Animals 
Female Lewis rats of approximately 175 gram were obtained from Charles River/ The 
Broekman Institute, Someren, The Netherlands. Female SILII mice (8-12 weeks) 
were obtained from the Erasmus University Rotterdam, The Netherlands. All animals 
were kept under filtertop hoods in a DII facility with free access to pelleted food and 
acidified water (pH 2.8). Experiments were performed according to regulations in the 
Dutch law on animal experimentation. 
Recombinant lactobacilli 
For the induction of tolerance by oral or nasal administration of recombinant 
lactobacilli in SILII mice or Lewis rats, a combination of the following vectors was 
used; pLP402-gpMBP, pLP402-hMBP, pLP402-MBP86 (pLP402-peptide), 
pLP402-gpMBP/u, pLP402-hMBP/u, pLP402-MBP72/u, pLP403-MBP72/u, 
pLP402-PLP 139/u, pLP402/u and pLP402-Halu (pLP402-peptide2/u). All pLP402 
vectors secrete heterologous protein. The pLP403 vector retains the heterologous 
protein intracellularly. The basic E. coli/Lactobacillus shuttle vectors and the general 
consltuction method have been described by Maassen et al. (I 999a). All pLP400/u 
vectors express a fusion protein with the marker enzyme fl-glucuronidase (fl-gluc) 
from E. coli. Vectors were transformed to L. case; (ATCC 393). 
gpMBP = guinea pig myelin basic protein, hMBP = human MBP, MBP86 = MBP86_98 
(VHFFKNIVTPRTP), MBP72 = MBPn _85 (QKSQRSQDENPV), PLP139 = proteo-
lipid protein 139-151 (HCLGKWLGHPDKF), Ha = hemagglutinin peptide 111-120. 
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Culturing of recombinant lactobacilli 
For the oral administration of recombinant lactobacilli, the cells were prepared as 
described below. One liter (rat experiments) or 500 ml (mouse experiments) of mMRS 
containing 1 % mannitol and erythromycin (Maassen et al., 1999a) was inoculated at 
1 :200 with a stationary phase culture of the recombinant Lactobacillus strains and 
cultured without aeration at 37"C till an OD69o of 1.0 was reached. For all 
recombinants used in this study the highest level of heterologous gene expression was 
approximately at the optical density of 1.0. The cells were harvested and washed twice 
with PBS and once with 0.2M NaHCO). The cells were resuspended in NaHCO) to a 
volume of 12 ml (rat) or 3 mI (mouse). A small volume was plated out to calculate the 
number of colony forming units (CFU) orally administered. 
For the induction of tolerance by nasal administration, extracts of recombinant 
lactobacilli were used. The cells were grown as described above, harvested and 
washed with PBS. The extracts were made by sonicating the cells in PBS as described 
before (Maassen et al., 1999a). The soluble fraction was used for intranasal 
administration. 
Intranasal tolerance induction 
Rats received either 80rll of Lactobacillus extracts (~320Ilg total protein), synthetic 
MBP""5 (100 Ilg or 200 Ilg), purified guinea pig MBP (Deibler et al., 1972)(lOOllg or 
200llg) or PBS divided over two nostrils. Nasal administration took place at day -15, 
-10 and -5. At day 0, EAE was induced (Prakken et al., 1997). 
In order to determine the dose dependent effect of nasal administration of 
PLP139. 151 in PLP139. 151 induced EAE, groups of 3 mice received 50llg, lOOllg or 200llg 
PLP 139. 151 in PBS 10 and 5 days prior to induction of EAE. To study the effect of nasal 
administration of Lactobacillus extracts on PLPJJ9. J51 induced EAE and spinal cord 
homogenate (mSCH) induced EAE, groups of 3 to 6 mice received either 20111 of 
Lactobacillus extracts or PBS, divided over two nostrils. The mice received 10 nasal 
applications from day -10 till day -1 (PLP139. 151 induced EAE and SCH induced EAE), 
or at day -10 and -5 (PLP139. J51 induced EAE). At day 0, EAE was induced. 
Oral tolerance induction 
Rats or mice were fed one strain of recombinant lactobacilli or NaHCO) buffer daily 
for 20 days (from day -10 till day 9). The cells were prepared as described above. The 
rats received approximately 2.1 0" lactobacilli in 2 ml with a gastric syringe, while the 
mice received approximately 5.1010 lactobacilli in 500111. At day 0, EAE was induced. 
EAE induction in Lewis rats 
EAE was induced by subcutaneous immunisation in the hind footpads with in total 
70llg MBP""5 emulsified in Difco's incomplete adjuvant with 4 mg/ml 
Mycobacterium tuberculosis H37Ra (Difco, Detroit, MI). Clinical disease was 
monitored daily from day 6 onward by weighing the rats, and by grading symptoms of 
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paralysis using an internationally accepted clinical scoring scale ranging from 0 (no 
signs) till 5 (death)(see Laman el al., 1998a). 
EAE illdliCtiOIl ill SJL mice 
Two mouse EAE models were used in this study. In the first model EAE was induced 
by subcutaneous immunisation with 50/1g synthetic PLP139-15 " in the other model the 
induction of EAE was performed with 1.8 mg spinal cord homogenate prepared from 
BALB/c mice (mSCH). On day 0, 200/11 of an emulsion of 9 parts homogenate in 
NaHCOJ with 11 parts Difco's complete adjuvant containing 1 mg/mI M. Iliberclilosis 
H37Ra (Difco) was divided over two flanks. At day 1 and 3, animals received 
intravenous injections with 1010 heat-killed Bordetella perlllssis bacteria (National 
Institute of Public Health and Environmental Protection, Bilthoven, The Netherlands). 
Weight and symptoms of paralysis were monitored from day 6 onward as described 
above. 
ELISA 
Setum was collected every 7 days and tested in ELISA for the presence of antibodies 
against myelin proteins and peptides as a measure of T cell and B cell stimulation and 
tolerance induction. Plates were coated with 5/1g/ml antigen in PBS (50/1l1well) 
overnight at 4°C. Non-specific antibody binding was blocked by incubation with 0.2% 
gelatin in PBS (50/1l/well) for I hour at 25°C. Subsequently the plates were incubated 
with dilutions of setum of treated animals and preimmune sera to correct for 
background reactivity for one hour at room temperature. For the detection of 19G 
antibodies specific for the diverse myelin antigens in rat, alkaline phosphatase-labelled 
goat anti-rat IgG (Sigma Chemical, La Jolla, CAl was used. For the detection of IgG 
antibodies specific for PLP139- 15 " gpMBP, hMBP, MBP86-98 or mSCH in mouse sera, 
alkaline phosphatase-labelled goat anti-mouse IgG (KPL, Gaithersburg, MD) was 
used. For the detection of PLPIJ9-151 specific IgG 1 or IgG2a antibodies, rabbit 
anti-mouse IgG 1 or rabbit anti-mouse 19G2a antibodies (lCN lmmunobiologicals, 
Costa Mesa, CAl were used respectively, followed by I hour incubation with alkaline 
phosphatase-labelled swine anti-rabbit Ig antibodies (Dako AlS, Glost11lp, Denmark). 
At several timepoints after addition of the substrate paranitrophenyl phosphate, the 
absorbance was read at 405nm. 
Statistics 
In the EAE experiments, the disease burden of each animal was calculated in 
percentages of the mean disease burden of the control group which received 
intranasally PBS or orally NaHCOJ only within the same experiment. The disease 
burden per treatment over several experiments was determined by calculating the 
mean disease burden of all animals that had received the same treatment in 
percentages. In order to determine whether differences reached significance, statistical 
analysis was performed using a single factor ANOVA, followed by calculating the 
least significant difference. 
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Results 
Exacerbation versus inhibition of EAE in Lewis rats by intranasal administration of 
MBP protein or peptide 
To investigate whether it was possible to induce tolerance in Lewis rats by intranasal 
administration of myelin antigen, guinea pig MBP (gpMBP) and the immunodominant 
synthetic peptide MBP72-S5 were administered intranasally before induction of EAE. 
The protein and the peptide were administered in two doses of 100[lg or 200[lg at 15, 
10 and 5 days before induction of EAE with MBPn-8s. The disease burden of each 
animal was expressed as percentage of the mean disease burden of the control group 
which intranasally received PBS only within the same experiment. The disease burden 
per treatment over 3 experiments was determined by calculating the mean disease 
burden of all animals which had received the same treatment (Figure 1). Intranasal 
administration of the MBP peptide 72-85 partially ameliorated EAE in a dose 
dependent manner. When 100[lg peptide was administered per application, the disease 
burden was reduced with 56%. A significant reduction of EAE with 85% compared to 
the control group was found when 200fig MBPn-8s was given intranasally (p<O.05). In 
contrast, when the whole MBP protein was administered intranasally, an enhancement 
of EAE was found. The increase of the disease burden was comparable for both doses 
applied (100[lg =171%, 200[lg =155%), and this was significant for the 100[lg dose 
(p<O.05). 
PBS 11=13 
l(X)lg ~mP72-85 
* 
200,Jg MBP72-8S n=9 
l(X)lg gpMBP n=9 
2(X)lg gpMBP 
o 50 100 150 200 250 
dise..1Se burden (mean % ± SEM) 
Figure 1: Exacerbation versus inhibition oj EAE ill Lewis rals by intranasal administration of MBP 
prolei" or peptide 
At day -15. -10 and -5 Lewis rals inlranasally received 100~g or 200~g MBP peplide 72-85 (black bars) 
or gpMBP protein (gray bars). At day 0 EAE was induced with MBPn_ss . TIle disease burden of each 
animal was expressed as a percentage of the mean disease burden of the control group which received 
intranasally PBS only within the same experiment. The disease burden per treatment over 3 experiments 
was determined by calculating the mean disease burden of all animals which had received the same 
treatment. n= number of animals per treatment 
* = p<O.05 compared to control group which nasally received PBS (white bar) 
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Illtranasal tolerallce illduction ill Lewis rats by Lactobacillus extracts colltailling 
myelin alltigells 
Prior to intranasal application of recombinant lactobacilli extracts containing myelin 
antigens for tolerance induction, expression of myelin antigens by the recombinants 
was analyzed. The constructs pLP402-MBP72/u and pLP402-gpMBP/u secrete 
MBPn _85 peptide and gpMBP protein fused to B-gluc, respectively. The construct 
pLP402/u, which secretes B-gluc only, was used as a negative control. Expression of 
these heterologous proteins by L. casei was confirmed by immunoblotting with anti-
B-glucuronidase antibody (Maassen et 01., 1999a; results not shown). The heterologous 
protein gpMBP fused to B-gluc was also detected with anti-gpMBP antibody (Maassen 
et 01., 1999a). The fusion protein MBP72-sslB-gluc was also demonstrated with anti-
MBP72-85 antibody (results not shown). Soluble fractions of recombinant lactobacilli 
were administered intranasally 3 times, at day -15, -10 and -5 prior to EAE induction 
with MBPn _85 on day O. The mean disease burden was calculated as a percentage of 
the mean disease burden of the control group which received PBS intranasally (Figure 
2). Intranasal application of Lactobacillus extracts of the control recombinant 
pLP402/u did not affect the EAE course, as expected. Intranasal pretreatment with 
Lactobacillus extracts of pLP402-gpMBP/u reduced the mean disease burden 
heterologous antigen 
expressed by lactobacilli 
no extract 
l3~glucurollidase 
MBP72-851B-glue 
gpMBPIB-glue 
o 25 
n=8 
n=4 
n=8 
* 
11=8 
'0 75 100 125 
disease burden (mean % ± SEM) 
Figure 2: Reduction of EAE after intranasal admiuistration of Lactobacillus extracts cOlltaining 
myelin antigells ill Lewis rats 
At day -15, -to and -5 Lewis rals intranasally received 80,..1 Lactobacillus extract containing 
approximately 320jlg protein, TIle Lactobacillus contained expressed heterologous myelin antigen fused 
to B-glue (black bars) or B-gluc only (white bar). At day 0 EAE was induced with MBP12-85. The disease 
burden was expressed as a percentage of the mean disease burden of the control group which intranasally 
received PBS only. The results of 2 experiments are shown. n=number of animals per treatmcnt 
* = p<O.05 compared to both control groups (white bars), **= p<O.Ol compared to both control groups 
(white bars) 
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significantly when compared to either of both control groups (pBS and pLP402fu) 
(both p<0.05). When Lactobacilllls extracts containing MBPn.85 were applied 
intranasally, EAE was even further ameliorated. The mean disease burden was 
reduced with almost 80% (p<O.OI) of the PBS treated group (Figllre 2). 
Oral tolerance induction in Lewis rats by recombinant lactobacilli expressing 
MBP72-85 intracelllliarly or extracellularly 
Three recombinant Lactobacilllls strains were used to test whether oral administration 
of live lactobacilli expressing myelin antigens could prevent EAE. In addition to the 
strains used in the intranasal tolerance experiments pLP402-MBP72fu (secretion of 
MBPn.85 fused to B-gluc) and the control strain pLP402fu (secretion of B-gluc), the 
strains with pLP402-gpMBP, which secretes guinea pig MBP protein and 
pLP403-MBP72fu, which intracellularly retains the MBPn.85 peptide fused to B-gluc, 
were used. Approximately 2.10" cells were orally administered per animal daily from 
day -10 to day 10. At day 0 rats were immunized with MBPn.S5 to induce EAE. When 
lactobacilli expressing B-gluc only (pLP402fu) was administered orally, only 3 out of 
5 rats developed EAE, but no significant difference was found in day of onset, mean 
maximum score or mean disease burden, when compared to the control group who had 
received buffer (NaHCOJ) orally (Figllre 3). Oral administration of pLP402-gpMBP 
had no effect on EAE, but when lactobacilli expressing the MBP peptide 72-85 
heterologous antigen 
localization by lactobacilli 
nO lactobacilli n=5 
secreted IJ-glucuronidase fl=5 
secreted gpMBP fl::::5 
secreted MBP72-85/Ll-g!uc n::::4 
intracellular MBP72-851fi-gluc 
0 15 100 
disease burden (mean % ± SEM) 
Figure 3: Oral lolerallce iuduction ill Lewis rats by recombi1lant lactobacilli expressing MBP71.S5 
illtracellularly or extracelllliarly 
Groups of 5 rats received oraBy 2.1011 live recombinant lactobacilli expressing myelin antigens for 20 
days (day ~10 till 10). The vectors used were designed for intracellular expression or secretion of the 
heterologous antigen. EAE was induced with MBP12-85 at day O. TIle disease burden was expressed as a 
percentage of the mean disease burden of the control group which received orally NaHCO) only (white 
bar).*=p<O.05 compared to the control group which received orally NaHCO), **=p<O.Ol compared to the 
control group which received orally NaHCO) only and p<O.05 compared to the group fed gpMBP. 
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intracellular or secreted (pLP402-MBP72/u and pLP403-MBP72/u), EAE was 
significantly inhibited (Figure 3). The mean disease burden of animals treated with 
pLP402-MBP72/n was significantly reduced to 35% compared to the NaHC03 buffer 
control group (p<0.05). A further reduction was achieved by oral administration of 
pLP403-MBP72/u. The mean disease burden was only 16% of the buffer control 
group (p<O.O I). This reduction was also significant compared to the group orally 
treated with pLP402-gpMBP (p<0.05) (Figure 3). 
Intranasal administration of Lactobacillus extracts containing MBP inhibits EAE in 
SJUJ mice 
In order to determine whether EAE could be inhibited by intranasal administration of 
Lactobacillus extracts containing myelin antigens in SJLlJ mice, two EAE models 
were used. EAE was induced with PLP139_ISI or with SCH isolated from BALB/c mice. 
To optimize the model for modulation experiments a dose response analysis with 
0-8001lg PLPIJ9-IS1 was performed previously (Laman et al., 1998a). 50llg of peptide 
induced an EAE of medium severity (mean maximum score 3.3) with 100% incidence, 
which could effectively be modulated by immunotherapy with antibodies against 
CD40L and CD44. Anderton and Wraith (I998) already demonstrated that it was 
possible to prevent PLPI39.ISI induced EAE by nasal administration of IOOllg 
PLP139•IS1 . In this study, three different doses were tested for their ability to prevent 
EAE. 50llg, IOOllg or 200llg PLP139-151 were administered intranasally at day -10 and 
-5 prior to EAE induction. A clear reduction in mean disease burden was observed, 
PBS 
200ttg PLP139.151 
o sO 100 150 
disease burden (mean % ± SEM) 
Figure 4: Iutrallosallo{erallce induction with PLPIJ9.151 ill 8JUJ mice 
Groups of 3 mice received different doses (0, 50~lg, lOOllg or 200!lg in PBS) of PLPI39.1.'S1 inlranasally at 
days -10 and -5. At day 0, EAE was induced with 50,..g PLPI39.ISI' TIle disease burden was expressed as 
percentage of the mean disease burden of the control group which received no PLPm.151 intranasally. 
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which was dose dependent (Figure 4). Due to the small groups (n=3) these differences 
did not reach significance. Fifteen days after EAE induction, relatively high PLP139. 151 
specific IgG2a levels were detected in the control group which had received PBS 
intranasally. The groups which showed reduced EAE after intranasal application of 
PLP139. 151 (50f\g or 200f\g), had relatively high levels of IgG I PLP139. 151 specific 
antibodies. The group treated with 100f\g PLPI39-I51 had diminished levels of 
PLP139. 151 specific antibodies. No correlation could be determined between the 
antibody levels and disease course. 
Mice intranasally received Lactobacillus extracts containing PLPI39I.151 fused to 
l3-gluc (pLP402-PLP139/u) or PLP139.151 only (pLP402-PLPI39) daily from day -10 to 
day 10 prior to induction of EAE with PLP139. 151 or at day -10 and day -5 prior to EAE 
induction. Lactobacillus extracts containing a hemagglutinin peptide fused to B-gluc 
(pLP402-peptide2/u) were used as negative control. None of these intranasal 
treatments had any effect on the disease course (data not shown). 
In contrast, when mSCH was used to induce EAE, intranasal administration of 
Lactobacillus extracts reduced the disease burden (Figure 5). The Lactobacillus strain 
secreting MBP86." was considered as a negative control, because this peptide could 
not be detected by innnunobiotting. The recombinant is further referred to as 
pLP402-peptide. Lactobacillus extracts containing pLP402-peptide, pLP402-hMBP 
heterologous antigen 
expressed by lactobacilli 
no extract 
control peptide 
huMBP 
gpMBP 
o 
11=6 
n=3 
n=4 
n=4 
50 100 150 
disease burden (mean % ± SEM) 
Figure 5. Intranasal administration of Lactobacillus extracts containing t.fBP inhibits EAE ill SJUJ 
mice 
Groups of mice received intranasally Lactobacillus extracts containing heterologous myelin antigens at 
day -15, ·10 and ·5. AI day 0, EAE was induced with msch. The disease burden was expressed as a 
percentage of the mean disease burden of the control group which did not receive Lactobacillus extracts. 
n= number of animals per group. 
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(human MBP) or pLP402-gpMBP (guinea pig MBP) were administered daily 10 days 
before EAE induction. No effect was found with pLP402-peptide treatment. Extracts 
with human MBP partially inhibited EAE (34% reduction of the mean disease burden) 
and extracts with guinea pig MBP showed further reduction of EAE (58% reduction), 
but both effects did not reach significance (Figure 5). 
No correlation was found between the reduction in EAE disease course and 
the antibody response, since no specific antibody responses could be detected against 
mSCH, PLP139•151 or MBP in any of the tested mouse sera as was also demonstrated by 
ai-Sabbagh et al. (1996b). 
Oral administration of recombinant lactobacilli expressing myelin antigens inhibits 
EAE in SJUJ mice 
In order to determine whether oral administration of live lactobacilli expressing 
myelin antigens can prevent EAE in SJLlJ mice, six recombinant Lactobacillus strains 
were tested. Three Lactobacillus strains with and three strains without Il-gluc were 
used. The strains without Il-gluc pLP402-hMBP (secreting hMBP) and 
pLP402-gpMBP (secreting gpMBP) were tested for their EAE reducing capacity, 
heterologous antigen 
secreted by lactobacilli 
no lactobacilli 
control peptidet======::J---------< 
huMBP 
gpMBP 
control peptide/G·gluc 1==========]--------< 
huMBPI3·gluc 
PLPI39-l5I1G-gluc 
o 50 100 150 
disease burden (mean % ± SEM) 
200 
Figure 6: Oral admi1listration o/recombinant lactobacilli expressillg myeli" a1ltigens i"hibUs EAE ill 
SJUJmice 
Groups of 5 mice were fed recombinant lactobacilli containing secretory vectors for the expression of 
myelin antigens. Approximately 5.1010 live lactobacilli were administered for 20 days, from day -lO till 
day 10. At day 0, EAE was induced with mSCH. Lactobacilli expressing myelin antigens fused to B-gluc 
and without B-gluc were tested for their effect on EAE. Lactobacilli expressing an irrelevant peptide fused 
to Il-gluc and lactobacilli expressing a control peptide were considered as controls for heterologous fusion 
proteins and non-fused heterologous proteins respectively. The disease burden was expressed as a 
percentage of the mean disease burden of the control group which did 110t receive lactobacilli. 
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whereas pLP402-peptide was used as negative control. The Il-gluc containing 
Lactobacillus strains are pLP402-hMBP/u (secreting hMBP fused to Il-gluc) and 
pLP402-PLP139/u (secreting PLP139_151 fused to Il-gluc) and the control 
pLP402-peptide2/u (secreting control peptide fused to Il-gluc). Approximately 5.1010 
live lactobacilli per animal were orally administered daily from day -10 to day 10. At 
day 0, EAE was induced with spinal cord homogenate. As expected, lactobacilli 
expressing the irrelevant peptide-Il-gluc fusion protein had no effect on EAE course 
(Figure 6). Although none of the tested recombinant lactobacilli had a significant 
effect on EAE, strong reductions in the mean disease burden were found after oral 
administration of pLP402-gpMBP (70% reduction), pLP402-PLP139/u (75% 
reduction) and pLP402-hMBP/u (66% reduction)(Figure 6). Lactobacillus 
recombinants expressing human MBP without Il-gluc slightly enhanced EAE (20% 
increase of disease burden). Small reductions in disease burden were determined with 
the control recombinants pLP402-peptide (29% reduction) and pLP402-peptide2/u 
(4% )(Figure 6). 
Similar to intranasal administration of recombinant lactobacilli, no correlation 
was found between disease reduction and antibody responses. Except for one mouse, 
orally untreated, which showed a low response against mSCH, no specific antibody 
responses occurred against any of tested myelin antigens, as was also demonstrated by 
aI-Sabbagh et al. (1996b). 
Antibody responses after il/tral/asal tolerance il/duction in rats 
In all rat experiments the animals were immunized with MBPn _85 to induce EAE. In 
none of the animals an anti-MBP72-85 antibody response could be detected, despite the 
fact that T-cell priming was effective as evidenced by a 100% incidence in control 
groups. In mucosally untreated animals which were immunized with MBPn _8S, no 
MBP specific antibodies could be detected. This gave us the opportunity to 
investigate whether intranasal application of gpMBP induced gpMBP specific 
systemic antibodies. Only in animals with an enhanced disease burden after intranasal 
treatment with gpMBP, IgG antibodies specific for gpMBP could be detected in 
selUm 14 days after EAE induction. No gpMBP-specific antibody responses could be 
detected in any of the rats which mucosally received lactobacilli expressing MBP or 
MBP peptide. 
Discussion 
General 
In this study we have demonstrated nasal as well as oral tolerance in a rat EAE model 
induced by MBP72-85, which was not previously used for mucosal tolerance induction. 
In the same model we also showed enhancement of disease after nasal administration 
of purified gpMBP. Further, we showed that nasal as well as oral administration of 
recombinant lactobacilli expressing myelin antigens could effectively reduce EAE. 
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Mucosal administration oj low al/tigen doses can prime iI/stead oj tolerize 
The MBP72-85 induced rat EAE model was not previously used for mucosal tolerance 
experiments. In another rat EAE model induced with gpMBP complete prevention of 
EAE was demonstrated with 5 nasal doses of either 61-lg or 120l-lg of purified gpMBP 
(Li et al., 1998). Five nasal administrations of 120l-lg of the immunodominant epitope 
MBP68-86 were slightly less effective in preventing EAE (Liu et al., 1998). Here we 
show that comparably high doses of MBP72-85 peptide reduced MBPn _B5 induced EAE 
to the same degree as was demonstrated in gpMBP induced EAE. In contrast, EAE 
induced by MBP72-B5 was enhanced by nasal administration of gpMBP, although it has 
been demonstrated that it is possible to induce oral tolerance with intact protein (MBP 
and PLP) in peptide (PLPI40-159) induced EAE (ai-Sabbagh et ai., 1994). It is known 
that the dose and administration regimen is clUcial for the induction of mucosal 
tolerance. Oral administration of low doses can enhance disease, as was demonstrated 
by Meyer et al. (1996). Also feeding of very low doses of OVA appears to prime 
rather than tolerize the immune response, resulting in enhanced DTH responses 
(Lamont et ai., 1989). Based on molarity, an approximately 15 times lower number of 
the MBP72-85 epitope was present in nasally administered gpMBP, compared to 
synthetic MBPn _85 peptide. In our experiments the amount of nasally administered 
gpMBP equalled 6,71-lg and 13,31-lg MBPn _85 peptide, indicating that much lower 
doses were administered than the lOOl-lg synthetic MBPn _B5 peptide that not even 
completely prevented EAE induction after nasal administration. However, this dose 
related explanation is not consistent with the findings that low doses (5 times 61-lg 
gpMBP) can prevent disease in a different EAE model (induced with gpMBP) in the 
Lewis rat (Li et al., 1998). Possibly, the fact that gpMBP harbours more Tcell and B-
cell epitopes has influenced the tolerizing properties of gpMBP. Also other myelin 
components which were retained in the purified MBP fraction could have affected the 
immune response. Benson et al. (1999) have demonstrated that heterogeneous antigen 
preparation such as myelin are less effective in inducing tolerance than single 
antigens (e.g. MBP). 
MBP72.85 does I/ot cOl/tain a B-cel/ epitopejor the Lewis rat 
No peptide specific antibody response could be detected after subcutaneous 
immunization of Lewis rats with MBPn _B5 (containing a T-cell epitope). Gould and 
Swanborg (1993) have demonstrated strong IgG antibody responses in Lewis rats 
against MBP67-B5 (YGSLPQKSQRSQDENPV). These apparent contradictory results 
may be explained by the additional residues of the MBP67_B5 peptide that could result 
in a B-cell epitope. Hashim et al. (1986) showed that the MBP peptide SQRSQDEN, 
which residues are also present in our MBP peptide 72-85, was able to induce weak 
antibody responses in Lewis rats. In accordance with the results of Gould and 
Swanborg (1993), elongation of the peptide by three or six naturally found residues at 
its N-terminal end, strongly increased the immunogenicity of the peptide (Hashim et 
ai., 1986). Also elongation at the C-terminus with the residues VHF increased 
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antibody levels (Fritz el al., 1979). These results indicate that the peptide used in our 
EAE model contains only part of the residues of two distinct B-cell epitopes, 
therefore hardly evoking an antibody response. Consequently, the MBP specific 
antibody response detected after nasal administration of whole gpMBP and 
subcutaneous immunisation with MBPn _B5 is probably only due to the nasally applied 
MBP. 
Presentation of recombinant myelin anligens to the mucosal immune syslem 
According to the general dogma, mucosal administration of soluble antigens leads to 
systemic T-cell tolerance whereas particulate antigens can induce local and systemic 
humoral and cellular responses (e.g. Benson et al., 1999; Fairweather el al., 1990). 
Therefore, we expected that oral administration of lactobacilli secreting soluble 
antigens would be more effective in reducing EAE than lactobacilli that retain the 
antigen intracellularly. Contrary to this expectation, lactobacilli that expressed 
MBP72-85 fused to (I-gluc intracellular appeared to reduce EAE f1ll1her than lactobacilli 
secreting the peptide-fusion protein. Interpretation of these findings is hampered by 
the general lack of insights into behaviour of Lactobacillus strains in the gut, as well 
as cellular uptake and processing of lactobacilli and their intracellular or secreted 
antigens. 
When antigens are presented by APCs without or with low levels of 
costimulatory molecules, anergy of CD4+ T cells can be induced. Increasing evidence 
is emerging that also dendritic cells can act as tolerogenic APCs in the mucosal 
immune system priming for Th2 responses (Viney et al., 1998; Kalinski et at., 1997). 
It has been proposed that such dendritic cells can sustain the induction of T-cell 
tolerance to soluble proteins or non-invasive micro-organisms, such as lactobacilli. 
Active immunity is generated only when the DCs are confronted with potentially 
harmful antigens in the context of appropriate secretion of cytokines or other 
inflammatory signals. 
gpMBP is less effective Ihan MBPn .85 in reducing MBP72-85 induced EAE 
In this study, nasal administration of gpMBP enhanced MBPn _85 induced EAE. 
However, nasal administration of gpMBP (fused to (I-gluc) expressed by lactobacilli 
did reduce EAE significantly, but less effectively than when lactobacilli expressing 
MBPn _85 fused to (I-gluc were used. Comparable results were obtained by oral 
administration of lactobacilli expressing gpMBP or MBP72-85, although in those 
experiments gpMBP was not fused to (I-gluc. In contrast to the experiments 
performed with purified gpMBP and synthetic peptide, equimolar amounts of 
recombinant gpMBP and MBP72-85 both fused to (I-gluc were administered. This was 
deduced from immunoblots that showed approximately equal amounts of (I-gluc per 
unit weight of total Lactobacillus protein, indicating equal numbers of molecules of 
heterologous antigen. This was true for all secretory vectors and not for vectors which 
retain the heterologous protein intracellularly. Therefore, the difference in inhibition 
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of EAE can not be explained by a difference in dose. Conformational differences 
between recombinant MBPn-85 and gpMBP both fused to Il-gluc, partially due to 
fusion to Il-gluc, could render the immunodominant epitope less accessible in the 
gpMBP recombinant than in the MBPn-85 recombinant. Differences in susceptibility 
to proteases can also playa role. 
Beneficial effects of lactobacilli on tolerance illductioll 
Although it was demonstrated that PLP139_15J induced EAE can be prevented by nasal 
administration of the same peptide, we were unable to prevent disease by nasal or oral 
application of Lactobacillus casei secreting PLP139_151 fused to Il-gluc (data not 
shown). The applied nasal dose of recombinant PLP139-151 (±I/-lg) was much lower 
than that used to prevent EAE with synthetic peptide (IOO/-lg, Anderton and Wraith, 
1998). However, in the other nasal experiments also lower doses of recombinant 
antigen were able to prevent EAE than those necessary to prevent EAE with synthetic 
or purified antigen. For instance, in rats significant reduction of EAE was 
demonstrated with Lactobacillus extracts containing approximately l/-lg MBP"_85 or 
lO/-lg gpMBP. This indicates that the presence of Lactobacillus antigens had a 
positive effect on disease reduction, even though administration of lactobacilli itself 
did not have any effect on the disease course (Figure 2, lactobacilli expressing 
Il-gluc). In a previous study, we demonstrated that wild type administration of L. casei 
did not influence EAE disease course (Maassen et al., 1998b). Also in SJUJ mice, 
nasal administration of low dosages of hMBP and gpMBP (both approximately 3/-lg) 
partially prevented EAE, although the reduction was not significant. 
Also in the oral tolerance experiments lactobacilli may have additional 
beneficial effects in the reduction of EAE. Effective oral tolerance can be achieved by 
oral administration of multiple doses of 1 mg gpMBP (5 times, Miller et al., 1992a) 
up to four doses of 5 mg gpMBP in gpMBP induced EAE in Lewis rats (Whitacre et 
al., 1991). When peptide containing the MBP residues 72-85 was used for peripheral 
T-cell tolerance induction, 4 oral administrations of 1.25 mg peptide were necessary 
to prevent EAE induced with the same peptide (Javed et al., 1995). In this study 
Lewis rats which were fed lactobacilli containing approximately 375/-lg gpMBP or 
25/-lg MBP"_'5 for 20 days showed significantly reduced signs of EAE. Even though 
the cumulative amount of recombinant gpMBP might be more than necessary to 
prevent EAE by oral administration with purified gpMBP in a 20-day administration 
regimen, this recombinant Lactobacillus strain was not able to suppress EAE by this 
administration regimen. The cumulative amount of MBP"_85 peptide was still lO-fold 
lower than the one used to suppress MBP68-88 induced EAE with MBP68_88• This 
implies that the presence of lactobacilli has additional beneficial effects. The results 
in the SJUJ mice are more difficult to interprete. The orally administered doses of 
recombinant antigens in lactobacilli containing secretory vectors in SJUJ mice were 
approximately 6/-lg of the peptides and 95/-lg of the MBP proteins, administered for 20 
days. The cumulative amount of MBP is similar to the cumulative amount used to 
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(partially) prevent myelin induced EAE (ai-Sabbagh et al., 1994; Miller et al., I 992a). 
Therefore it can not be concluded that in this case lactobacilli have an additional 
beneficial effect. As there are no published reports on oral tolerance induction in 
myelin or SCH induced EAE by MBP or PLP peptides, no definite conclusions about 
the contribution of lactobacilli can be drawn. 
The higher efficacy in tolerance induction by oral administration of lactobacilli 
retaining MBPn _85 fused to !I-gluc intracellularly, could simply be the result of the 
higher expression level of this heterologous protein (approximately 3 times higher 
than secretory MBPn_85 fused to !I-gluc). There is currently no obvious explanation 
for the different effects found with lactobacilli expressing hMBP fused to !I-gluc and 
lactobacilli expressing hMBP without !I-gluc. Conceivably, it could be that different 
conformation renders the recombinant hMBP more susceptible to proteases, possibly 
affecting an important epitope. 
Comparison of the results obtained by nasal and oral tolerance induction 
suggests that the efficacy of the nasal route is higher than the oral route, requiring 
lower doses of antigen, which is in accordance with the current view derived from 
studies with soluble antigens (Ma et al., 1995; Metzler and Wraith, 1993). It has to be 
kept in mind that the form in which the antigens administered was different for nasal 
versus oral administration (soluble extracts versus particulate live bacteria). 
Concluding remarks 
This study has provided 'proof of principle' that EAE can be reduced by nasal as well 
as oral administration of recombinant lactobacilli expressing myelin antigens. 
Tolerance induction may be improved by optimizing expression, dose and 
administration regimen. The importance of the dose in mucosal tolerance induction 
was demonstrated by the enhancement of EAE disease burden by nasal administration 
of gpMBP in Lewis rats. 
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5.1 Introduction 
Multiple sclerosis is a T-cell dependent autoimmune disease causing chronic 
inflammation of the central nervous system. The cause of MS and the autoantigen(s) 
involved are still unknown. Consequently, the currently available therapies for this 
severe disease are all non-antigen-specific. Antigen-specific therapy was effective in 
the experimental animal model EAE by oral administration of myelin antigens 
inducing peripheral T-cell tolerance (e.g. ai-Sabbagh et al., 1994; Benson et al., 1999). 
However, oral administration of myelin failed as a treatment of MS patients (Fukaura 
et al., 1996). The purity, the heterogeneity of myelin proteins and degradation of 
antigen in the stomach could be among the causes of this failure. To circumvent large-
scale purification of myelin antigens and to avoid infection with prions and viruses, 
recombinant proteins produced by microorganisms could be a solution. This way also 
homologous (human) protein antigens can be used. In the human trials, bovine myelin 
was given orally since it was practically impossible and considered unethical to 
administer purified human brain antigens. Additional advantages for local delivery of 
myelin antigens are provided by using non-pathogenic bacteria as a delivery system, 
such as Lactobacillus strains. Oral administration of these recombinant Gram-positive 
bacteria circumvents antigenic degradation in the stomach. The large genus 
Lactobacillus provides the opportunity to select a Lactobacillus strain with properties 
that may increase peripheral T-cell tolerance induction. 
These studies provide 'proof of principle' that mucosal administration of 
recombinant Lactobacillus strains expressing myelin antigens can reduce EAE. 
Further studies could potentially develop this approach for treatment of MS in man. 
5.2 Lactobacillus strain selection 
Gel/eral Lactobacillus properties 
The genus Lactobacillus consists of many species and strains (Klein et al., 1998). 
Several of these strains are used as probiotics, which are defined as 'mono- or mixed 
cultures of live microorganisms which, when applied to animal or man, beneficially 
affect the host by improving the properties of the indigenous microflora' (Havenaar et 
al., 1992). A main probiotic effect is the enhancement of immune responses against 
enteric pathogens, preventing diarrhoea (reviewed by Salminen et al., 1996). The 
extent to which Lactobacillus strains have probiotic activity and the mechanisms of 
probiotic activity are clearly different between individual Lactobacillus strains. 
Lactobacillus strains transformed to express antigens from pathogens or autoantigens 
for use as oral vaccine or therapeutic in autoimmune disease respectively, do not 
necessarily have to possess probiotic activities. Examples of criteria for Lactobacillus 
strain selection for use as recombinant oral vaccines or recombinant mucosal 
therapeutics are listed in Table 1. All mentioned properties are strain dependent and 
may influence the efficacy of vaccination or tolerance induction. However, the impact 
of each individual property is difficult to predict and requires empirical evaluation. 
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Adherence and persistence of lactobacilli 
Adhesion of lactobacilli to the mucosa enhances the persistence of the strains in the 
gastro-intestinal tract (and possibly aids in colonization) but as a result may also 
facilitate uptake by the body. Longer persistence also increases the opportunity to 
locally produce and secrete recombinant heterologous antigen, which is important for 
both tolerization and vaccination purposes. Persistence is Lactobacillus strain and host 
dependent. Shaw et al. have demonstrated that the persistence of different 
Lactobacillus strains in BALB/C mice varies between 3 and 30 days (personal 
communication). In mice, niche colonization of the gut by orally administered 
lactobacilli is unlikely to happen because of competition with the existing microflora. 
A promising approach to increase persistence is cloning the gene encoding the S-Iayer 
protein from L. acidophilus into the Lactobacillus strain chosen for a certain 
application (Pouwels et al., 1998), since this protein is thought to be involved in 
adherence to the mucosa (Coconnier et al., 1992; Schneitz etal., 1993). 
Table 1: Cn"en'a!or Lactobacillus straiu selection 
General properties: 
Non-adhering ~ ~ Adhering 
Non-persisting .. ~ Persisting <II .. Colonizing 
Low intrinsic immullogenicity ..... I----1"'~ High intrinsic inununogenicity 
Properties affecting the immune system: 
Induction of cytokines in gut (proinflammatory ... <III----1 .. ~ non-inflammatory) 
No adjuvanticity <Ill '" High adjuvanticity 
Growth phase dependent skewing ofT-cell pathways (Till <II<III----l .. 1> Th2) 
Proinflammatory properties of cell wall components (low <II .. high) 
Properties in relation to heterologous antigen expression: 
Suitable for transformation (yes/no) 
Expression level (low <II '" high) 
Efficacy translocation system (low <II .. high) 
Intrinsic immunogenicity of lactobacilli 
We have indications that the intrinsic immunogenicity (i.e. ability to elicit an adaptive 
immune response against Lactobacillus antigens) after oral administration of the 
Lactobacillus strains is positively related to the intrinsic adjuvanticity of the 
Lactobacillus strain. Orally administered Lactobacillus strains that enhance the 
antibody response against a parenterally immunized antigen, evoke an antibody 
response against themselves, in contrast to non-adjuving Lactobacillus strains 
(unpublished observation and in chapter 2.3). This is consistent with data that an 
immunogenic Lactobacillus strain induces higher antibody responses against the 
expressed heterologous antigen than a non-inmmnogenic Lactobacillus strain (Shaw et 
145 
Summarizing discussion 
al., personal communication). Exactly how the immunogenicity of Lactobacillus 
strains is related to persistence is currently unknown. 
The composition of the cell wall is strain- and growth phase-dependent (Logardt 
and Neujahr, 1975; Wicken et al., 1982; Knox and Wicken, 1978). Probably, the 
differences in cell wall composition are related to the persistence and intrinsic 
immunogenicity of individual Lactobacillus strains (Knox and Wicken, 1978). Since it 
is known that peptidoglycan, a major cell wall component, can influence cytokine 
expression ill vitro (reviewed by Henderson et al., 1996), it is assumed that the 
differential effects of various Lactobacillus strains on the immune system are at least 
partially due to differences in cell wall composition. 
Lactobacillus properties affectillg the immulle system 
Intrinsic adjuvanticity and cytokine inducing properties of lactobacilli 
Several of the effects which lactobacilli may have on the immune system as 
mentioned in Table 1 were investigated in this thesis for a proper selection of 
Lactobacillus strains. From the species L. pialltarlllll, two strains were tested for 
cytokine profiles in the gut and adjuvanticity after oral administration. No differences 
were detected between those two strains. Adjuvanticity, here defined as enhancement 
of the specific humoral response against a parenterally administered antigen, appeared 
to be dependent both on the Lactobacillus strain as well as on the mouse strain. 
Analysis of the antibody subclasses of the induced antibodies revealed that the strain 
with the strongest adjuvanticity, L. rellteri, induced relatively high antigen specific 
IgG2a levels when compared to specific IgGI (chapter 2.2). In mice, IgG2a 
specifically mediates opsonization and complement activation. IgG2a reflects 
activation of Th I cells which can activate macrophages and may provide help to 
cytotoxic T-cells. Direct and indirect evidence of activation of Thl cells is provided 
by a strong induction of TNF-a, IL-JB and IL-2 positive cells in the gut villi of mice 
fed L. rellte"; and immunized parenterally with Chikungunya vims. Since IL-2 is 
produced by proliferating Thl cells, IL-2 induction may be considered as direct 
evidence of activation of Thl cells. TNF-a can be produced by Thl cells, but it is 
more likely that this cytokine is produced by macrophages as is IL-Ill (Arai et al., 
1990). The induction of IL-lll and probably TNF-a indicates that macrophages are 
activated. Transformation of this particular Lactobacillus strain with viral antigens 
containing B-cell and T-cell epitopes might induce protective immunity by activating 
humoral as well as cell-mediated immunity upon oral administration. Multiple 
administrations of large numbers of these bacteria theoretically may have adverse 
effects due to the inflammatory response they can evoke, but we did not find 
indications of damage to the mucosa after oral administration of L. reuteri or L. brevis 
(cf Bloksma et al., 1979). 
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Growth phase dependent effects of lactobacilli in BALB/c mice 
As was demonstrated in the Th 1 biased SILII mouse strain, the growth phase of the 
individual Lactobacillus strains can differentially affect the IgGlllgG2a ratio (chapter 
2.3). Stationary phase cultures of L. casei and L. /IIurilles induced high ratios of 
IgG l/IgG2a. The tendency to induce Th2 cytokines after oral administration of log 
phase cultures in BALB/c mice (chapter 2.2) may be further increased by oral 
administration of stationary phase cultures of recombinant L. casei or L. IIll/rilles. It 
appeared that after oral administration of stationary phase cultures of L. casei, the total 
IgG response specific for the i.p. administered antigen was significantly increased 
(p<0.05) compared to the control group and the group fed log phase cultures 
(unpublished observation). However, oral administration of stationary phase cultures 
of L. casei only slightly increased the IgG IIIgG2a ratio (unpublished observation). 
The increase of the IgG l/IgG2a ratio in BALB/c mice probably was not as 
pronounced as in SILII mice due to the relatively high IgG IIIgG2a ratio of the control 
group that did not receive lactobacilli and of the group fed log phase cultures in this 
Th2 biased mouse strain. For vaccination purposes L. casei and probably also L. 
/IIurilles can therefore best be used in stationary phase. 
Intrinsic adjuvanticity of the Lactobacillus strain: An advantage or disadvantage 
for the induction of peripheral T-cell tolerance? 
The advantage of a Lactobacillus strain with high adjuvant activity for the use in 
vaccination is clear. Whether adjuvanticity is an advantage or disadvantage in oral 
tolerance induction is not that obvious. Therefore it is necessary to point out that we 
want to achieve peripheral T-cell tolerance in a Thl mediated autoimmune disease by 
mucosal administration of autoantigen. Oral co-administration of the systemic 
adjuvant LPS with MBP enhanced T-cell tolerance in EAE (Khoury et al., 1990). Oral 
administration of MBP or insulin conjugated to cholera toxin subunit B (CTB) was 
also found to enhance T-cell tolerance in EAE and diabetes respectively (Bergerot et 
al., 1997; Sun et al., 1996). This latter findings present an apparent paradox, because 
CTB is also used to increase the efficacy of mucosal vaccines (e.g. Dertzbaugh and 
Elson, 1993). The resulting responses of CTB conjugates in tolerance induction as 
well as in vaccination are closely related to the induction of Th2-associated cytokines 
and antibody isotypes (IgG I)(reviewed by Williams et al., 1999). 
The occurrence of T-cell tolerance without B-cell tolerance is a comparable 
paradox. The antibody responses to soluble antigens are generally more difficult to 
suppress than T-cell responses (B-cell versus T-cell tolerance)(Husby et al., 1994; 
Mowat et al., 1982). However, it remains controversial how local mucosal immune 
responses to orally administered soluble antigens are generated. Some reports suggest 
that suppression of systemic immunity is accompanied by local secretory IgA 
production (Challacombe and Tomasi, 1980; Husby et al., 1994), but others have 
reported that intestinal IgA antibody production is reduced by oral administration of 
soluble antigen (Kelly and Whitacre, 1996). A possible explanation for this apparent 
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contradiction is the fact that different mechanisms of T-cell tolerance can be induced. 
It can be reasoned that when the mechanism of oral tolerance induction is based on 
active suppression involving TGF-Il and/or immune deviation towards Th2, a local 
IgA response may be increased, since TGF-Il and the Th2 cytokine IL-5 are involved 
in isotype switching to IgA as well as in IgA production. Alternatively, TGF-Il is 
known to inhibit Th I as well as Th2 responses, suggesting reduction of antibody 
responses in addition to suppression of cell-mediated immunity (Higgins and Weiner, 
1988; Lider et al., 1989). Induction of T-cell anergy as the main mechanism of oral 
tolerance induction may lead to inactivation of antigen specific B-cell responses as 
well. Consistent with this hypothesis are the fmdings of Kelly and Whitacre (1996), 
who found reduced numbers of IgA antibody forming cells in Peyer's patches in 
experiments where an anergy inducing protocol in EAE was used. Also IgG antibody 
responses were reduced in tolerized animals in which anergy is the main mechanism 
of peripheral T cell tolerance (Inada et al., 1997; Melamed and Friedman, 1994; 
Mowat et al., 1996). When T-cell tolerance is due to immune deviation towards a Th2 
response, in addition to a possible increase in IgA, a reduction of the specific IgG2a 
response against the orally administered antigen can be observed as well as an 
increase in the antigen specific IgG I response. This is supported by findings of Bai et 
al. (1997), Staines et af. (1996) and Tian et al. (1996), who demonstrated increased 
levels of IgG 1 and/or reduced levels of IgG2a after mucosal administration of 
autoantigen. Active suppression was the main mechanism of tolerance in these 
experimental models of autoimmunity (Bai et al., 1997; Staines et al., 1996; Tian et 
al., 1996). In contrast, Ke and Kapp (1996) reported suppression of both IgGI and 
IgG2a responses, and this suppression could be adoptively transferred with CD8+ T 
cells. 
All these data together imply that adjuvanticity can be advantageous in mucosal 
tolerance induction dependent on the mechanism of tolerance induction. When 
immune deviation towards Th2 is preferred as the mechanism of mucosal tolerance, a 
Lactobacillus strain with high adjuvanticity could be advantageous, with the 
restriction that IgG2a production (in mice) will not be enhanced. 
Orally administered lactobacilli affect EAE disease course 
Some of the properties of lactobacilli affecting the immune system appeared to be 
growth phase dependent. Different growth phases may also account for the different 
results obtained when L. casei was orally administered before induction of EAE. In 
chapter 2.1 enhancement of EAE was shown after oral administration of stationary 
phase cultures of L. casei. In experiments using log phase cultures of L. casei 
(Maassen et al., 1998b) or end-log-phase cultures of L. casei transformed with an 
irrelevant antigen, no effect on EAE could be demonstrated (chapter 4.2). The 
enhancement of EAE by orally administered L. casei was surprising and not in 
accordance with the results obtained with respect to the growth phase dependent 
effects on IgG 1 and IgG2a. However, we and others have demonstrated that oral 
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administration of L. casei can induce proinflammatOlY cytokines such as TNF-a, 
IL-12 and IFN-V (Maassen et al., 1999b; Matsuzaki et al., 1998; Tejada-Simon et al., 
1999). These seemingly contradictory results could also be due to the number of CFUs 
administered. Approximately 10'0 (or 5.10'0 in the case of control recombinant) 
lactobacilli were orally administered of L. casei log phase cultures, whereas only 108 
cells of stationary phase cultures were orally administered (chapter 2.1). Low doses of 
stationary phase cultures of L. casei may have been presented by professional APCs 
such as dendritic cells with high levels of co-stimulatory molecules such as B7-1, 
leading to activation of T cells. High doses of log phase cultures may have led to 
presentation of Lactobacillus antigens by na'ive B cells which outnumber professional 
APCs (Brandtzaeg et al., 1999). Moreover, there are indications that presentation by 
na'ive and memory B cells can result in down-regulation of the T-cell response by 
engagement of B7 with CTLA-4, transiently expressed on activated T-cells (Alegre et 
al., 1998; Samoilova et al., 1998). 
Noteworthy are the effects of orally administered log phase cultures of L. 
/IIurines, L. reuteri and L. plantarulll NClB on EAE disease course in SILII mice. L. 
plantarllln did not affect EAE, L. reuteri increased the severity of EAE and L. lIIurines 
significantly reduced EAE (Maassen et al., 1998b). Possibly EAE can be further 
reduced by oral administration of L. /Ill/rines, since stationary phase cultures of this 
Lactobacillus strain induce relatively more IgGI, reflecting activation of Th2 cells, 
without enhancing the overall humoral response. We do not have results in SILII mice 
which support or oppose these findings. However, the results in BALB/c mice are 
consistent with the observations in EAE. Log phase L. reuteri enhanced the antibody 
response by inducing relatively high levels of IgG2a and induced inflammatory 
cytokines in the gut villi, properties that could be related to enhanced EAE disease 
course. The tendency to induce TGF-Il and the induction of relatively high levels of 
IgG I, could be cause of the disease limiting effect of L. murines. 
Selection of a Lactobacillus strain for oral tolerance induction in EAE 
The strain of choice for use in mucosal tolerance induction in EAE, based on the 
results obtained in chapter 2, (without taking into account the effects of heterologous 
antigen expression), would be L. /IIurines in stationalY phase. This choice is based 
upon the reduction of EAE, the skewing towards Th2 when stationmy phase cultures 
were used, no (strong) induction of inflammatory cytokines and the tendency to 
induce TGF-Il by wild type L. lIIurines. The second choice would be log phase L. 
casei, mainly for the same reasons as L. lIIurines. Log phase culture is preferred since 
it lacks the enhancing effects of stationmy phase cultures of L. casei on EAE. Another 
advantage of L. casei is the existing experience in industrial production. 
Lactobacillus and vector properties in relation to heterologous antigen expression 
Not only the intrinsic characteristics of Lactobacillus strains influence the efficacy of 
tolerance induction, also properties in relation to transformation may playa role. The 
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ability to genetically transform the Lactobacillus strain is of utmost importance for the 
use of recombinant lactobacilli as oral vaccine or therapeutic. Despite considerable 
effort, we were not able to transform our Lactobacillus strain of choice, L. murines. 
Gram-positive bacteria in general are difficult to transform due to their peptidoglycan 
layer, in contrast to the easy to transform Gram-negative bacteria, such as E. coli. The 
difference in cell wall composition of Lactobacillus strains requires specific 
electroporation settings for each individual strain, and no settings are yet known for L. 
l1lurilles. 
A series of expression vectors was developed which are segregationally stable 
in many Lactobacillus strains (Pouwels et al., 1996 and chapter 3.1). These plasmids 
allow expression of the antigen of choice at three defined cellular locations under 
control of a constitutive or regulatable promoter. The antigen can be expressed either 
in the intracellular compartment, anchored to the cell wall, or secreted into the 
environment. A continuous presence of soluble antigen locally at the gut mucosa was 
thought to be the most efficient way to induce tolerance, because oral administration 
of purified soluble antigens, in contrast to most particulate antigens, induced 
hyporesponsiveness in previous studies (e.g. Benson et al., 1999; Fairweather et al., 
1990; Melamed et al., 1996). In order to achieve high levels of soluble protein, vectors 
that secrete myelin antigens were chosen for oral tolerance induction purposes. 
Attempts to clone PLP!39.151 and human MBP behind the constitutive Idh promoter in a 
secretion vector failed. Although the vector without heterologous antigen was stable, 
insertion of cDNA of the myelin antigens caused segregational instability in E. coli. 
cDNA from PLPJ39.151 and other myelin antigens were successfully cloned in secretion 
vectors containing the regulatable alllY promoter. In addition, cDNA from MBPn.85 
was cloned in an expression vector under control of the regulatable amy promoter 
which retained the antigen intracellularly. 
The expression level of an intracellularly expressed antigen is much higher than 
the same antigen expressed to be secreted (both under control of the alllY promoter). In 
alii)' controlled vectors resulting in secretion of the heterologous antigen, the 
expression levels of antigen per colony forming unit increased during growth, with an 
optimum at the end of log phase and a decrease in stationary phase. This has 
implications for the choice of growth phase of recombinant lactobacilli for use in oral 
tolerance induction. Based on the highest expression level we have chosen to use L. 
casei recombinants grown tiII end-log-phase for oral tolerance experiments. In 
contrast to mid-log phase cultures, no enhancing effects on EAE disease course were 
found after oral administration of end-log phase cultures of L. casei expressing an 
irrelevant antigen (chapter 4.2). 
The expression level of heterologous protein is not solely dependent on the 
expression vector. It appeared that the expression levels varied between Lactobacillus 
strains when genetically transformed with the same vector. Strain dependent 
differences were also found when the amount of secreted heterologous protein was 
analyzed. This could be due to differences in the efficacy of the translocation systems. 
150 
Chapter 5 
In addition to the continuous translocation of antigen, an inefficient translocation 
system could be the cause of the presence of heterologous antigen at the cell surface of 
L. casei recombinants containing a secretory expression vector (chapter 3.1). 
5.3 Intranasal versus oral tolerance 
Three mechanisms have been described for the induction of oral tolerance in 
autoimmune disease; active suppression, anergy and deletion of auto-reactive T-cells. 
In general, active suppression mechanisms are induced with (multiple) low doses of 
antigen (see introduction, section 1.4). Anergy and deletion were repOlted to result 
from high (single) dose administrations (Chen et al., 1995a; Whitacre et al., 1991). 
These dose dependent mechanisms have also been described for nasal tolerance 
induction (Li et al., 1998). The doses necessary to induce the different mechanisms via 
the nasal route are much lower than via the oral route. Approximately ten fold higher 
doses are necessary to induce tolerance by oral administration (Ma et al., 1995; 
Metzler and Wraith, 1993). The reason of this more efficient tolerance induction via 
the nasal route is not known. Orally administered soluble antigens may be degraded in 
the acidic environment of the stomach, decreasing the local antigenic dose at the gut 
mucosa. But also a more rapid uptake of antigen, uptake by other cells or drainage to 
functionally different lymph nodes after nasal administration may be responsible for 
this difference. Wolvers et al. (1999) have demonstrated that superficial cervical 
lymph nodes, the nose-draining lymph nodes, are necessary for nasal tolerance 
induction. Removal of these lymph nodes abrogates nasal tolerance induction. 
Tolerance can be restored by transplantation of the superficial cervical lymph nodes 
but not by replacing them with peripheral lymph nodes, indicating that intrinsic 
properties of the draining cervical lymph nodes are important in nasal tolerance 
induction. Removal of Peyer's patches does not abolish oral tolerance induction 
(Enders et al., 1986). Whether oral tolerance can be induced in animals without lymph 
nodes is interesting in order to elucidate the function of these lymph nodes in oral 
tolerance (Fu et al., 1997). 
Dosing appears to be important in nasal as well as in oral tolerance induction. 
The low zone and high zone tolerance as demonstrated after a second s.c. or i.p. 
immunization with antigen do not occur after mucosal administration. Low zone and 
high zone tolerance have been extensively investigated for humoral responses against 
various parenterally administered antigens with low and high doses respectively. A 
broad dose range between low and high induces humoral immunity. After mucosal 
administration of soluble antigen enhancement of the response occurs at the very low 
doses (Figure l)(Lamont et al., 1989). It has been demonstrated that (very) low doses 
of antigen can enhance EAE severity (Bai et al., 1998; Meyer et al., 1996). Low doses 
are associated with the induction of active suppression mechanisms and very high 
dosages can lead to anergy and possibly deletion. However, it is important to consider 
that all of these tolerance mechanisms may coexist and are not mutually exclusive. 
Which mechanism predominates depends on the frequency of antigen administration 
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Figure 1. Dose dependellt effects of antigen Olllllucosal tolerallce induction 
Mucosal administration of soluble antigens induces peripheral T cell tolerance, in particular of the Thl 
subset. In this figure the dose dependent effects of mucosally administered soluble antigen on a TIll 
mediated autoimmune disease are depicted. TIle horizontal line in the middle of the graph indicates the 
mean disease severity in animals which did not receive 3utoantigen rnucosally. Mucosal administration of 
very low doses of autoantigen can enhance disease severity (left part). Higher doses of autoantigen 
probably suppress disease via active suppression (middle part), Very high doses of autoantigen suppress 
disease via the induction of anergy or deletion (right part), The three mechanisms of tolerance induction 
are dose dependent but not mutually exclusive as indicated by the arrows, 
in addition to the dose. The dose range determining the mechanism of T-cell tolerance 
is different per peptide, protein or antigenic mixtures administered, and in addition 
dependent on the mucosal route, host and state of disease (prevention or treatment). 
When mucosal routes are used to apply therapeutics in order to restore tolerance 
towards autoantigens or allergens, it is important that no adverse effects occuI'. From 
Figllre 1 it can be deduced that very low doses need to be avoided, but it is hard to 
predict what minimal dose will be effective. Taking into account that tolerance 
induction occurs after intranasal administration at far lower doses compared to oral 
administration, it can be argued that the risk of stimulating the immune response is 
higher via the oral route (chapter 4.2). Especially when antigen availability is a 
limiting factor, nasal application can be preferred. Antigen availability is no longer an 
issne when recombinant lactobacilli are used. In our experiments the soluble fraction 
of Lactobacillus extracts, without cell wall components, was used, because the effect 
of induction of intranasal tolerance is unknown. It appeared that the presence of 
152 
Chapter 5 
soluble Lactobacilills components enhanced tolerance induction, because much lower 
doses of recombinant antigen were effective as compared to the amount of synthetic 
peptide used to decrease EAE. Although the EAE reducing effects can be achieved by 
intranasal administration of lower doses than for equal reduction after oral 
administration, the oral route may be preferable. Since it was reported that 
maintenance of oral tolerance requires continuous antigenic presence, daily oral intake 
of recombinant lactobacilli could be a suitable strategy. It is not likely that the dose 
administered will be too high to induce oral tolerance. However, when bystander 
suppression is desired as the mechanism of T cell tolerance, theoretically the 
administered dose can be too high, resulting in the induction of anergy. Lactobacilli do 
not persist in the nose or in the normally sterile lungs, and negative effects of multiple 
nasal administrations of large numbers of live lactobacilli cannot be IUled out. 
It has been demonstrated that the nasal route also can be used for vaccination 
purposes. Nasal application of live lactobacilli expressing an immunogenic bacterial 
antigen intracellularly induced antigen specific IgG and IgA responses (Shaw et al., 
manuscript in preparation). The efficacy of this route for vaccination could be due to 
the particulate nature of the lactobacilli, according to the current dogma that the 
soluble versus particulate nature of the antigens is at least partially responsible for the 
induction of T cell tolerance versus immunity respectively. 
5.4 Orally administered lactobacilli 
Persistellce 
After oral administration most protein antigens are proteolytically digested in the 
stomach and the rest of the gastro-intestinal tract. Cytoplasmic presence in lactobacilli 
protects the antigen against this degradation. From all known probiotic lactic acid 
bacteria Lactobacilills strains were chosen because of their live passage of the acidic 
environment of the stomach, in contrast to Lac/OCOCCIIS species. Live (attenuated) 
bacteria are more efficient inducers of immunity than dead bacteria (Kaul and Ogra, 
1998). This live passage could therefore be an advantage for the use of recombinant 
lactobacilli as oral vaccines. In addition, this live passage allows persistence and 
subsequent ill vivo expression of the heterologous antigen. In order to determine the 
importance of persistence/colonization in oral tolerance induction, experiments could 
be performed in germ-free mice. A disadvantage is that those mice have small Peyer's 
patches with quiescent B cell follicles through the lack of interaction with the 
indigenous microflora (Cebra et al., 1998). Alternatively, deliberately colonized adult 
mice with a simple mixture of bacterial strains (gnotobiotic mice) including the wild 
type form of the chosen Lactobacilills strain as the only Lactobacilills strain 
introduced, can be used (Cebra, 1999). By treating those mice with huge amounts of 
recombinant lactobacilli, a competition will take place, possibly resulting in 
colonisation by the recombinant strain. Another method is to remove the present 
microflora physically or by treatment with antibiotics before the start of treatment with 
recombinant lactobacilli. This latter method could also be applied in humans. 
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In vivo expression 0/ heterologous proteins 
A non-persisting Lactobacillus strain was used in the mucosal tolerance experiments 
described in chapter 4.2. It is known that L. casei passes the gastrointestinal tract in 
two to three days. The dividing rate of the used recombinant lactobacilli under optimal 
conditions in vitro is around 2.5 hours in log phase. Since the growth conditions ill 
vivo are not optimal (e.g. limited availability of nutrients), it is unlikely that the 
recombinant lactobacilli will multiply in the gastro-intestinal tract. There are two 
related arguments to assume that no de novo synthesis of heterologous protein under 
control of the regulatable amy promoter will occur when the lactobacilli do not 
multiply ill vivo. First, under control of the amy promoter, the highest rate of 
heterologous antigen synthesis is observed in log phase cultures. In stationary phase 
the level of heterologous protein expression is decreased. Second, the regulatable amy 
promoter is de-repressed in the presence of a carbon source other than glucose, with 
the prerequisite that the Lactobacillus strain is able to ferment the particnlar sugar. In 
vitro, the stationary phase is entered when the carbon source is exhausted, resulting in 
repression of the alllY promoter. When the Lactobacillus strain manages to multiply ill 
vivo, glucose will be the most probable carbon source. As a result, the amy promoter 
will remain repressed and no de IlOVO synthesis will take place. However, in case of a 
colonized recombinant Lactobacillus strain, feeding sugar that results in derepression 
of the amy promoter could provide an in vivo regulatable system of myelin protein 
expression. Since the constitutive ldh promoter is not dependent on the carbon source, 
synthesis of heterologous proteins under control of this promoter is more likely to 
happen in vivo. 
Mechanisms a/tolerance induction 
Even when orally administered recombinant lactobacilli are able to secrete 
heterologous proteins, it will be only trace amounts, because we assume that de novo 
synthesis of heterologous antigen will not occur ill vivo. The same is hue for the 
surface associated heterologous proteins from a secretory vector that could be detected 
by flow cytometry (chapter 3.1). The proteins associated with the cell wall at the 
moment of administration probably will be (partially) degraded. This implies that in 
the gastro-intestinal tract Lactobacillus strains secreting heterologous antigen are 
comparable to Lactobacillus strains expressing the heterologous antigen 
intracellularly. Both Lactobacillus strains expressing the heterologous MBPn .85 
peptide fused to B-glucuronidase, intracellularly or secreted, were able to reduce EAE. 
How this MBP peptide was presented to the immune system is not known. Two 
possible ways of antigen uptake and presentation can be distinguished. First, the 
antigen is released from the cytoplasm of the lactobacilli upon death and cytolysis in 
the gut lumen. This results in soluble antigen, which can be taken np by epithelial cells 
of the gut villi and probably presented to CD8+ intraepithelial lymphocytes (JEL), 
leading to T-cell tolerance induction (Yamamoto et al., 1998). Although lactobacilli 
are quite resistant to proteolytic digestion (bacteria in log phase probably are more 
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susceptible to enzymatic lysis than stationary phase bacteria (Logardt and Neujahr, 
1975)) eventually also these bacteria will be lysed. Another pathway is the uptake of 
lactobacilli via the Peyer's patches, which has been demonstrated by Claassen et al. 
(1995). When the second mechanism is the main mechanism of antigen presentation, 
the question remains why particulate stluctures containing autoantigen were able to 
induce T-cell tolerance. Possibly adjuvanticity and cytokine induction playa role. 
In the dome of the Peyer's patch the lactobacilli probably will be taken up by 
APC. Studies have revealed that conventional APC, abundantly present throughout the 
intestinal wall, PPs and MLNs are likely to contribute to the induction of tolerance 
(Mowat and Viney, 1997). APCs isolated from the lamina propria of normal mice, 
preferentially induce tolerance when transferred to naIve animals after stimulation 
with antigen ill vitro (Harper e/ al., 1996). Although the nature of these APCs is 
unknown, recent studies implicate a role for dendritic cells in tolerance induction. 
Administration of the growth factor Flt3 ligand to mice expands the number of DCs in 
the intestine and other lymphoid organs. This increase in number of DCs enhanced the 
susceptibility to tolerance induction by feeding OVA (Viney et al., 1998). These 
findings are in contrast with the common assumption that DCs have a constitutive 
ability to activate T cells. It seems that the phenotype of DC is tissue dependent. The 
DC reclUited to the intestine by Flt3 ligand express only low levels of B7-1 or CD40 
costimulatory molecules, supporting the view that intestinal DC may normally be in a 
resting state without the ability to prime T cells. It has been proposed that DCs are 
important regulators of the mucosal immune response (Mowat and Viney, 1997). The 
induction of T-cell tolerance to soluble proteins or non-invasive microorganisms is 
supported by DC. However, when confronted by potentially harmful antigens 
accompanied by appropriate cytokines or other inflammatory signals, active immunity 
can be stimulated. When the low immunogenicity and non-invasive character of the 
Lactobacillus strains used is considered, induction of anergy via DC expressing low 
levels of costimulatory molecules could be a possible mechanism for oral tolerance 
induction. When presentation of antigen by DC leads to the priming of Th2 cells, 
active suppression mechanisms could be underlying T-cell tolerance induction. The 
increase of IL-IO and TGF-J3 in gut villi after oral administration of L. casei suggests 
that active suppression occurs as a tolerance induction mechanism (chapter 2.2). 
Whether this is the case can not be deduced from our data, although the reduction of 
EAE by oral administration of MBPn -85 in a spinal cord homogenate induced EAE 
could be due to bystander suppression (chapter 4.2). When oral administration of 
MBPn _85 induced regulatory cells that secreted the appropriate cytokines, the 
inflammatory response against various, anatomically co-localized myelin antigens 
present in the spinal cord homogenate could be suppressed. This bystander 
suppression allows oral treatment with antigens which are present at the site of 
inflammation without the need to identify the initiating autoantigen(s)(reviewed by 
Weiner, 1997). 
ISS 
Summarizing discllssion 
5.5 Future directions 
In this thesis it has been demonstrated that lactobacilli can be genetically engineered 
to express myelin antigens, and that mucosal administration of some of these 
recombinant lactobacilli reduced the severity of the T-cell mediated experimental 
autoimmune disease EAE. In order to improve this method of mucosal tolerance 
induction several directions can be followed. Approaches that could lead to enhanced 
T-cell tolerance induction are discussed below. 
Genetic engineering 
Since it does not seem important that the tolerogenic myelin antigen is secreted by the 
lactobacilli, the myelin antigens can be expressed in vectors that express the antigen 
intracellularly, leading to increased expression levels. By choosing a vector containing 
the constitutive ldh promoter, the expression levels are further increased. Constructing 
vectors with even stronger promoters than Ielh, such as the promoter of the S-Iayer 
protein, would lead to an additional increase in expression level (Savijoki et al., 1997). 
In case of heterologous peptide expression, using a vector containing repeated cDNA 
sequences of the peptide increases the number of epitopes per microbe. Another 
method to achieve this, is the use of superoxide dismutase (SOD). This protein is 
expressed as a tetramer, allowing 4 pep tides to be expressed in one molecule. 
Design 0/ a possible/lltllre experiment 
The design of an experiment to improve tolerance induction by recombinant 
lactobacilli could be as follows. L. rellteri and L. IIll/rines containing vectors for the 
intracellular expression of MBP"'85 and a control peptide of hemagglutinin (Ha) both 
fused to B-glucuronidase are used. These Lactobacilllls strains are of special interest 
because they have the most extreme properties with respect to modulation of the 
induction of cytokines in the gut, EAE severity and IgG l/lgG2a ratio. The expression 
is under control of the Idh promoter, in order to express as much antigen as possible. 
The maximum dose that can be handled practically is approximately 2.1011 CFU per 
oral administration. Ha is used as a control antigen, because it is an (immunogenic) 
peptide. Parenteral challenge with the same peptide will reveal whether B cell 
activation occurs. In order to be able to detect the effects on antibody levels, the rat 
EAE model induced with gpMBP will be used. After determining the persistence of L. 
mllrines and L. rellteri, two oral administration regimens will be used to determine the 
importance of the maintenance of antigen. Animals will be fed antigen from day -2 till 
day 2, or from day -6 throughout the experiment. When EAE can be prevented by 
recombinant lactobacilli expressing MBP"'85 fused to B-gluc, adoptive transfer 
experiments to determine whether active suppression mechanisms underlie the 
induction of tolerance can be designed. 
Therapy in established EAE 
In humans recombinant lactobacilli expressing myelin antigens must function as a 
therapeutic in established disease. Since we demonstrated prevention of disease in 
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animal models, it remains to be shown that oral administration of recombinant 
lactobacilli can have beneficial effects in a chronic disease model. Possibly this can be 
achieved by simple administration of recombinant lactobacilli after onset of EAE. 
However, it is known that it is difficult to tolerize an ongoing vigorous Thl response, 
therefore co-administration of for instance anti-ILl2 (Matth et al., 1996) or lactococci 
expressing TGF-B could enhance the efficacy of tolerance induction. Alternatively, 
suppression the total immune response prior to mucosal treatment with recombinant 
lactobacilli to induce tolerance may increase the efficacy as well. The immune system 
can be suppressed by for instance corticosteroids or blocking the interaction of T-cells, 
B-cells and APC by injection of antagonist anti-CD40 or anti-CD40L monoclonal 
antibodies (Gerritse et aI., 1996; Laman et al., 1998a). 
Potential application ill humalls 
In this thesis we demonstrated proof of principle that recombinant lactobacilli 
expressing myelin antigens can partially prevent EAE. Before we can apply this 
approach to humans with MS, we have to make sure that it is possible to treat chronic 
EAE in animals. It also has to be elucidated whether active bystander suppression is 
the main mechanism of T-cell tolerance induction. If not, this would be an obstacle for 
use in the heterogeneous human MS population. When it appears to be possible to 
treat chronic disease mediated by regulatory T-cells, several approaches can be 
followed to use recombinant lactobacilli in MS patients. 
When Lactobacillus strains can be identified which are commensals in a large 
part of the (European/American) population, such strains can be characterized for 
properties such as intrinsic inununogenicity, adjuvanticity and transformation 
suitability after isolation. Factors responsible for adhesion and persistence can be 
important but may be altered by in vitro culturing (Pouwels et al., 1998). 
Alternatively, Lactobacillus strains can be isolated from individual MS patients. A 
Lactobacillus strain against which no antibodies can be detected in the patient and 
which can be transformed could be a useful strain for that particular patient. 
The efficacy of peripheral T-cell tolerance induction by oral administration of 
recombinant lactobacilli may be enhanced when the microflora is removed physically 
or by treatment with antibiotics. This should be studied in animal models first. 
In addition, no harmful effects are reported so far after oral intake of 
lactobacilli. When a study reveals that (daily intake) of industrial Lactobacillus strains 
do not negatively affect the MS course, such a strain could also be used after extensive 
in vitro evaluation. 
Recombinant lactobacilli can only be used in humans when the vectors are food 
grade. Food grade vectors are characterized by the absence of an antibiotic resistance 
marker and by the presence of a nutritional selection system, which allow bacteria 
containing such vector to be distinguished from the indigenous microflora ill vitro. 
Such food grade vectors are currently under development. III vitro, lactobacilli 
containing vectors with an antibiotic resistance gene will loose the vector after a 
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number of cycles when cultured without selection pressure. Since in vivo no selection 
pressure is present for lactobacilli containing a food grade vector, the lactobacilli 
probably will discard the vector after a number of cycles. Therefore it is also very 
unlikely that bacterial strains of the host will inherit the vectors. 
5.6 Concluding remarks 
The aim of this thesis was to prevent EAE by oral administration of recombinant 
lactobacilli expressing myelin antigens. However, since the genus Lactobacillus is 
very large and diverse in genetic and biochemical properties, we first studied some of 
the effects lactobacilli can have on the immune system. The large diversity within the 
Lactobacillus genus opens opportunities to increase the desired effects by choosing an 
appropriate strain. However, the demonstrated strain and growth phase dependent 
differences cautions that not all Lactobacillus strains have beneficial effects on human 
health. 
Based on the effects of Lactobacillus strains and the analysis of the recombinant 
lactobacilli, we have chosen L. Nisei grown till end-log phase for mucosal tolerance 
experiments. We succeeded in reducing EAE disease burden by nasal administration 
of soluble recombinant Lactobacillus extracts and by oral administration of live 
recombinant lactobacilli. These results are 'proof of principle' that it is possible to 
reduce EAE by mucosal administration of recombinant lactobacilli. Oral 
administration of recombinant lactobacilli expressing myelin antigen can therefore be 
a promising antigen specific approach for the treatment of multiple sclerosis. 
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Samenvattillg 
Samenvatting voor niet-ingewijden 
Multiple sclerose (MS) is een chronische aandoening van het centrale zenuwstelsel. In 
het centrale zenuwstelsel van MS patienten zijn meerdere ontstekingshaarden 
aanwezig en wordt de myelineschede rondom de zenuwbanen afgebroken. Het wordt 
aangenomen dat MS een autoimmuunziekte is. Dat betekent dat het immuunsysteem 
lichaamseigen eiwitten (autoantigenen) aanvalt, in dit geval myeline eiwitten. 
Normaliter bestaat er tolerantie voor lichaamseigen eiwitten, maar blijkbaar is die 
tolerantie niet meer aanwezig in MS patienten. Het is daarom van belang om opnieuw 
tolerantie te verkrijgen voor de myeline eiwitten. Hiertoe kunnen wij gebtuik maken 
van het immuunsysteem in het maag-darm kanaal (een onderdeel van het mucosale 
immuunsysteem)(mucosa = slijmvlies). Tegen voedseleiwitten wordt normaliter geen 
sterke immuunrespons opgewekt, omdat dat tot een continue ontsteking zou leiden en 
tot beschadiging van de darmwand. Het mucosale innnuunsysteem is dus een 
natuurlijke plaats voor tolerantie-inductie. Het autoantigeen aanbieden aan het 
mucosale immuunsysteem, dus via de orale route (mond), maar ook via de nasale 
route (neus) zou tot tolerantie kunnen leiden voor het autoantigeen. Orale en nasale 
toediening van autoantigenen remt ziekteverschijnselen in diennodellen voor 
verschillende autoimmuunziekten. Ook in het diermodel voor MS, experimentele 
autoimmuun encefalomyelitis (EAE) kan orale en nasale toediening van myeline 
eiwitten de ziekteverschijnselen voorkomen. 
Om de efficientie van de inductie van orale tolerantie te verhogen maken wij 
gebtuik van genetisch gemodificeerde lactobacillen die het autoantigeen kunnen 
uitscheiden in de darm. Lactobacillen zijn Gram-positieve bacterien die van nature 
voorkomen in de menselijke darm. Omdat ze in het algemeen als veilige 
microorganismen worden beschouwd (GRAS-status), zijn ze uitermate geschikt als 
aanbieder van het autoantigeen. 
Het is bekend dat melkzuurbacterien zoals lactobacillen gezondheids-
stimulerende eigenschappen kunnen bezitten. Dit komt onder meer doordat 
verschillende Lactobacillus stammen in staat zijn om het immuunsysteem te 
moduleren. Dit geldt echter niet voor aile stammen. Om de inductie van tolerantie te 
stimuleren en niet tegen te werken, is het van belang om de meest geschikte 
Lactobacillus stam te kiezen. Daarom hebben wij van verschillende Lactobacillus 
stammen diverse immuunsysteem modulerende eigenschappen na orale toediening 
bestudeerd. Ten eerste is onderzocht of verschillende Lactobacillus stammen 
intrinsieke adjuvant activiteit bezitten, dat is de mogelijkheid om de antilichaam 
respons tegen een ge'injecteerd eiwit te verhogen. Van de acht onderzochte stammen, 
bleken L. reuteri, L. brevis en L. jerll1elltlllll intrinsieke adjuvant activiteit te bezitten. 
Cytokinen, uitgescheiden door cellen van het inmmunsysteem, worden beschouwd als 
belangrijke regulatoren van de immuunrespons. Cytokine profielen in de darmen 
werden bestudeerd na orale toediening van lactobacillen. Twee van de Lactobacillus 
stammen die een adjuverende activiteit vertoonden, bleken cytokinen te induceren die 
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betrokken zijn bij ontstekingsreacties (Thl). Twee andere Lactobacillus stammen, 
L.casei en L. murilles leken juist onstekings-remmende cytokinen te induceren, TOF-Il 
en !L-lO (Th2). Deze laatste twee stammen zouden mogelijk geschikt zijn voor de 
inductie van orale tolerantie nadat ze getransformeerd zijn vectoren die coderen voor 
myeline eiwitten. 
Niet aileen wctobacillus stam afhankelijke effecten op het immuunsysteem 
werden gevonden, ook de groeifase waarin de lactobacillen zich bevinden bij de orale 
toediening bleek van invloed te kunnen zijn op het immuunsysteem. Het antilichaam-
isotype subklasse Ig02a een reflectie is van een ontstekings-inducerende Thl respons 
en IgO I een reflectie is van een Th2 respons die mogelijk betrokken is bij T-cel 
tolerantie inductie. Wij hebben gevonden dat de [gO l/Ig02a ratio verhoogd is 
wanneer stationaire culturen van L. casei of L. murilles oraal werden toegediend. De 
ratio was verlaagd wanneer log fase culturen oraal aan nmizen werden toegediend. Dit 
impliceert dat, afhankelijk van de groeifase, lactobacillen de Th IfTh2 balans 
differentieel kunnen beinvloeden. Op grond van deze gegevens hebben wij gekozen 
voor L. casei als drager van de myeline antigenen voor de inductie van orale 
tolerantie. 
Extracten van getransformeerde L. casei die myeline basisch eiwit (MBP)(een 
myeline eiwit) of een klein stukje hiervan (MBP peptide MBPn.85 ) tot expressie 
brengen, werden intranasaal toegediend aan Lewis ratten, voordat EAE werd 
geinduceerd. Beide L. casei transformanten remden de ziekte significant. Ook orale 
toediening van dezelfde recombinanten, maar dan levend, verminderde de 
ziekteverschijnselen significant. Ook orale en nasale toediening van lactobacillen die 
myeline antigenen tot expressie brengen, aan SJL muizen lijkt tot vermindering van 
EAE te leiden. 
Uit dit onderzoek is dus gebleken dat het mogelijk is om met oraal en nasaal 
toegediende recombinante lactobacillen die myeline antigenen tot expressie brengen, 
EAE te remmen. Verder onderzoek is nodig naar mogelijkheden voor deze vorm van 
therapie voor MS. 
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Eindelijk is het dan zover, het proefschrift is goedgekeurd. Maar voor het naar de 
dmkker kan moet eerst nog het meest gelezen onderdeel geschreven worden, het 
dankwoord. Ik wil beginnen met iedereen te bedanken die direct of indirect heeft 
bijgedragen aan de tot stand korning van dit boekje, op de werkvloer, erboven, in de 
sporthal, op het terras, aan het thuisfront of waar dan ook. 
Wim, Jon en Eric, jullie hebben rnij alledrie na ongeveer een jaartje begeleiden 
verlaten, maar nooit in de steek gelaten. Al geeft het natnurlijk weI te denken als al je 
begeleiders er vandoor gaan. 
Wim, het moet je ego toch weI gestreeld hebben dat de afdeling op zijn kop stond toen 
je vertelde dat je naar Lelystad vertrok. Er hebben zelfs tranen gevloeid. Een betel' 
bewijs dat wij je zouden rnissen was er niet. Bedankt dat je ook vanuit Lelystad altijd 
enthousiast en betrokken bent gebleven bij mijn promotieonderzoek. 
Jon, daar was ik dan ineens. Jij kreeg mij en mijn project met bacterien en moleculaire 
biologie toegeschoven. Gelukkig heb je je dit onderwerp snel eigen gemaakt. Het feit 
dat jij vaak je yinger op de zere plek legde en ALTUD gelijk had, maakte mij soms 
wanhopig. Acllteraf ben ik je erg dankbaar voor alles wat ik van jou geleerd heb en 
kan ik lachen over het feit dat je zelfs begeleidende briefjes corrigeerde. Bedankt voor 
je stimulerende begeleiding en correcties, tot in de trein naar je vakantiebestemming 
toe. 
Eric, jouw nimmer aflatende enthousiasme en de manier waarop jij alles 
aanelkaarwisttebreien hebben altijd motiverend gewerkt. Zelfs in jouw positie wist je 
toch altijd weI wat tijd voor mij vrij te maken, met name in het laatste jaar. Bedankt 
voor het zijn van een 'Iaag drempelige' promotor. 
Conny, het is maar goed datjouw tolerantie niveau za hoog is. Zoals je zelf altijd zei, 
zat je niet voor niets op het tolerantie-project. Ik heb heel veel van je gevraagd en 
altijd zander mopperen gekregen. Het weekendwerk is afgelopen, zodat je straks ook 
in de weekenden heerlijk van je kindje kan genieten. Het was fijn met je te werken. 
Linsy en Lizet, ik yond het leuk om jullie te begeleiden. Bedankt voor al het verzette 
werk. 
Op de MS-AIO-kamer zijn heel wat biertjes gedronken, chips veroberd, doosjes 
tissues doorgedraaid om tranen te drogen, felle discussies gevoerd en hebben wij krom 
gelegen van het lachen. Arianne, jouw geschater deed altijd goed en het maakte je ook 
nog gemakkelijk vindbaar. Stip, de beklimming was zwaar, maar ik heb de top 
gehaald. Jeffrey, heerlijk he, om als glazenwasser alles te kunnen zeggen. Anette, zo 
gezand eten als jij zou ik nooit kunnen (nou zag die fles met bruine inhoud er ook niet 
erg aantrekkelijk uit). Marc, de roeitocht over de Leidse grachten, de kuif van Suske 
(inclusief het achterlaten van rnijn haar in Luciennes kapsalon) en de Duvels in de zan 
zal ik nooit vergeten. Kees, pas op, dit proefschrift staat vol met Kitty-curves. Jeroen, 
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jij en verhalen ...... Michele, ik hoop dat je snel weer nieuwe collega AIO's zult 
krijgen. 
Toen ik zo'n 5 jaar geleden aan dit project begon, was het lactobacillenclubje erg 
klein. Inmiddels is het lab uit zijn voegen gegroeid en prive roddelen is er dan ook niet 
meer bij (helaas Marie-Joan). Lacto's (en andere CI-ers) bedankt voor de goede sfeer 
en het voor elkaar klaar staan. Chantal, jonw vraag: Kitty, is die muis echt dood?, staat 
in mijn geheugen gegrift. Mike, thanks for your comments, fmitful discussions and 
chats. If you stay here, you have to get used to the three kisses. Zeister, voorheen 
Rijswijkse, lacto's bedankt voor de eerste stappen in het lacto-onderzoek. 
Naast het beroep dat ik altijd op iedereen kon doen wat betreft werk, wil ik aile (ex) 
I&I-ers ook bedanken voor de gezellige, vaak spontane borrels, de uitbundige 
verkleedpat1ijen tijdens de retraites, van pimat tot oermens, het stelen van mijn fiets en 
het ketenen aan Frank (was best leuk, he Frank), ijskoude nachten in de Ardennen en 
meer van dit soort activiteiten. 
EAE scoorders, bedallkt. Malika, bedankt voor jouw hulp bij het maken van de foto 
voar de omslag. Zonder hulp van Hans en Thijs had het lac to-lab nooit kunnell 
draaiell. Ik hoop dat jullie niet gek zijn geworden van mij. Jaap, bedankt voor de 
mooie posters. Gerrit en Kees, bedankt voor het verzorgen van al die muizen en ratten. 
Het is vast een stuk mstiger in DII, zo zonder mij en mijn diet·en. 
Lieve Marie-Joan, ik had nooit gedacht zo'n vriendin over te houden aan mijn 
promotietijd. Samen, min of meer opgesloten in het CI of DrI, heb jij mij wegwijs 
gemaakt in het lactobacillenwerk. Maar wij hebben ook heel wat afgeroddeld, 
gelachen en gehuild en zijn wij elkaars deelgenoot geweest van wat er dageJijks 
gebeurde inclusief trouwen en zwangerschappen. Bedankt. 
Lieve pap, mam en Helma. Altijd zijn jullie er geweest om met mij mee te leven, te 
steullen, op te beuren en met mij in spanning te zitten. Al lijkt dit voorlopig de laatste 
fase, er komt vast weI weer iets nieuws. Bedankt voar jullie liefde en vertrouwen. 
Lieve Koen, het was weI erg bijzonder om met onze dochter Lysanne spelend op de 
grond, tegelijk aan de afronding van onze proefschriften te werken. Promoveren was 
voor ons beiden erg belallgrijk, maar wat jij, en nu ook Lysanne voor mij betekenen is 
simpelweg niet te verwoorden. 
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Abbreviations 
AA adjuvant arthritis IL interleukin 
AChR acetylcholine receptor IRBP interphotoreceptor retinol binding 
AlA antigen~induced arthritis protein 
amy a-amylase gene i.p. intraperitoneal 
APC antigen presenting cell i. v. intravenous 
APL altered peptide ligand kDa kilodalton 
a.lI. arbitrary unit KLH keyhole limpet haemocyanin 
Il-gluc Il-glucuronidase Idh L-( + )-Iactate dehydrogenase gene 
CII type II collagen LP80 Lactobacillus plalltarum 80 
CFA complete Freund's adjuvant Mab monoclonal antibody 
CFU colony forming units MBP myelin basic protein 
CGG chicken gamma globulin MCS multiple cloning site 
CIA collagen induced arthritis MHC major histocompatibility complex 
CNS central nervous system MLN mesenteric lymph nodes 
CTB cholera toxin subunit B MRI magnetic resonance imaging 
DAS disability scale MS multiple sclerosis 
DC dendritic cell mSCH mouse spinal cord homogenate 
DTH delayed type hypersensitivity NIDDM non-insulin-dependent diabetes 
EAE experimental autoimmune mellitus 
encephalomyelitis NRS normal rabbit serum 
EAMG experimental autoimmune OD optical density 
myasthenia gravis orf open reading frame 
EAN experimental autoimmune neuritis ori origin of replication 
EAT experimental autoimmune thyroiditis OVA ovalbumin 
EAU experimental autoimmune PAGE polyacrylamide gel electrophoresis 
uveoritinitis PBS phosphate buffered saline 
EGC experimental granulomatous colitis PLP proteolipid protein 
ELISA enzyme-linked immunosorbent assay PP Peyer's patches 
FITC fluorescein isothiocyanate- PVC polyvinyl chloride 
conjugated rMBP rat myelin basic protein 
GAD65 glutamate decarboxylase peptide rt-PCR reverse transcriptase polymerase 
GALT gut associated lymphoid tissue chain reaction 
GRAS generally regarded as safe S-Ag S-antigen 
gpMBP guinea pig myelin basic protein SDS sodium dodecyl sulphate 
Hig hamster immunoglobulin TCR T cell receptor 
HLA human leukocyte antigen TGF transforming growth factor 
hMBP human myelin basic protein T helper (cell) 
HRP horseradish peroxidase trinitrobenzene sulfonic acid 
IDDM insulin-dependent diabetes mellit 
IEL intraepitheliallymphocyte 
IFA incomplete Freund's adjuvant 
IFN interferon 
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